id,title
1,
2,T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
3,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination
4,response bottleneck of COVID-19 vaccine candidates
5,Qualitatively 814 distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants
6,World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 Vaccine
7,dehydrated paraffin sections (3-4 µm in thickness) were treated with an antigen retrieval kit
8,Abdel-Moneim AS. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
9,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdox1 nCov-19/bnt162b2 vaccination
10,A SARS-CoV-2 surrogate virus 526 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 527 interaction
11,Antibody Response to Inactivated COVID-19 Vaccine (CoronaVac) in Immune-Mediated Diseases: A Controlled Study Among Hospital Workers and Elderly
12,The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
13,Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study
14,A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
15,SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape
16,Heterologous ChA-dOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers
17,"UNESCO Office Montevideo and Regional Bureau for Science in Latin America and the Caribbean. COVID-19 and vaccination in Latin America and the Caribbean: challenges, needs and opportunities"
18,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
19,"Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection"
20,Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
21,Press release. CureVac Final Data from Phase 2b/3 Trial of First-Generation
22,Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
23,Next-generation vaccine platforms for COVID-19
24,The association of PM2.5 with airway innate antimicrobial activities of salivary agglutinin and surfactant protein D
25,Host genetic factors determining COVID-19 susceptibility and severity
26,Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
27,Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
28,Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis
29,Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
30,Serial interval of novel coronavirus (COVID-19) infections
31,"B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. arXiv 2021"
32,Thematic household survey report no. 58. Hong Kong
33,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials
34,NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
35,CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
36,Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021
37,rombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
38,Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: an observational study
39,São paulo passa para fase vermelha a partir de hoje
40,Effects of exercise on vaccine-induced immune responses
41,"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis"
42,"Tropical Medicine and Infectious Disease High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil"
43,Worldwide maternal deaths due to COVID-19: A brief review
44,References: 'metafor' P. Package 'metafor'
45,Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
46,Correlates of protection against symptomatic and 228 asymptomatic SARS-CoV-2 infection
47,Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
48,"COVID-19): serology, antibodies and immunity. World Health Organization"
49,• Discusses the importance of COVID-19 vaccines in patients with cancer
50,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
51,Status of COVID-19 vaccines within WHO EUL/PQ evaluation process
52,Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine
53,"Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med. 2021, 41, 100998"
54,Reduced serum neutralization capacity against SARS-CoV-2 variants 621 in a multiplex ACE2 RBD competition assay
55,A new accelerated vaccination schedule for rapid protection against hepatitis A and B
56,Report of the SAGE Working Group on Vaccine Hesitancy
57,Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: a systematic review and pooled analysis
58,COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study
59,Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
60,Interim statement on COVID-19 vaccine booster doses
61,Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support
62,Vacunación contra COVID-19 Bogotá D.C.2022
63,Safety monitoring of an additional dose of COVID-19 vaccine-United States
64,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet
65,National Health Commission of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
66,Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
67,Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero cells). (2020)
68,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in"
69,Immune responses against SARS-CoV-2 variants after heterologous and 479 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
70,Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution
71,European Centre for Disease Prevention and Control. Rapid Literature Review on Motivating Hesitant Population Groups in Europe to Vaccinate; ECDC Technical Report
72,How COVID vaccines shaped 2021 in eight powerful charts
73,Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
74,Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
75,Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study
76,Serum neutralising activity against SARS-CoV-2 837 variants elicited by CoronaVac
77,The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine
78,Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up
79,mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
80,SARS-CoV-2 igg antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (coronavac) at phyathai 3 hospital
81,Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers
82,Viral targets for vaccines against COVID-19
83,"Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety"
84,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine"
85,Cultivation of a novel type of common-cold virus in organ cultures
86,Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease
87,The importance and challenges of identifying SARS-CoV-2 reinfections
88,Peculiarities of the T Cell Immune Response in COVID-19
89,Waning immune humoral response to BNT162b2
90,"Restoring effect of selenium on the molecular content, structure and fluidity of diabetic kidney brush border cell membrane"
91,Correlation of SARS-CoV-2-breakthrough 155 infections to time-from-vaccine
92,SARS-CoV-2 Lambda 927 Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies
93,"Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey"
94,Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
95,Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
96,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
97,Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
98,Correlates of protection 533 against symptomatic and asymptomatic SARS-CoV-2 infection
99,Vacinas-COVID-19
100,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance -eight U.S. locations
101,The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
102,International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
103,A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
104,The low acceptance rate of COVID-19 vaccines suggested that both the public and health professionals need to sufficient evidence and accurate information about COVID-19 vaccines to boost confidence in vaccination
105,Pathophysiology of Migraine: A Disorder of Sensory Processing
106,The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine
107,Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review
108,Discusses news about approval of CoronaVac by WHO
109,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic? Risk Manag
110,"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial"
111,RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol
112,mRNA vaccine CVnCoV protects nonhuman primates from SARS-CoV-2 challenge infection
113,Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
114,"MAFFT online service: Multiple sequence alignment, interactive sequence choice and visualization"
115,Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
116,Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation
117,Resistance to COVID-19 vaccination has increased in Ireland and the United Kingdom during the pandemic
118,The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
119,Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults. medRxiv
120,Análise da distribuição e tendência de coberturas vacinais para crianças indígenas menores de cinco anos de idade. Brasil
121,"Safety and 486 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral 487 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-488 inferiority trial"
122,Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
123,"Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)"
124,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid"
125,BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
126,"Triggers, protectors, and predictors in episodic migraine"
127,Surveillance for Adverse Events After COVID-19 mRNA Vaccination
128,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type5 vectorbased COVID19 vaccine (Ad5nCoV) in adults: preliminary report of an openlabel and randomised phase 1 clinical trial"
129,A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
130,New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin
131,Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines
132,BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting
133,T cell immunity to SARSCoV2 following natural infection and vaccination
134,WHO. WHO Coronavirus (COVID-19). 2022. Accessed
135,High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
136,"Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies"
137,Vaccines and Related Biological Products Advisory Committee
138,"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review"
139,Commercialized kit to assess T-cell responses against SARS-592
140,Moderna announces preliminary booster data and updates strategy to address Omikron variant. News release on DSecember 12th
141,Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report
142,mRNA-based COVID-19 vaccine boosters induce 507 neutralizing immunity against SARS-CoV-2 Omicron variant
143,Mechanisms of innate events during skin reaction following intradermal injection of seasonal influenza vaccine
144,SARS-CoV-2 incidence and vaccine escape
145,A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine
146,Thailand Allows Emergency Use of Sinovac's COVID-19 Vaccine
147,Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
148,COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere
149,"Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world"
150,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label
151,Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
152,Immunemediated adverse reactions to vaccines
153,A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
154,mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
155,Covid-19 and kidney transplantation
156,Endocrine Significance of SARS-CoV-2's Reliance on ACE2
157,A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19
158,Thematic household survey report no
159,Immune response elicited from heterologous SARS-CoV-2 602 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 603
160,SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
161,Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
162,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
163,The vaccine journey for COVID-19: A comprehensive systematic review of current clinical trials in humans
164,Module 2: Types of Vaccine and Adverse Reactions
165,&#x007E;:text=COVID%2D19%20vaccines%20are%20sa fe
166,Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
167,Genomic surveillance tracks the first communitary outbreak of Delta (B.1.617.2) variant in Brazil. SARS-CoV-2 coronavirus / nCoV-2019
168,Beyond binding: Antibody effector functions in infectious diseases
169,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 491 administered in a prime-boost regimen in young and old adults (COV002): a single-blind, 492 randomised, controlled, phase 2/3 trial"
170,Direct gene transfer into mouse muscle in vivo
171,Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand
172,Migraine associated cerebral hyperperfusion with arterial spin-labeled MR imaging
173,Respiratory follow-up of patients with COVID-19 pneumonia
174,Antibody responses in COVID-19: a review
175,COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey
176,Mix-and-match COVID vaccines trigger potent immune response
177,Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins. medRxiv
178,Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities
179,CDC. Vaccines: The Basics
180,Waning ımmune humoral response to BNT162b2 COVİD-19 vaccine over 6 months
181,Evidence for increased breakthrough rates of SARS-413
182,World Health Organization. WHO Coronavirus (COVID-19) Dashboard
183,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
184,Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India
185,Efficacy of the ChAdOx1 474 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
186,Coronavirus disease pandemic (COVID-19): challenges and a global perspective
187,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific
188,Naming the coronavirus disease (COVID-19) and the virus that causes it
189,mRNAbased COVID19 vaccine boosters induce neutralizing immunity against SARSCoV2 Omicron variant
190,Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China
191,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
192,A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation
193,Key roles of adjuvants in modern vaccines
194,Association of age with SARS-CoV-2 antibody response
195,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial"
196,Confounding by indication in non-experimental evaluation of vaccine effectiveness: The example of prevention of influenza complications
197,Developing Covid-19 vaccines at pandemic speed
198,The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
199,Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
200,Case Report Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
201,"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers Letter to the Editor Data availability statement Letter to the Editor Letter to the Editor"
202,Department of Statistics Malaysia
203,Sinovac Biotech Limited; 2020. Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
204,"Vaccinated participants plasma reactivity to RBD measured by ELISA. b, Plasma neutralization titers measured at baseline, previously to BNT162b2 booster shot against ancestral virus, Delta and Omicron variants. Regression lines are shown over time as days post 2 CoronaVac dose vaccination, as purple (ancestral), dark green (Delta) and light green (Omicron)"
205,Omicron (BA. 1) and Sub-Variants (BA
206,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2
207,"Vaccine Development, Testing, and Regulation | History of Vaccines"
208,A serological assay to detect SARS-CoV-2 seroconversion in humans
209,Epub ahead of print
210,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma-variant transmission in Manaus, Brazil: a test-negative case-control study"
211,Vaccine confidence and hesitancy in Brazil. Cadernos de Saúde Pública
212,High efficiency of antiviral CD4(+) killer T cells
213,Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
214,Antibody response to Covıd-19 infectıon clinical variables at play. medRxiv
215,Ongoing global and regional adaptive evolution of SARS-CoV-2
216,"Oxford COVID vaccine trial group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
217,Sex-and age-specific clinical and immunological features of coronavirus disease 2019
218,Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
219,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
220,"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations, WHO Technical Report Series 1004"
221,"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data"
222,"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: meta-analysis with 55 studies and 10014 cases"
223,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)
224,Acceptance of COVID-19 Vaccination during the COVID-19
225,Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs
226,Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)
227,Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
228,COVID-19 (Novel Coronavirus 2019) -418 recent trends
229,WHO Approval of Chinese CoronaVac COVID Vaccine Will be Crucial to Curbing Pandemic
230,Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
231,WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply: An Approach to Inform Planning and Subsequent Recommendations Based on Epidemiological Setting and Vaccine Supply Scenarios
232,"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix"
233,Draft landscape and tracker of COVID-19 candidate vaccines 415
234,COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
235,Heterologous SARS-CoV-2 booster vaccinations -preliminary report
236,Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events
237,Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear
238,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data. Res Sq
239,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
240,Culture and identification of a Deltamicron SARS-CoV-2 in a three cases cluster in southern France
241,BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
242,"Organización Panamericana de la Salud,organización Mundial de la Salud"
243,C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
244,Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
245,Coronavirus disease (COVID-19) advice for the public
246,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
247,The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
248,Infectious complications in polymyositis and dermatomyositis: a series of 279 patients
249,"Null hypothesis significance testing, p-values, effects sizes and confidence intervals"
250,"CoG-UK), o.b.o.C.-G.C.U, 2020. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations"
251,"Sweden joins Germany, France, and 15 other countries in suspending AstraZeneca's vaccine over possible side effects"
252,Diagnosis of breast cancer with infrared spectroscopy from serum samples
253,Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
254,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
255,Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
256,Subject_term: Protein analysis;SARS-CoV-2;Vaccines;Viral evolution
257,Long-lived plasma cells are contained within the CD19− CD38hiCD138+ subset in human bone marrow
258,T cell responses to SARS-CoV-2 spike cross-recognize Omicron
259,Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq
260,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
261,"Production, titration, neutralisation and storage of SARS-CoV-2 605 lentiviral pseudotypes (preprint)"
262,Novavax COVID-19 Vaccine Demonstrates 89 . 3 % Efficacy in UK Phase 3 Trial
263,The Government of the Hong Kong Special Administrative Region. CHP investigates six cases tested positive for SARS-CoV-2 virus involving Silka Seaview Hotel Hong Kong
264,CoV-2 that interact with ACE2 and neutralizing antibodies
265,Homens e masculinidades e o novo coronavírus: compartilhando questões de gênero na primeira fase da pandemia. Ciência & Saúde Coletiva
266,"Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021, 372, n743"
267,International Study Group for Behçet's Disease (1990) Criteria for diagnosis of Behçet's disease
268,"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial"
269,Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET
270,Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine
271,Low COVID-19 Vaccine Hesitancy in Brazil
272,"Safety and Immunogenicity of an Inactivated SARS-Cov-2 Vaccine, BBIBP-Corv: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial"
273,Correlates of protection against symptomatic and asymptomatic SARSCoV2 infection
274,COVID-19: Characteristics and Therapeutics
275,Draft Guidelines for Adverse Event Reporting and Learning Systems
276,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study. SSRN
277,Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine
278,COVID-19 Situation Report for the Western Pacific Region #70: 8-14
279,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health -Europe
280,An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
281,Population and Housing Census
282,A simple 592 protein-based surrogate neutralization assay for SARS-CoV-2
283,Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
284,Human neutralizing antibodies elicited by SARS-CoV-2 infection
285,"Public health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
286,Programa nacional de imunizações (pni) e covid-19: desafios a uma história de quase meio século de sucesso | cee fiocruz
287,A strategic approach to COVID-19 vaccine R&D
288,Clinical Characteristics and Predictors of Short-Term Outcome in Mexican Adult Patients with Guillain-Barré Syndrome
289,Mapa da vacinação contra covid-19 no brasil
290,COVID-19 infection in kidney transplant recipients: Disease incidence and clinical outcomes
291,Prevalence and types of vaccination errors from 2009 to 2018: a systematic review of the medical literature
292,COVID-19: why we can't use antibody tests to show that vaccines are working
293,Serum anti-Spike antibody titers before and after heterologous booster with mRNA- 1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine
294,Safety 976 and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients 977 with cancer: interim analysis of a prospective observational study
295,Cell entry mechanisms of SARS-CoV-2
296,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the first case report
297,Validation of a commercially available SARS-CoV-2 serological immunoassay
298,Covid-19 and autoimmunity
299,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv
300,Sample size determination in health studies: A practical manual. Geneva: World Health Organization
301,Serial Interval of COVID-19 among Publicly Reported Confirmed Cases
302,COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries
303,To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination
304,"Compulsory COVID-19 Vaccination? Only as a Policy of Last Resort. Voices Bioeth. 2020, 6"
305,"Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens"
306,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: Decline in antibodies 12 weeks after two doses
307,Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review
308,Execution of laboratory tests were performed by Rosemeire Yamashiro and Marcia J. Castejon. Samples management was performed by
309,World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
310,"Por conta de fake news, 70% dos índigenas do Tapajós resistem à vacinação. CNN Brasil"
311,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind"
312,Thrombotic thrombocytopenia after Ad26.COV2.S vaccination -response from the manufacturer
313,Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool
314,Efficacy of NVX-CoV2373 COVID-19 Vaccine against the B.1.351 Variant
315,Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients
316,Coronavirus Pandemic (COVID-19) 2020
317,Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose
318,Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
319,Origin and evolution of pathogenic coronaviruses
320,Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine
321,T cell response to SARS-CoV-2 infection in humans: A systematic review
322,"Immunogenicity and safety of a recombinant adenovirus type5vectored COVID19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebocontrolled, phase 2 trial"
323,"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination"
324,"RHH-001): a phase 4, non-inferiority, single blind, randomised study"
325,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19
326,AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire
327,Characterization of water soluble inorganic ions and their evolution processes during PM2.5 pollution episodes in a small city in southwest China
328,Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination
329,SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
330,"Evaluating ELISA, Immunofluorescence, and Lateral Flow Assay for SARS-CoV-2 Serologic Assays"
331,Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates
332,Boletim do Observatório Covid-19 -semanas 31 e 32 de 2021
333,World Health Organization. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
334,"COVID-19-associated hospitalizations mong vaccinated and unvaccinated adults ≥18 years -COVID2 NET, 13 states"
335,Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice
336,Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
337,Acute pericarditis
338,Emerging SARS-CoV-2 variants reduce neutralization 405 sensitivity to convalescent sera and monoclonal antibodies
339,"Population and Housing Census, Census"
340,Covid-19 deaths in Africa: prospective systematic postmortem surveillance study
341,"Sinovac's COVID-19 shot is 83% effective, not 91%, Turkey says"
342,Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity
343,Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination
344,Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices-United States
345,Ad26 vectorbased COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses
346,Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines (Basel)
347,Serum Neutralizing Activity of 878 mRNA-1273 against SARS-CoV-2 Variants
348,Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
349,Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections versus Breakthrough Infections
350,"European Centre for Disease Prevention and Control. COVID-19 Situation Update Worldwide, as of Week 49"
351,Covid-19 vaccine tracker
352,Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
353,Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
354,Vaccine effectiveness against infection with the delta (B.1.617.2) variant
355,Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
356,IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis
357,SARS-CoV-2 spreads through cell-to-cell transmission
358,Delivery systems for intradermal vaccination
359,Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation
360,Vaccine-associated hypersensitivity
361,"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis"
362,IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders
363,Events After COVID-19 mRNA Vaccination
364,Progress and Prospects on Vaccine Development Against SARS-CoV-2. Vaccines (2020)
365,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among 678
366,Susceptibility of Circulating 832 SARS-CoV-2 Variants to Neutralization
367,Virological and serological 704 kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort 705 study
368,What do we know about China's covid-19 vaccines?
369,Identification of Novel Consensus CD4 T-Cell Epitopes From Clade B HIV-1 Whole Genome That Are Frequently Recognized by HIV-1 Infected Patients
370,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses
371,Guidelines for Standard Criteria for Adverse Events in Clinical Trials of Vaccines
372,Cellular and humoral immune responses in Covid-19 and immunotherapeutic approaches
373,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
374,Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
375,Rapid healing with topical INH powder
376,Welcome to the Tidyverse
377,"COVID-19 Epidemic in Malaysia: Epidemic Progression, Challenges, and Response. Front. Public Health"
378,Over 1.8 bln doses of COVID-19 vaccines administered in China
379,Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac
380,Genomics and 428 epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
381,"Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes"
382,Heterologous Prime-Boost Vaccination
383,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
384,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R)"
385,"Table Table: Age, sex and geometric mean 50% plaque reduction neutralization test (PRNT 50 ) titres vs"
386,Maternal and Perinatal Outcomes in Patients with Suspected COVID-19 and Their Relationship with a Negative RT-PCR Result
387,SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network
388,Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults
389,Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan
390,Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv
391,Complete mapping of mutations to the SARS-CoV-2 spike 462 receptor-binding domain that escape antibody recognition
392,International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis?
393,Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
394,Surveillance on emerging coronavirus variant of concern (VOCs) on
395,Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
396,SARS-CoV-2 Variants of Concern and Variants Under Investigation in England
397,"Russia's Sputnik V shot around 90% effective against Delta variant, developers say. Reuters"
398,Strategies for Vaccine Prioritization and Mass Dispensing. Vaccines
399,Unconditional or Conditional logistic regression model for age-matched case-control data. Front Public Health
400,"Reported RT-PCR or Antigen confirmed COVID-19 rates in the general population of the São Paulo State, Brazil from"
401,SARS-CoV-2 Detection by Nasal Strips: A Superior Tool for Surveillance of Paediatric Population
402,R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing
403,"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges"
404,"Food and Drug Administration, Ministry of Public Health, Thailand. Details of Medicinal Product"
405,Neurological Events Reported after COVID
406,Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
407,The Architecture of SARS-CoV-2 Transcriptome
408,"-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
409,"Excess deaths associated with COVID-19, by age and race and ethnicity: United States"
410,Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission
411,Informes e notas técnicas
412,Will Omicron finally overpower China's COVID defences?
413,The immunogenicity and safety of different COVID-19 booster vaccination following 1
414,and Author Information Accepted for Publication
415,Influence of immune aging on vaccine responses
416,China's COVID vaccines have been crucial -now immunity is waning
417,Prevention and 690 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
418,"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group"
419,Correlates of protection against SARS-CoV-2 in rhesus macaques
420,Highlights from the meeting of the strategic advisory group of experts (SAGE) on immunization
421,Centro de Vigilância Epidemiológica
422,The relationship between influenza vaccine-induced specific antibody responses and vaccine-induced nonspecific autoantibody responses in healthy older women
423,Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
424,"Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity Keywords COVID-19 · Immunogenicity · Safety · SARS-CoV-2 · Sjögren's syndrome · Vaccine"
425,Analysis by real-time pcr of five transport and conservation medium of nasopharyngeal swab samples to covid-19 diagnosis in Santiago of Chile
426,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data"
427,Post-adenoviral-based vaccines Guillain-Barre Syndrome: A proposed mechanism
428,Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. InSeminars in Arthritis and Rheumatism
429,World Health Organization W. Evaluation of COVID-19 vaccine effectiveness
430,Novel coronavirus 2019 (COVID-19) pandemic outbreak: a comprehensive review of the current literature
431,"Development of an inactivated vaccine candidate, BBIBPCorV, with potent protection against SARSCoV2"
432,COVID-19 vaccine hesitancy among medical students
433,Data from the Ministry of Public Health
434,Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
435,The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
436,"Effectiveness of inactivated COVID-19 vaccines against illness caused by the B.1.617.2 (Delta) variant during an outbreak in Guangdong, China: a cohort study"
437,"SARS-CoV-2/ COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
438,"reactogenicity, and immunogenicity of homologous and heterologous primeboost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study"
439,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet
440,Iads-Score. Universal predictors of dental students' attitudes towards COVID-19 vaccination: machine learning-based approach
441,World Health Organization W. WHO SAGE Roadmap For Prioritizing Uses Of
442,Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers
443,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study"
444,PMCID:PMC8213359)
445,A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19
446,Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
447,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
448,Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
449,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
450,"Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis"
451,Safety and Efficacy of 446 the BNT162b2 mRNA Covid-19 Vaccine
452,Anonymized datasets generated for the current study are available from the corresponding author upon reasonable request
453,Role of genetic variants and gene expression in the susceptibility and severity of COVID-19
454,the USA: a retrospective cohort study
455,Thai Healthcare Workers. medRxiv
456,SARS-CoV-2 immunity: review and applications to phase 3
457,Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men
458,Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
459,Statistics in Clinical Vaccine Trials
460,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coro-naVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
461,A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
462,Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review. Vaccine
463,Factors associated with COVID-19 vaccine hesitancy
464,COVID-19 vaccine hesitancy: A survey in a population highly compliant to common vaccinations
465,The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
466,"Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. medRxiv"
467,Microchip-based structure determination of low-molecular weight proteins using cryo-electron microscopy
468,Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
469,Chinese COVID-19 Vaccine Candidate the First to Start Phase 3 Clinical Trials Worldwide
470,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia"
471,C4591001 clinical trial group: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
472,Diagnostic and therapeutic aspects of hemiplegic migraine
473,COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir. Viruses
474,Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity
475,"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel)"
476,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight US locations"
477,who-director-general-s-opening-remarks-at-the-media-briefing-on-covid
478,Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
479,Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19
480,Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)
481,Vaccine -United States
482,"Aceptado para su publicación, tras revisión, el 13 de octubre del 2021. coronavirus-vacuna-plan-estrategico-vacunacion-covid-19-diciembre -2020.pdf 26. Ministério da Saúde"
483,COVID-19 Vaccine Tracker
484,Dynamics of antibody response to CoronaVac vaccine Funding information
485,"Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
486,Prevalence and outcome of COVID-19 infection in cancer patients: a National Veterans Affairs study
487,Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
488,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence"
489,Respiratory Syndrome Coronavirus 2 T-Cell Response
490,"Safety and efficacy 470 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 471 randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
491,Phase II/III Study of COVID-19 DNA Vaccine (AG0302-COVID19)-Full Text View-ClinicalTrials.gov
492,"Immunogenicity and safety of two-visit, intradermal pre-exposure rabies 559 prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis 560 vaccine in children living in rabies and Japanese encephalitis endemic country"
493,Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world
494,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination -Kentucky
495,Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
496,Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
497,Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa
498,Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Survival at Intensive Care Unit: A Cross-sectional Study
499,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled"
500,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
501,Antibody status and incidence of SARS-CoV-2 infection in health care workers
502,The structural and functional damages of whole body ionizing radiation on rat brain homogenate membranes and protective effect of amifostine
503,Mild or moderate Covid
504,Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
505,Efficacy of Important COVID-19 Vaccine in Real-World
506,BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
507,Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus
508,Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain
509,COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
510,Molecular Screening
511,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: A retrospective analysis of nationwide data"
512,The hindrances to perform the COVID-19 vaccination in Brazil
513,"Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study"
514,Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study)
515,Incidence of post-vaccination adverse events in children
516,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex
517,A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2
518,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2"
519,Increased mortality in 423 community-tested cases of SARS-CoV-2 lineage B.1.1.7
520,"Secretaria de Vigilância em Saúde, Departamento de Imunizações e Doenças Transmissíveis. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação"
521,Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study
522,Neutralizing antibody 931 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
523,Virological 708 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers 709
524,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
525,European Medicines Agency. 2021. COVID-19 Vaccine AstraZeneca. AMSTERDAM: European Medicine Agency
526,A comparison of plasmid DNA and mRNA as vaccine technologies
527,"Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
528,Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adults
529,Suspending social vaccination against COVID-19 and concentrating on case findings
530,"Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers"
531,Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
532,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia"
533,Seasonal influenza vaccine in immunocompromised persons
534,Spatiotemporal pattern of COVID-19 spread in Brazil
535,Covid-19 Vaccine Effectiveness in New York State
536,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
537,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
538,COVID-19) Dashboard with Vaccination Data
539,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
540,ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine
541,SARS-CoV-2 Testing in Elective Surgery Collaborators. A dual-antigen enzyme-linked immunosorbent assay allows the assessment of severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in a low-transmission setting
542,Performance of vaccination with coronavac in a cohort of healthcare workers (HCW) -preliminary report
543,The Government of the Hong Kong Special Administrative Region. Vaccination priority groups to be expanded to cover people aged 30 or above
544,"The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses"
545,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial"
546,Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity
547,Real world effectiveness of covid-19 vaccines
548,The effect of covid-19 on the economy: Evidence from an early adopter of localized lockdowns
549,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial"
550,Association between 3 doses of mRNA COVID-19 Vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants
551,Covid-19: a brief overview of the discovery clinical trial
552,Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
553,Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases
554,Impact of prior influenza and pneumoccocal vaccines on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. Vaccines (Basel)
555,Coverage of COVID-19 Vaccines In Electronic Healthcare Databases: A Protocol Template From The ACCESS Project
556,Adenovirus receptors and their implications in gene delivery
557,Impact of maternal immunization on influenza hospitalizations in infants
558,Association between COVID-19 and myocarditis using hospital-based administrative data -United States
559,Neutralizing activity of BNT162b2-elicited serum-Preliminary report
560,"Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: A systematic review and meta-analysis"
561,Africa's preparedness towards COVID-19 vaccines: Demand and acceptability challenges
562,Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
563,SARS-CoV-2 Vaccines in Development
564,Electron microscopy of SARS-CoV-2: a challenging task
565,Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by 618
566,Seasonal influenza vaccine-induced pneumonitis presenting with multiple pulmonary nodules
567,A human coronavirus evolves antigenically to escape antibody immunity
568,Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant
569,"Severe acute respiratory syndrome coronavirus 2 P.2 lineage associated with reinfection case, Brazil"
570,ASIA syndrome and endocrine autoimmune disorders
571,Neutralizing Activity of 789 BNT162b2-Elicited Serum
572,Antibodies and vaccines target RBD of SARS-CoV-2
573,A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
574,Convergent antibody responses to SARS-400
575,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin
576,How could a COVID vaccine cause blood clots? Scientists race to investigate
577,Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel) 2021
578,"Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice"
579,COVID-19 vaccines: where we stand and challenges ahead
580,Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
581,COVID-19 Aşısı Ulusal Uygulama Stratejisi
582,Plano Nacional de Operacionalização da Vacinação Contra a COVID-19
583,Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay
584,Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine
585,"Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy"
586,"Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence -China, 2021"
587,COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1
588,Homeostatic proliferation of B cells
589,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
590,"Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort"
591,Centre for Health Protection. Hong Kong Vaccination Dashboard
592,Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey
593,BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
594,Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2
595,WHO Coronavirus (COVID-19) Dashboard
596,"Public Health Service (PHS), Centers for Disease Control (CDC) /Food and Drug Administration (FDA)"
597,A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)
598,Government of the Hong Kong Special Administration Region. Government tightens restrictions and compulsory quarantine requirements for persons arriving at Hong Kong who have stayed in places outside China
599,Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
600,Effectiveness of covid-19 vaccines against the B16172 (Delta) variant
601,Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants
602,Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review
603,Understanding Vaccine Hesitancy around Vaccines and Vaccination from a Global Perspective: A Systematic Review of Published Literature
604,Immunological memory to SARS-CoV-2 assessed for up to 8 months 478 after infection
605,Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized
606,Antibody Responses in Seropositive 468 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
607,Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
608,Explosion in mortality in the Amazonian epicenter of the COVID-19 epidemic 19. Cad
609,Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein
610,Comparison of 875 Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-876
611,Multiple drug hypersensivity: insight into the underlying mechanism and correlation with autoimmune diseases
612,Levantamento -Plano de Vacinação nos Estados e nas Cidades do Brasil
613,"STF obriga governo a priorizar indígenas urbanos em vacinação, mas medida ainda tem obstáculos"
614,"Title: Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study Author names and affiliations: Antibody kinetics in HCWs after CoronaVac vaccination"
615,Nota Técnica N° 467/2021-CGPNI/DEIDT/ SVS/MS -Vaccination for pregnant and postpartum women without comorbidities
616,"Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial"
617,Estados · observatório covid-19 br
618,The immune response to influenza in older humans: beyond immune senescence
619,An analysis on the anti-vaccination movement in Turkish digital platforms: Ekşisözlük and Facebook. Eskişehir Türk Dünyası Uygul. Araştırma Merk. Halk Saglıgı Derg
620,Cancer treatment during COVID-19 pandemic
621,Comparison of the immunogenicity of bnt162b2 and coronavac COVID-19 vaccines in hong kong
622,Secretaria de Vigilância em Saúde. Painel Coronavírus
623,West Nile virus: recent trends in diagnosis and vaccine development
624,Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile
625,Sars vaccines: where are we?
626,for technical support; all individuals involved in the diagnosis and generation of SARS-CoV-2 sequences as part of the CADDE-Genomic-Network; and the MCTI and all members of the Corona-ômica network for support
627,New onset guttate psoriasis following pandemic H1N1 influenza vaccination
628,Correlation of SARS-CoV-2-breakthrough infections to time-fromvaccine
629,BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
630,Socioeconomic status determines covid-19 incidence and related mortality in santiago
631,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
632,Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273
633,"COVID-19 in association with development, course, and treatment of systemic autoimmune rheumatic diseases"
634,"COVID-19 Vaccination and Cancer, the Need for More Data"
635,"Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) for 766 the Scientific Advisory Group for Emergencies (SAGE). SPI-M-O: Consensus statement on 767 COVID-19"
636,Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study
637,Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treatment Guidelines; 2021. National Institute of Health
638,"examined 19 hydrolysable tannins against 3CLpro of SARS-CoV-2, and they found that of these (Figure 25), pedunculagin (205), tercatain (206) and castalin (207) showed the best binding affinities of −18.58, −23.11 and −14.04 kcal/mol, respectively, on the selected target"
639,ATR-FTIR spectroscopy for virus identification: a powerful alternative
640,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary serie. medRxiv
641,SARS-CoV-2 Omicron Has Extensive but Incomplete Escape of Pfizer BNT162b2 Elicited Neutralization and Requires ACE2 for
642,Part II-The Positive Sense Single Stranded RNA Viruses
643,"Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network -United States"
644,Bullous pemphigoid and COVID-19 vaccine
645,Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination
646,Transcriptome-wide off-target effects of steric-blocking oligonucleotides
647,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: Interim results from a double-blind, randomized"
648,A rare case of shingles after covid-19 vaccine: is it a possible adverse effect?
649,Subacute thyroiditis following seasonal influenza vaccination
650,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
651,Bats as reservoirs of severe emerging infectious diseases
652,Geneva: WHO
653,Clinical characteristics of 852 patients with subacute thyroiditis before treatment
654,WHO. COVID-19 Clinical Management: Living Guidance
655,Effect of Vaccination on 712 Household Transmission of SARS-CoV-2 in England
656,Novel prime-boost vaccine strategies against HIV-1. Expert review of vaccines
657,Republic of Turkey Ministry of Health. Frequently Asked Questions. COVID-19 Vaccination Information Platform
658,Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
659,Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland
660,Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
661,Safety of COVID-19 vaccines administered in the EU: should we be concerned?
662,Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination
663,CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
664,Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
665,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
666,"Vaccine Hesitancy: COVID-19 and Influenza Vaccine Willingness among Parents in Wuxi, China-A Cross-Sectional Study"
667,Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
668,China's COVID vaccines have been crucial-Now immunity is waning
669,Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials
670,SARS-CoV-2 vaccines in development
671,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind"
672,Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy
673,CoV-2 variants by convalescent and vaccinated serum. medRxiv. 9 avr 809 2021
674,SARS-CoV-2 B. 1.1. 529 variant (Omicron
675,"Reduced 914 neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1"
676,ChAdOx1 Overall infection N/A 64%
677,"Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) microscope. For IHC staining, to identify the expression of SARS-CoV-2 S protein"
678,Vaccine allergy
679,"Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
680,Cidara: Membership on an entity's Board of Directors or advisory committees
681,SARS-CoV-2 specific antibody responses after third coronavac or bnt162b2 vaccine following two-dose coronavac vaccine regimen
682,Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNTech and Moderna mRNA vaccines
683,Months After SARS-CoV-2 Infection. Front Immunol
684,Cationic liposome-mediated RNA transfection
685,Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
686,COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection
687,"Safety and immunogenicity of a candidate Middle East 639 respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-640 label, non-randomised, uncontrolled, phase 1 trial. The Lancet Infectious Diseases"
688,Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS
689,Spike mutation D614G alters SARS-CoV-2 fitness
690,Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting
691,"The Janssen COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events"
692,SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
693,"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis"
694,Public health surveillance for COVID-19. Interim guidance
695,Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine
696,Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 1 Infection and Severe Disease in Singapore
697,Fiocruz detecta mutação associada a variantes de preocupação no país
698,CoV-2 S peptides. A pilot study in Health Care Workers
699,CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis
700,COVID-19) -the data -Statistics and Research
701,Factors that influence the immune response to vaccination
702,Review on up-to-date status of candidate vaccines for COVID-19 disease
703,Coronavac induces lower neutralising activity against variants of concern than natural infection
704,WHO declares COVID-19 a pandemic
705,Intradermal COVID-19 vaccination could solve supply problems
706,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A testnegative case-control study"
707,Development of an inactivated vaccine candidate for 484 SARS-CoV-2
708,Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination
709,The people's vaccine: How a covid-19 vaccine will be a test of global accountability and equity
710,Potential ınteraction between SARS-CoV-2 and thyroid: a review. Endocrinology
711,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study
712,Brazilian Ministry of Health
713,Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis
714,Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine. Vaccines
715,Early Release -Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-686
716,Basophil activation test application in drug hypersensitivity diagnosis: an empirical approach
717,AdviseDx SARS-CoV-2 IgG II instructions for use
718,Neutrilizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patients cohort and their implications
719,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience"
720,Comprehensive Assessment of Humoral Response After Pfizer BNT162b2 mRNA Covid-19 Vaccination: A Three-Case Series
721,Humoral responses and serological assays in SARS-CoV-2 infections
722,SARS-CoV-2 vaccines: Lights and shadows
723,T cell response to SARS-CoV-2 infection in humans: a systematic review
724,"Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality"
725,Single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
726,Time interval between onset of symptoms and COVID-19 testing in Brazilian state capitals
727,Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils
728,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel)
729,Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
730,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: preclinical studies
731,IFN-Gamma) Technical Document
732,Subacute thyroiditis after hepatitis B vaccination
733,Long-Term Protection at 20-31 Years After Primary Vaccination With Plasma-Derived Hepatitis B Vaccine in a Chinese Rural Community
734,Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients
735,mRNA vaccines-A new era in vaccinology
736,"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"
737,Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
738,"Transmission dynamics of the delta variant of SARS-CoV-2 infections in Daejeon, South Korea"
739,mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
740,Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria
741,Who should be vaccinated first? Comparing vaccine prioritization strategies in Israel and European countries using the Covid-19 Health System Response Monitor
742,CoronaVac COVID-19 vaccineinduced anaphylaxis: clinical characteristics and revaccination outcomes
743,Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months
744,Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus 2 heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Professor of Pediatrics
745,Naming SARS-CoV-2 variants
746,Vaccination-Protection for those most at risk of Influenza Denmark: World Health Organization; 2022 [Protection for those most at risk of Influenza
747,Delayed onset of clozapineinduced leucopenia
748,COVID-19 vaccine development and a potential nanomaterial path forward
749,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
750,Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine
751,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind"
752,Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards
753,Serum-based diagnostic prediction of oral submucous fibrosis using FTIR spectrometry
754,Effectiveness of BNT162b2 647 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers
755,A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2
756,Immunity to SARS-CoV-2: Lessons Learned. Front Immunol
757,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial"
758,SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
759,World Health Organization. World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. World Health Organization
760,Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study
761,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
762,Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series
763,Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
764,Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study
765,Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-a multicenter study
766,Quantifying adenovirusneutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
767,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID19 vaccine (ComCOV): a singleblind, randomised, noninferiority trial"
768,The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
769,CoV-2 Vaccine
770,Evaluation of the QuantiFERON SARS-CoV-2 interferon-G release assay in mRNA-1273 vaccinated health care workers
771,Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
772,COVID-19 Vaccine acceptance of pregnant and lactating women (PLW) in Czechia: an analytical cross-sectional study
773,Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
774,What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule
775,Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
776,National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines
777,IDSA clinical practice guideline for vaccination of the immunocompromised host
778,Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
779,gclid= CjwKC Ajwvu GJBhB 1EiwA CU1Ai dX-t9s2o kQDMm PxKmJ-pL9iA zrq0L ZrTJb GcmQx mWAzg D6yCi Jjbxo CZl4Q AvD_ BwE
780,"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study"
781,Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
782,"Effectiveness of BNT162b2 and 1079 ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 1080 80 years: a test-negative, case-control study"
783,"Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study"
784,Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
785,What policy makers need to know about COVID-19 protective immunity
786,A nationwide cohort study
787,Vaccines 2021
788,Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
789,Infection and vaccine-induced neutralizing-antibody 453 responses to the SARS-CoV-2 B.1.617 variants
790,Repurposed antiviral drugs for COVID-19 -interim WHO Solidarity Trial results
791,Populist politics and vaccine hesitancy in Western Europe: An analysis of national-level data
792,Kawasaki disease and immunisation: A systematic review
793,Optic neuritis and myelitis after booster tetanus toxoid vaccination
794,Treatment of antiphospholipid syndrome
795,Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
796,Comparing the clinical efficacy of COVID-19 14 vaccines: a systematic review and network meta-analysis
797,The interplay between HIV and COVID-19: Summary of the data and responses to date
798,Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19
799,"Veesler D (2020b) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
800,Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
801,COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses
802,Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
803,"A review of novel coronavirus disease ( COVID -19 ): based on genomic structure , phylogeny , current shreds of evidence , candidate vaccines , and drug repurposing"
804,Advances in gene-based vaccine platforms to address the COVID-19 pandemic
805,A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
806,Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis
807,Accessed on 22 nd February 2022 499 2. The New York Times. Tracking Coronavirus Vaccinations Around the World
808,Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals
809,"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes"
810,COVID-19 Vaccine Tracker and Landscape
811,"), and National Institute of Allergy and Infectious Diseases (ZIA AI001273). JDS, LRG and BMA have received postdoctoral fellowships by the Brazilian Ministry of Health while conducting this study. References Artic Network"
812,Covid-19 vaccines: delivering protective immunity
813,Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
814,COVID-19 vaccines: the status and perspectives in delivery points of view
815,Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine. Emerg Infect Dis
816,Learning from the past: development of safe and effective COVID-19 vaccines
817,Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1
818,"COVID-19: progress in diagnostics, therapy and vaccination"
819,Striking antibody evasion manifested by the Omicron 388 variant of SARS-CoV-2
820,Evolution of antibody immunity to SARS-CoV-2. bioRxiv
821,Pan American Health Organization. Case definitions for COVID-19 surveillance
822,Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2
823,Immune Correlates of Protection by mRNA-1273
824,World Health Organization Reference Panel. First WHO international reference panel for anti-SARS-CoV-2 immunoglubulin NIBSC code: 20/268 instructions for use
825,Tracking SARS-CoV-2 variants
826,Covid-19: Chile joins top five countries in world vaccination league
827,Case of Guillain-Barré syndrome following COVID-19 424 vaccine
828,COVID-19: Prevention and control measures in community
829,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: Comparison with neutralization titers
830,"Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. Quest answers"
831,COVID-19 Vaccination for People with Comorbidities
832,"Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government"
833,"Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant"
834,Identification of a novel coronavirus in patients with severe acute respiratory syndrome
835,CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
836,"active site C, respectively"
837,"Peripheral innate and adaptive immune cells during COVID-19: Functional neutrophils, pro-inflammatory monocytes and halfdead lymphocytes"
838,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
839,Economic value of treatment and vaccine to address the COVID-19 pandemic
840,Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease
841,"Egypt to vaccinate children aged between 15, 18 against COVID-19"
842,Recent advances in design of immunogenic and effective naked DNA vaccines against cancer
843,Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
844,Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test
845,SARS-CoV-2 IgG II Quant Assay User Manual
846,Pfizer-BioNTech and Sinopharm: A 19 Comparative Study on Post-Vaccination Antibody Titers
847,Effectiveness of the CoronaVac Vaccine in the Elderly Population During a P.1 Variant-Associated Epidemic of COVID-19 in Brazil: A Test-Negative Case-Control Study
848,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2
849,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) -preliminary report
850,Innate immune sensing of coronavirus and viral evasion strategies
851,Safety of the BNT162b2 1048 mRNA Covid-19 Vaccine in a Nationwide Setting
852,Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency
853,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
854,"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study"
855,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv
856,Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy
857,Social Media Vaccine Websites: A Comparative Analysis of Public and Moderated Websites
858,World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021
859,Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
860,US authorization of first COVID vaccine marks new phase in safety monitoring
861,Early Programming and Late-Acting Checkpoints Governing the Development of CD4 T-Cell Memory
862,Operacionalização Da Vacinação Contra a Covid-19
863,Vaccinations in patients with immunemediated inflammatory diseases
864,Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
865,World Health Organization. COVID-9 Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide
866,Spreading depression and the clinical correlates of migraine
867,Vaccines Candidates by Trial Phase
868,Understanding Viral Vector COVID-19 Vaccines|CDC
869,Vaccine effectiveness when combining the ChAdOx1 vaccine as 636 the first dose with an mRNA COVID-19 vaccine as the second dose
870,The Equitable Distribution of COVID-19 Therapeutics and Vaccines
871,BNT162b2 mRNA COVID-19 Vaccine in AYA with cancer: A monocentric experience
872,"A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
873,Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-a nationwide survey
874,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study
875,Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
876,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. 2021. received. *A seropositivity of neutralizing antibody against SARS-CoV-2 before receiving a boost vaccination"
877,Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
878,Reactogenicity and immunogenicity after a late second dose or a third dose of chadox1 ncov-19 in the uk: A substudy of two randomised controlled trials (cov001 and cov002)
879,Prevention of dabigatranrelated gastrointestinal bleeding with gastroprotective agents: a population-based study
880,New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
881,"Antibodies Against Receptor Binding Domain of SARS-CoV-2 Spike Protein Induced by BNT162b2 Vaccine: Results From a Pragmatic, Real-Life Study"
882,Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -united states
883,Safety and efficacy 270 of the BNT162b2 mRNA Covid-19 vaccine
884,Age-related changes in lymphocyte development and function
885,Vaccine allergy: evidence to consider for COVID-19 vaccines
886,Prediction of long-term kinetics of vaccine- elicited neutralizing antibody and time- varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
887,"Aging in COVID-19: vulnerability, immunity and intervention"
888,"Confronting the Delta variant of SARS-CoV-2, Summer"
889,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
890,Population By-census-Thematic Report: Ethnic Minorities
891,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VI-VALDI): a prospective cohort study
892,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine 646 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised 647 controlled trial"
893,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
894,Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination
895,"but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases"
896,Heterologous versus homologous COVID-19 booster 573 vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in 574
897,Assessment: Sinopharm/BBIBP COVID-19 vaccine
898,Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight
899,The continuous 775 evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations 776 of concern and global detection
900,Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection
901,Neutralizing Activity of BNT162b2-Elicited Serum
902,BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant
903,Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease
904,Covid-19 Vaccine Tracker: Latest Updates -The New York Times
905,Sinovac Shot Shown 78% Effective in Brazil after Data Confusion. Bloomberg News
906,"Development of an inactivated vaccine candidate, BBIBP-corv, with potent protection against SARS-cov-2"
907,Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
908,Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
909,WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
910,Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center
911,Omicron and Delta Variants
912,Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
913,Ranking treatments in frequentist network meta-analysis works without resampling methods
914,Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
915,Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
916,IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
917,Instituto Brasileiro de Geografia e Estatística (IBGE)
918,"SARS-CoV-2 Variants, Spike Mutations and Immune Escape"
919,COVID-19 vaccine Spikevax Approved for children aged 12 to 17 in EU
920,Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant
921,"The impact of Vaccination worldwide on SARS-CoV-2 infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants"
922,Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study
923,Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection
924,Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques
925,"Data, design, and background knowledge in etiologic inference"
926,COVID-19 in Cancer and Non-Cancer Patients
927,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis
928,HIV/SARS-CoV-2 coinfection: A global perspective
929,Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
930,"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2"
931,COVID-Pain: Acute and Late-Onset Painful Clinical Manifestations in COVID-19-Molecular Mechanisms and Research Perspectives
932,World Health Organization. COVID-19 clinical management: living guidance
933,The race for coronavirus vaccines: a graphical guide
934,SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
935,mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant
936,"Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine"
937,Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
938,Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
939,Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
940,Coronavirus vaccines leap through safety trials -but which will work is anybody's guess
941,Antibody response to SARS-CoV-2 infection in humans: a systematic review
942,Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
943,The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
944,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebocontrolled phase 2 clinical trial"
945,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind"
946,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
947,Adverse effects of the COVID-19 vaccine reported by lecturers and staff of Kabul University of medical sciences
948,Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the covid-19 era
949,"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations"
950,Reduced mortality rate after coronavac vaccine among healthcare workers
951,WHO international standard for anti-SARS-CoV-2 immunoglobulin
952,Safety and efficacy of an 483 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis 484 of a randomised controlled phase 3 trial in Russia
953,SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
954,"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis"
955,A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
956,How cooperative engagement programs strengthen sequencing capabilities for biosurveillance and outbreak response
957,Thailand sticks with Sinovac vaccine after cases of''stroke-lik'' side effects
958,Draft Landscape of COVID-19 Candidate Vaccines
959,Hospitalisation among vaccine breakthrough COVID-19 infections
960,Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
961,Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations
962,In vivo kinetics of SARS-CoV-2 infection and its relationship with a persons infectiousness
963,Preparation of viruslike particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells
964,Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
965,A Package for Survival Analysis in R.; 2021
966,Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
967,"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans"
968,Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant
969,Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
970,Herd Immunity: Understanding COVID-19
971,Intradermal chadox1 vaccine following two coronavac shots: A case report
972,Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system
973,Interim Public Health Considerations for COVID-19 Vaccination of Adolescents in the EU/EEA
974,Organization WH (2021) Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization
975,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience
976,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
977,Vaccines for the elderly
978,Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
979,"Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study"
980,Should a third booster dose be scheduled after two doses of coronavac? A single-center experience
981,"Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial"
982,Diyanet: Salgında Aşı Yaptırmamak Kul Hakkına Girer
983,Levels of SARS-CoV-2 lineage P.1 neutralization by antibodies elicited after natural infection and vaccination
984,SARS-CoV-2 Variants and Vaccines
985,The N501Y Spike Substitution Enhances SARS-CoV-2 Transmission
986,Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
987,Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
988,The Turkish Ministry of Health Covid19 information page n.d
989,"CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, openlabel, randomised, controlled, phase 2 trial"
990,Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab
991,CoV-2 Vaccine in Chile
992,A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh
993,"BNT162b2 Vaccine-Induced Immune Responses and Dynamics Vary Among Age Groups, Sex and Co-Morbidities: A Longitudinal Prospective Cohort Study n"
994,Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
995,Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions
996,Profiling Cases With Nonrespiratory Symptoms and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Mexico City
997,"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2"
998,Identification of a SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations
999,A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State
1000,Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
1001,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers"
1002,Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America
1003,What we know about the COVID-19 immune response: the latest on COVID-19 immunity & the current global situation (Coronavirus Update 34
1004,Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group
1005,Coronavirus: Vaccination
1006,Isolation of whole mononuclear cells from peripheral blood and cord blood
1007,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
1008,An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
1009,Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination
1010,Antibody-dependent enhancement and COVID-19: moving toward acquittal
1011,2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
1012,"Allele frequency net database (AFND) 2020 update. How to cite this article: Noikongdee P, Police P"
1013,What can we learn from Israel's rapid roll out of COVID-19 vaccination?
1014,Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19
1015,IgA dominates the early neutralizing antibody 199 response to SARS-CoV-2
1016,Three SARS-CoV-2 Reinfection Cases by the New Variant of Concern (VOC) P.1/501Y.V3. PREPRINT Available at Research Square
1017,Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
1018,The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients
1019,"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies"
1020,Mini-Review Discussing the reliability and efficiency of COVID-19 vaccines
1021,"The international EAACI/GA2LEN/EuroGuiDerm/ APAAACI guideline for the definition, classification, diagnosis, and management of urticaria"
1022,Covid-19: Canada relaxes age limits on AstraZeneca vaccine as Ontario cases surge
1023,Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil
1024,Effectiveness of 682 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the 683 USA: a retrospective cohort study. The Lancet
1025,"Recombinant protein vaccines, a proven approach against coronavirus pandemics"
1026,SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination
1027,The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review of the current global status
1028,Factors That Influence the Immune Response to Vaccination
1029,SARS-CoV-2 Isolation From the First Reported Patients in Brazil and Establishment of a Coordinated Task Network
1030,Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
1031,World Health Organization. COVID-19 advice for the public: Getting vaccinated
1032,Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark
1033,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study"
1034,Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings
1035,Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis b vaccine with a novel adjuvant
1036,The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older
1037,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
1038,"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect"
1039,A Review of the progress and challenges of developing a vaccine for COVID-19
1040,Structural basis of receptor recognition by SARS-CoV-2
1041,Manual para la elaboración de análisis de impacto presupuestal
1042,COVID-19 vaccines and vaccine administration
1043,Heterologous ChAdOx1 nCoV19 and mRNA1273 vaccination
1044,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1045,Malaysia: Ministry of Health Malaysia
1046,Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay
1047,The overlooked superpower of mRNA vaccines
1048,Criteria for the diagnosis of familial Mediterranean fever
1049,Vaccine Safety: Evidence-based research must prevail
1050,The post primary series GMC 623 (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac
1051,New-onset cutaneous lichen planus triggered by COVID-19 vaccination
1052,Increased 763 transmissibility and global spread of SARS-CoV-2 variants of concern as at
1053,Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for 1098 COVID-19. medRxiv
1054,"Covid-19: How the UK vaccine rollout delivered success, so far"
1055,Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
1056,Journal Pre-proof Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine Type 1 Kounis syndrome induced by inactivated SARS- CoV-2 vaccine
1057,IgG subclasses and allotypes: From structure to effector functions
1058,The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013
1059,Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies
1060,Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review
1061,RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study
1062,Peraturan Presiden Republik Indonesia Nomor 14 Tahun 2021
1063,"SARS-CoV-2 variants, spike mutations and 384 immune escape"
1064,reactive T cells in healthy donors and patients with COVID-19
1065,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
1066,Receipt of mRNA Covid-1036 19 Vaccines and Risk of Spontaneous Abortion
1067,Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series -465 Health Care Facilities
1068,Adenovirus receptors
1069,Global burden of COVID-19: situational analysis and review
1070,Mortality in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. Rheumatology (Oxford) keab364
1071,A single-cell atlas of the peripheral immune response in patients with severe COVID-19
1072,279 non-serious AEFI 81
1073,"Case-control vaccine effectiveness studies: Data collection, analysis and reporting results"
1074,Could mixing COVID vaccines bolster immune response?
1075,Optic neuritis after meningococcal vaccination
1076,Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents
1077,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
1078,Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
1079,Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals
1080,The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety
1081,"Lymphocyte Homing to Bronchus-Associated Lymphoid Tissue (BALT) Is Mediated by L-Selectin/PNAd, Alpha4beta1 Integrin/VCAM-1, and LFA-1 Adhesion Pathways"
1082,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
1083,Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
1084,Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine
1085,The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
1086,Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?
1087,Effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers
1088,National Pharmaceutical Regulatory Agency (NPRA); Ministry of Health Malaysia. Frequently Asked Questions (FAQ) about COVID-19 Vaccine
1089,Effectiveness and Durability of Protection against Future SARS-CoV-2 Infection Conferred by COVID-19 Vaccination and Previous Infection; Findings from the UK SIREN Prospective Cohort Study of Healthcare Workers
1090,Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
1091,AstraZeneca to Deliver Six Million COVID-19 Vaccine Doses in THAILAND
1092,Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs
1093,The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution
1094,World Health Organization. WHO R&D Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis
1095,Prolonged hemiplegic migraine associated with unilateral hyperperfusion on perfusion weighted magnetic resonance imaging
1096,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study
1097,Half-vs full-dose trivalent inactivated influenza vaccine
1098,Minist erio da Sa ude. COVID-19 vacinação -distribuição de vacinas
1099,Immunogenicity of a DNA vaccine candidate for COVID-19
1100,"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination"
1101,Economic evaluation for mass vaccination against COVID-19
1102,Neurological complications of COVID-19: guillain-barre syndrome following pfizer COVID-19 vaccine
1103,Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
1104,World Health Organization. WHO Coronavirus (COVID-19) Dashboard.; 2021
1105,Omicron variants following heterologous CoronaVac plus BNT162b2 booster 581 vaccination
1106,Guillain-Barré syndrome associated with COVID-19 vaccination
1107,Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine
1108,Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with and without HIV-Infection
1109,Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies
1110,Effectiveness data of the COVID-19 vaccine collected in Israel until 13.2.2021
1111,Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review
1112,Pregnancy and COVID-19
1113,"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (covid-19): a review"
1114,Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
1115,Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19
1116,T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
1117,"Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection 480 in a Population in Lombardy, Italy"
1118,Un ensayo clínico evaluará una segunda dosis de la vacuna de 950
1119,Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination
1120,Animal and Human Coronavirus Disease
1121,CD107a as a functional marker for the identification of natural killer cell activity
1122,Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
1123,Potential host range of multiple SARSlike coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
1124,Influenza vaccination in patients with breast cancer: a case-series analysis
1125,Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
1126,Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern
1127,Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
1128,Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
1129,SARS-CoV-2-Specific T cell responses in patients with COVID-19 and unexposed individuals
1130,From vaccines to memory and back
1131,63rd ASH Annual Meeting Abstracts ONLINE PUBLICATION ONLY 632.CHRONIC MYELOID LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients
1132,Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
1133,Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
1134,SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
1135,Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
1136,Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
1137,La salud pública en la primera ola: una agenda para la cooperación ante Covid-19
1138,A Rapid Systematic Review of Public Responses to Health Messages Encouraging Vaccination against Infectious Diseases in a Pandemic or Epidemic
1139,Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in central Europe
1140,Global Vaccine Summit 2020
1141,Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
1142,A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
1143,Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
1144,Elevated biomarkers of sympatho-adrenomedullary activity linked to ewaste air pollutant exposure in preschool children
1145,SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
1146,The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data
1147,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
1148,Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
1149,"Effectiveness 1103 of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant 1104 transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health -Am 1105"
1150,"Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers"
1151,Understanding T-cell responses to COVID-19 is essential for informing public health strategies
1152,Does incubation period of COVID-19 vary with age? A study of epidemiologically linked cases in Singapore
1153,Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis
1154,An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
1155,Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
1156,Association of risk of suicide attempts with methylphenidate treatment
1157,Circular RNA vaccines against SARS-CoV-2 and emerging variants
1158,Ineffective 825 neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
1159,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021: published online
1160,Government of Chile. Effectiveness of the SARS-CoV-2 Vaccination Program
1161,"Local Transmission of SARS-CoV-2 Lineage, B.1.1.7, Brazil"
1162,Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
1163,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
1164,Pathologic Antibodies to Platelet Factor 4 after
1165,"Nadthanan Pinyosukhee 1 , Rattanawadee Wichajarn 1 Public Health 32"
1166,Vaccine breakthrough infections with SARS-CoV-2 variants
1167,COVID-19 Treatment and Vaccination Trackers
1168,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial"
1169,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study"
1170,Adverse events following immunization associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea
1171,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using 19 national surveillance data"
1172,Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
1173,A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination
1174,Second Quarter 2021 Financial Results and Operational Highlights
1175,Factors Associated with Parents' Willingness to Enroll Their Children in Trials for COVID-19 Vaccination
1176,"COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence"
1177,Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience
1178,WHO Statement on AstraZeneca COVID-19 Vaccine Safety Signals
1179,RoB 2: a revised tool for assessing risk of bias in randomised trials
1180,The emergence of new SARS-CoV-2 variant (omicron) and increasing calls for COVID-19 vaccine boosters-the debate continues
1181,Vaccines In The Context Of Limited Supply
1182,Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients
1183,Plan Nacional de Vacunación contra COVID-19
1184,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coron-aVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey"
1185,Turkish Medical Oncology Society COVID-19 pandemic advisory board updated recommendations for medical oncologists: included vaccination
1186,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
1187,Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
1188,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
1189,SARS-CoV-2 vaccinationinduced transverse myelitis
1190,Vaccine Breakthrough Infections With SARS-CoV-2 Variants
1191,Sars-cov-2 incidence and vaccine escape
1192,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines
1193,SARS-CoV-2: monitoramento -vigilância epigenômica
1194,"Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, ailand"
1195,"Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv 2021"
1196,Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents
1197,Oral Side Effects of COVID-19 Vaccine (OSECV). ClinicalTrials.gov. 2021
1198,Comparison 629 of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant 630 prevalence
1199,Neutralizing antibody levels are highly predictive of immune and Hospitalizations Among Adults During Periods of Delta and Omicron Variant 570
1200,Kenyataan Media Pejabat Perdana Menteri
1201,"Immunogenicity and Safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial. medRxiv"
1202,Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
1203,Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
1204,2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
1205,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
1206,Immunogenicity of Heterologous Prime/Booster-Inactivated and Adenoviral-Vectored COVID-19 Vaccine: Real-World Data
1207,SARS-CoV-2 B.1.1.529 (Omicron) Variant -United States
1208,Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
1209,COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment
1210,"Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England"
1211,Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
1212,First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing
1213,Population-based incidence and prevalence of systemic 563 lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program
1214,Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
1215,Qualitative assessment of early adverse effects of Pfizer-BioNTech and Sinopharm COVID-19 vaccines by telephone interviews
1216,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized"
1217,Dynamic igg seropositivity after rollout of coronavac and bnt162b2 COVID-19 vaccines in chile: A sentinel surveillance study
1218,The New York Times
1219,COVID-19 vaccine induced interstitial lung disease
1220,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, Phase 1/2 trial"
1221,Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries
1222,Fatal anaphylaxis in children in France: analysis of national data
1223,A decade after SARS: strategies for controlling emerging coronaviruses
1224,Impact and effectiveness of mRNA
1225,Algeria's response to COVID-19: an ongoing journey
1226,Montefiori DC (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2
1227,Política nacional rectora de vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México
1228,Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
1229,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
1230,Avaliação do sistema brasileiro de vigilância de eventos adversos pós-vacinação
1231,Coronavirus vaccine-associated lung immunopathology-what is the significance
1232,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
1233,"A Novel and 911 Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York"
1234,Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
1235,Development of an inactivated vaccine candidate for SARS-CoV-2. Science
1236,The impact of the COVID-19 pandemic on medical education
1237,Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons
1238,Emergencia de variante delta-b. 1.617. 2. su impacto potencial en la evolución de la pandemia por sars-cov-2
1239,Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
1240,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv
1241,Administration of a second dose of the Moderna CO-VID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
1242,Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data
1243,Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
1244,Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation
1245,Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings
1246,Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
1247,"Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes"
1248,Funding information WHO Regional Office for Europe
1249,Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against middle east respiratory syndrome coronavirus challenge
1250,The complementary roles of Phase 3 trials and postlicensure surveillance in the evaluation of new vaccines
1251,Vacunas e inmunización: ¿qué es la vacunación? [Internet] Ginebra: Organización Mundial de la Salud
1252,Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry 622 of Health of Indonesia)
1253,The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans
1254,Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses
1255,"The current COVID-19 situation, Iran (Islamic Republic of)"
1256,Cerebral vein thrombosis with vaccine-induced immune thrombotic thrombocytopenia
1257,Comorbidities in the Elderly and Their Possible Influence on Vaccine Response
1258,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
1259,"Safety and 954 immunogenicity of heterologous versus homologous prime-boost schedules with an 955 adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, 956 non-inferiority trial. The Lancet"
1260,Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View
1261,Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
1262,SARS-CoV-2 Nsp14 Activates NF-kb Signaling and Induces IL-8 Upregulation
1263,COVID-19 vaccine-breakthrough infections requiring hospitalization in Mayo Clinic Florida through
1264,"The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs Open Access"
1265,Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2
1266,Early recognition of poor prognosis in Guillain-Barre syndrome
1267,"Children and adolescents with SARS-CoV-2 infection: epidemiology, clinical course and viral loads"
1268,Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases
1269,Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine
1270,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv
1271,Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus
1272,Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination
1273,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India"
1274,Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts
1275,Comparison of ESS-DAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry
1276,Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
1277,Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
1278,Analysis of matched case-control studies
1279,The 2019-new coronavirus epidemic: evidence for virus evolution
1280,"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. Rmd Open"
1281,Guidelines for grading standards of adverse events in clinical trials of preventive vaccines
1282,"COVID-19 vaccine makers plan for annual boosters, but it's not clear they'll be needed"
1283,SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area
1284,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
1285,Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
1286,SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
1287,Our World in Data. Coronavirus (COVID-19) Vaccinations
1288,Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
1289,Vacina Adsorvida COVID-19 (Inativada)
1290,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/ Oxford's AZD1222 SARS-CoV-2 vaccines
1291,COVID-19 (SARS-CoV-2 INFECTION) LABORATORY BIOSAFETY GUIDE
1292,Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection
1293,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
1294,"The swine flu vaccine, public attitudes, and researcher interpretations: A systematic review of qualitative research"
1295,"Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines. 2021, 9"
1296,"Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, united states"
1297,The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis
1298,Estimating the Early Impact of Vaccination Against COVID-19 on Deaths Among Elderly People in Brazil: Analyses of Routinely-Collected Data on Vaccine Coverage and Mortality
1299,"Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study"
1300,SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
1301,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)
1302,Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission
1303,First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. medRxiv
1304,Covid-19 breakthrough infections in vaccinated 157 health care workers
1305,SARS-CoV-2 immune evasion 919 by variant B.1.427/B.1.429
1306,Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
1307,.351 and P.1 escape from neutralizing antibodies
1308,Prevalence of frailty among kidney transplant candidates and recipients in the United States: Estimates from a National Registry and Multicenter Cohort Study
1309,Distinct 1015 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals 1016 following mRNA vaccination
1310,Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients
1311,SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
1312,"Physical activity and influenza-coded outpatient visits, a population-based cohort study"
1313,Interferongamma is a master checkpoint regulator of cytokine-induced differentiation
1314,Neutralizing antibody levels are highly 225 predictive of immune protection from symptomatic SARS-CoV-2 infection
1315,Side effects after COVID-19 vaccinations among residents of Poland
1316,The Government of the Hong Kong Special Administrative Region. Hong Kong vaccination dashboard
1317,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
1318,46 anos do Programa Nacional de Imunizações: uma história repleta de conquistas e desafios a serem superados
1319,SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors
1320,Coronavírus -dados completos
1321,The emergence of sars-cov-2 variant lambda (c. 37) in south america. medRxiv
1322,Middle Cerebral Artery Stroke
1323,Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
1324,Did pangolins spread the China coronavirus to people? Nature 2020
1325,COVID-19 vaccination and antirheumatic therapy
1326,"Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
1327,Protection of BNT162b2 vaccine booster against Covid19 in Israel
1328,Safety and Immunogenicity of Intradermal Delivery of a Fractional Dose mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults as a Dose Sparing Strategy
1329,Clinical and epidemiological features of 36 children
1330,"COVID-19 vaccination hesitancy, misinformation and conspiracy theories on social media: A content analysis of Twitter data"
1331,Guillain-Barré syndrome associated with SARS-CoV-2
1332,"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity"
1333,Thrombocytopenia and splenic platelet directed immune responses after intravenous chadox1 ncov-19 administration
1334,COVID-19: learning from lessons to guide treatment and prevention interventions
1335,Safety of COVID-19 mRNA vaccines in patients with cancer enrolled in early-phase clinical trials
1336,Angiotensin-convertingenzyme2 is a functional receptor for the SARS coronavirus
1337,Coronavirus vaccine weekly summary of yellow card reporting
1338,"A focused 581 review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
1339,Acute exacerbation of idiopathic pulmonary fibrosis after pandemic influenza A (H1N1) vaccination
1340,Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents
1341,Sex Differences in Vaccine-Induced Humoral Immunity
1342,The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation
1343,Menstrual migraine: a distinct disorder needing greater recognition
1344,IgA dominates the early neutralizing antibody response to SARS-CoV-2
1345,"Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (zycov-d): Results of an open-label, non-randomized phase i part of phase i/ii clinical study by intradermal route in healthy subjects in india"
1346,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
1347,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
1348,Estimating rotavirus vaccine effectiveness in Japan using a screening method
1349,Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
1350,Vasospastic angina induced by nonsteroidal antiinflammatory drugs
1351,"Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment"
1352,"Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime"
1353,Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes
1354,Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
1355,Humoral Responses and Serological Assays in SARS-CoV-2 Infections
1356,Acute transverse myelitis following COVID-19 vaccination. Vaccines (Basel)
1357,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study
1358,Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases
1359,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"
1360,Planificación: vacunación contra sars-cov-2
1361,COVID-19 vaccines: keeping pace with SARS-CoV-2 variants
1362,"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, doubleblind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)"
1363,Methods for identifying 30 chronic conditions: application to administrative data
1364,Clinical performance of different SARS-CoV-2 IgG antibody tests
1365,American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis
1366,Impact of coronaphobia on treatment and follow-up compliance of cancer patients
1367,Antibody response and variant cross-172 neutralization after SARS-CoV-2 breakthrough infection
1368,Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance -eight U.S. locations
1369,Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
1370,Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID19 patients
1371,Severe necrotizing pancreatitis following combined hepatitis A and B vaccination
1372,"Risk factors and disease 724 profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study 725 app: a prospective, community-based, nested, case-control study"
1373,Gisaid: Global initiative on sharing all influenza data -from vision to reality
1374,Transmission of SARS-CoV-2 Omicron VOC subvaraints BA.1 and BA.2: Evidence from from Danish households
1375,Good recovery of immunization stress-related responses presenting as cluster of stroke- 2 like events following CoronaVac and ChAdOx1 vaccinations
1376,Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance -nine states
1377,Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
1378,Delivery Routes for COVID-19 Vaccines. Vaccines
1379,Epidemiology and public health in the COVID-19 epidemic
1380,Novel viral vectors in infectious diseases
1381,"Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60"
1382,Multiple SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity
1383,The pulmonary pathology of COVID-19
1384,"Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19"
1385,Moderna COVID-19 Vaccine -United States
1386,Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles
1387,Mortalidad y factores pronósticos en pacientes hospitalizados por COVID-19 en la Unidad de Cuidados Intermedios de un hospital público de Lima
1388,Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel
1389,"Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo state, Brazil"
1390,Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort
1391,Effectiveness of Influenza Vaccination on Influenza-Associated Hospitalisations Over Time Among Children in Hong Kong: A Test-Negative Case-Control Study
1392,Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 CLINICAL SCIENCE Rheumatology
1393,Temporal dynamics in viral shedding and transmissibility of covid-19
1394,Vaccine Advocacy Infographics: What age groups do AU Member States need to target to reach 70% COVID-19 vaccination coverage?
1395,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac"
1396,Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
1397,Distinct conformational states of SARS-CoV-2 spike protein
1398,A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
1399,Abnormal parietal function in 319 conversion paresis
1400,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273
1401,Sanctioned countries in the global COVID-19 568 vaccination campaign: the forgotten 70
1402,Lb0003 Immunogenicity and Safety of the BNT162B2 mRNA Covid-19 Vaccine in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Population: a Multicenter Study
1403,Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
1404,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
1405,"Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine"
1406,Portal do COVID-19 -Coronavírus Brasil
1407,"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections"
1408,A review of Dengvaxia R : development to deployment
1409,MSD was supported by a grant from the National Institutes of Health (U01 grant AI151810). We thank Wendy Barclay for helpful discussions
1410,Omicron: Call for updated vaccines
1411,Oxford-AstraZeneca COVID-19 vaccine efficacy
1412,Guidance for Industry Toxicity Grading 584
1413,Understanding the social determinants of vaccine acceptance and hesitancy: evidence from Hong Kong
1414,Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing
1415,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
1416,"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques"
1417,Enhanced SARS-CoV-2 Neutralization by Dimeric IgA
1418,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
1419,HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
1420,Effectiveness 476 of an Inactivated SARS-CoV-2 Vaccine in Chile
1421,Inferring the effectiveness of government interventions against COVID-19
1422,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv 2021
1423,High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
1424,Immunotoxicity and environment: immunodysregulation and systemic inflammation in children
1425,Observed impacts of the COVID-19 pandemic on global trade
1426,Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report
1427,Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3. In Review
1428,"*The post primary series GMC was derived from the study in the same setting as the current study 620 (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against 621 the SARS-CoV-2 Circulating Variants of Concern"
1429,Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report
1430,Impact of Delta 621 on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK 622
1431,The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects
1432,COVID-19 vaccine: Where are we now and where should we go?
1433,"ARTICLE Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques"
1434,Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV
1435,Optimize Prime/Boost Vaccine Strategies: trained Immunity as a New Player in the Game
1436,"Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern 896 (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. 897 Vaccines"
1437,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity
1438,Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong
1439,Herd immunityestimating the level required to halt the COVID-19 epidemics in affected countries
1440,ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
1441,• Discusses phase I and II CoronaVac trial results
1442,condicionantes e desafios de coordenação do Estado federativo brasileiro no contexto da COVID-19
1443,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines
1444,A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic
1445,An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials
1446,COVID-19 vaccine trial ethics once we have efficacious vaccines
1447,Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
1448,Ensuring uptake of vaccines against SARS-CoV-2
1449,Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
1450,"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product"
1451,One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: a political and social overview
1452,Investigation of SARS-CoV-2 in hospital indoor air of COVID-19 patients' ward with impinger method
1453,Accessed 16
1454,Waning immunity after the BNT162b2 vaccine in Israel
1455,Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
1456,Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
1457,Decoupling of omicron variant infections and severe COVID-19
1458,"Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care"
1459,Title: Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines
1460,Screening of protective effect of amifostine on radiation-induced structural and functional variations in rat liver microsomal membranes by FT-IR spectroscopy
1461,Turkish Society of Clinical Microbiology and Infectious Diseases
1462,The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis
1463,"The World Bank, Data. GDP per Capita (Current US$)-Iran, Islamic Rep"
1464,"Antibody titers against SARS-CoV-2 decline, but do not disappear for several months"
1465,"Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants"
1466,"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study"
1467,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil
1468,SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
1469,World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine
1470,Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
1471,COVID infection severity in children under 5 years old before and after Omicron emergence in the US
1472,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273
1473,"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada"
1474,"Safety and Immunogenicity of the ChAdOx1 Ncov-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial"
1475,Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the 317 first case report
1476,Characterising the background incidence rates of adverse events of special interest for Covid-19 vaccines in eight countries: multinational network cohort study
1477,COVID-19 autopsy cases: detection of virus in endocrine tissues
1478,Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
1479,Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines
1480,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial"
1481,Immunogenicity and safety of two doses of the
1482,Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
1483,Regional Induction of Adhesion Molecules and Chemokine Receptors Explains Disparate Homing of Human B Cells to Systemic and Mucosal Effector Sites: Dispersion From Tonsils
1484,Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
1485,Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
1486,Structural basis of a shared antibody response to SARS-CoV-2
1487,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a webbased survey"
1488,"Transmission and containment of the SARS- CoV-2 Delta variant of concern in Guangzhou, China: A population-based study"
1489,World Health O. Polio vaccines: WHO position paper
1490,The Government of the Hong Kong Special Administrative Region. Government announces 2019 COVID-19 vaccination programme
1491,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
1492,Humoral immune response in inactivated SARS-CoV-2 vaccine: when should a booster dose be administered? medRxiv
1493,"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines"
1494,Vaccination campaign for Seychellois children begins Friday
1495,Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian 5 origin harbouring both substitutions N501Y and E484K in the spike protein
1496,"COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?"
1497,Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
1498,Fundamental Immunology. Fundamental Immunology
1499,Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases
1500,Antiphospholipid antibodies in patients with COVID-19: A relevant observation?
1501,Modeling COVID-19 vaccine-induced immunological memory development and its links to antibody level and infectiousness
1502,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
1503,"Study to evaluate the safety, tolerability, and immunogenicity of SARS CoV-2 RNA vaccine candidate (BNT162b2) against COVID-19 in healthy pregnant women 18 years of age and older"
1504,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: Pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials"
1505,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States
1506,Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
1507,"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact"
1508,The granting of emergency use designation to COVID-19 candidate vaccines: Implications for COVID-19 vaccine trials
1509,Anadolu Agency.1st Doses of Pfizer-BioNTech Jab Administered in Turkey
1510,Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
1511,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals
1512,Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose
1513,Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study Open Access †
1514,Adverse Effects When Being Vaccinated Against Covid-19
1515,Thromboembolic events in the South African Ad26.COV2.S vaccine study
1516,"Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada"
1517,Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
1518,Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform
1519,Immunogenicity of a third dose viralvectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
1520,BNT162b2-Elicited Neutralization against New SARS-CoV-2 spike variants
1521,Persistence and evolution of SARS-CoV-2 in an immunocompromised host
1522,Available online at
1523,COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns
1524,Efcacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
1525,Subject_term: Classification and taxonomy;Phylogenetics;Phylogeny;SARS-CoV-2;Viral evolution Subject_term_id: classification-and-taxonomy
1526,SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
1527,Comparison of lentiviral 431 vector titration methods
1528,"Clinical manifestations, risk 1038 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living 1039 systematic review and meta-analysis"
1529,The presence of SARS-CoV-2 RNA in human sewage
1530,mRNA Covid-19 Vaccine
1531,Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine 1029 Recipients: Update from the Advisory Committee on Immunization Practices -United States
1532,SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
1533,Fundação Cultural Palmares. Informações Quilombolas. 2021
1534,Informativo da Sociedade Brasileira de Infectologia: Primeiro Caso Confirmado de Doença Pelo Novo Coronavírus (COVID-19) No Brasil-26/02/2020. Soc. Bras. Infectol. Sao Paulo Brasil 2020
1535,Emerging SARS-CoV-2 variants: shooting the messenger
1536,Sinovac Announces Phase III Results of Its
1537,European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
1538,Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
1539,Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
1540,Guillain-Barré syndrome
1541,Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8)
1542,Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
1543,Importance of COVID-19 vaccine efficacy in older age groups
1544,Breakthrough ınfections of SARS-CoV-2 gamma variant in fully vaccinated gold miners
1545,"SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges"
1546,Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
1547,CoronaVac induces lower 398 neutralising activity against variants of concern than natural infection
1548,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases"
1549,Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
1550,Twoyear prospective study of the humoral immune response of patients with severe acute respiratory syndrome
1551,Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
1552,COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons -United States
1553,SARS-CoV-2 vaccıne-assocıated subacute thyroıdıtıs
1554,National Health Commission of the People's Republic of China. Novel coronavirus vaccine technical guide
1555,Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
1556,"Ministry of Public Health, a goverment organization. The Coronavirus disease 2019 situation"
1557,Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective singlecenter study
1558,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera
1559,Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
1560,"Immunogenicity and safety ofa third dose, and immune persistence of CoronaVac vaccine in healthy adultsaged 18-59 years: interim results from a double-blind, randomized,placebo-controlled phase 2 clinical trial. medRxiv"
1561,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
1562,Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
1563,Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
1564,SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
1565,Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo
1566,"Safety and immunogenicity of the Chadox1 ncov-19 vaccine against SARS-cov-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
1567,"Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in kidney transplant recipients"
1568,Tianjin Municipal Health Commission. Vaccination of COVID-19 in Tianjin
1569,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"
1570,Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine
1571,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda
1572,History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic
1573,BNT162b2 mRNA COVID-19 Vaccine Effectiveness among Health Care Workers
1574,Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
1575,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
1576,Inflammatory response to fine particulate air pollution exposure: neutrophil versus monocyte
1577,"COVID-19 vaccination in people living with HIV (PLWH) in China: a cross sectional study of vaccine hesitancy, safety, and immunogenicity"
1578,Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
1579,Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in nonhuman primates
1580,The importance of cell-mediated immunity in COVID-19 -An opinion
1581,Results of the Coviran Barekat Vaccine Trials
1582,SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
1583,"Comprehensive assessment of humoral response after Pfizer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
1584,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy"
1585,HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol
1586,Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion
1587,Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at
1588,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
1589,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis
1590,Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein
1591,The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey
1592,Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China
1593,Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study
1594,Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity 1 and persistence of anti-SARS-CoV-2 S antibodies 2 3 Short title: Serological Study of CoronaVac vaccine and heterologous boosters. 4 5
1595,Lessons learned from frontline skilled nursing facility staff regarding COVID-19 vaccine hesitancy
1596,Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
1597,Influence of Age on the Effectiveness and Duration of Protection of Vaxzevria and CoronaVac Vaccines
1598,Global strategy for asthma management and prevention (update 2021)
1599,SARS-CoV-2 infection in fully vaccinated individuals of old age strongly boosters the humoral immune response
1600,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1601,Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination
1602,Viruses and thyroiditis: an update
1603,Effectiveness of CoronaVac among healthcare workers in the setting of high SARS
1604,Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
1605,National Health and Nutrition Survey 2020 on Covid-19. National results
1606,How to cite this article
1607,Licence: CC BY-NC-SA 3.0 IGO.). Available at
1608,Single-cell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection
1609,Screening for SARSCoV-2 antibodies in convalescent plasma (CCP) in Brazil: preliminary lessons from a voluntary convalescent donor program
1610,"Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials"
1611,Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice
1612,WHO International Standard for anti-SARS-CoV-2 immunoglobulin
1613,Potential adverse effects of COVID19 1076 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a 1077 retrospective cross-sectional study
1614,A novel Coronavirus from patients with pneumonia in china
1615,Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?
1616,Mild adverse events of Sputnik V vaccine in Russia: social media content analysis of telegram via deep learning
1617,Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
1618,Impact of age and sex on antibody response following the second dose of COVID-19
1619,Correlates of protection 494 against symptomatic and asymptomatic SARS-CoV-2 infection
1620,Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1
1621,Effects of a Taiji and Qigong intervention on the antibody response to influenza vaccine in older adults
1622,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in
1623,Bogóta: Ministerio de Saud y Protección Social
1624,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
1625,Efficacy and SAFETY of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
1626,Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination Asia syndrome
1627,Open Data on the COVID-19 Epidemic in Malaysia
1628,Seasonal influenza vaccine dose distribution in 157 countries
1629,Reactive Arthritis A006. 29 October
1630,Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
1631,"Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
1632,The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
1633,Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil
1634,"Dynamic Changes in Serum IL-6, IL-8, and IL-10 Are Associated With the Outcome of Patients With Severe COVID-19 in ICU"
1635,"851 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant 852 spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies"
1636,Immunopathology of hyperinflammation in COVID-19
1637,Self controlled case series methods: an alternative to standard epidemiological study designs
1638,Ministry of Health Malaysia
1639,Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates
1640,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
1641,Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study
1642,Effectiveness of coronavac in the setting of high SARS-CoV-2 P1 variant transmission in brazil: a testnegative case-control study
1643,"COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia"
1644,Developing a Small-Area Deprivation Measure for Brazil
1645,COVID-19). World Health Organization
1646,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study
1647,A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein
1648,IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
1649,Data. Coronavirus Pandemic (COVID-19). 2022. Available online
1650,Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC -Supply Vaccines to Eliminate Human Diseases
1651,Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 vaccine
1652,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Front Immunol
1653,Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
1654,The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
1655,"Covid-19, and the debunking of conspiracy theories"
1656,Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
1657,FDA-606 authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across 607 a multi-state health system
1658,COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision
1659,Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
1660,Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
1661,Allergische Reaktionen auf COVID-19-Impfstoffe-Evidenz und praxisorientiertes VorgehenAllergic reactions to COVID-19 vaccines: Evidence and practice-oriented approach
1662,Inactivated Virus Vaccine-An Overview | ScienceDirect Topics
1663,Oral Candidiasis of COVID-19 Patients: Case Report and Review of Evidence
1664,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
1665,The Price Tags on the COVID-19 Vaccines
1666,"9%) 127,713 (90.1%) Family income (monthly) None ≤ $197.17 $197"
1667,Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
1668,Posterior Cerebral Artery Stroke
1669,Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
1670,For recommendatıon by the Strategıc Advısory Group of Experts (Sage) on Immunızatıon. Prepared by the SAGE Working Group on COVID-19 vaccines; 2021. Accessed
1671,Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
1672,Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials
1673,Risk of COVID-19 for Patients With Obesity
1674,BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees
1675,T cell responses to SARS-CoV-2 spike crossrecognize Omicron
1676,Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
1677,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
1678,"Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, randomised, observer-blinded, placebocontrolled clinical trial in ten countries in Europe and Latin America"
1679,"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine"
1680,Williams textbook of endocrinology
1681,Correlates of Vaccine-Induced Protection against SARS-CoV-2
1682,Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
1683,Neutralizing antibody titres in SARS-CoV-2 infections
1684,Correlation between commercial anti-RBD IgG titer and neutralization titer against SARS-CoV-2 beta variant
1685,Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan
1686,Recurrence of Acute Myocarditis Temporally Associated With Receipt of the mRNA COVID-19 Vaccine in an Adolescent Male
1687,Evolution of Immune Res1ponses to SARS-CoV-2 in Mild-Moderate COVID-19
1688,Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
1689,Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
1690,COVID-19 Vaccine Technical Working Group. Technical vaccination recommendations for COVID-19 vaccines in China
1691,"Vaccine 905 effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
1692,Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
1693,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action
1694,Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
1695,Tracking excess deaths associated with the COVID-19 epidemic as an epidemiological surveillance strategy-preliminary results of the evaluation of six Brazilian capitals
1696,"Keinan-Boker, L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data"
1697,COVID-19: vaccine's progress. Microb Biotechnol
1698,Testing fractional doses of COVID-19 vaccines
1699,Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in
1700,The anti-vaccination infodemic on social media: A behavioral analysis
1701,2020. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
1702,BMI-based body size guides for women and men: development and validation of a novel pictorial method to assess weight-related concepts
1703,The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients
1704,Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States
1705,COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
1706,"Extended Data Table 1 | Patient data: Dominican Republic SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
1707,Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
1708,SARS-CoV-2 monitoramento atualizado em 21 de maio
1709,SARS-CoV-2 Mutations and Variants of Interest
1710,Interım report: safety and immunogenicity of an inactivated vaccine agaınst SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv
1711,/fulltext#coronavirus-linkback-header
1712,Age-sex population adjusted analysis of disease severity 487 in epidemics as a tool to devise public health policies for COVID-19
1713,Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
1714,Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
1715,Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant
1716,"SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions"
1717,Bayesian phylodynamic inference with complex models
1718,The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus
1719,Singledose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
1720,Principal Component Analysis. Springer Series in Statistics
1721,TITLE PAGE Title: Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization in Mexico: A nation-wide registry of seven COVID-19 vaccines
1722,Preprint manuscripts and servers in the era of coronavirus disease 2019
1723,Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
1724,Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
1725,"Structure, function, and evolution of coronavirus spike proteins"
1726,Disorder After SARS-CoV-2 Vaccines: Two Case Reports and Discussion of Potential Public Health 339 Implications
1727,Dynamics of antibody 736 response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg 737 Health -Eur
1728,SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children
1729,Practical Statistics for Medical Research
1730,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
1731,World Health Organization; Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Work Group on Vaccine Pharmacovigilance. Geneva: WHO/CIOMS
1732,Differential CD147 functional epitopes on distinct leukocyte subsets
1733,Safety and efficacy of single-dose Ad2.6COV2.S vaccine against COVID-19
1734,Cochrane Handbook for Systematic Reviews of Interventions
1735,"Clinical validation of the Siemens All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers"
1736,Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
1737,Vaccine hesitancy in turkey
1738,Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
1739,Waning Immunity after the BNT162b2
1740,Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
1741,Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults
1742,Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
1743,"A single-blind, randomised, phase II UK multi-Centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules -stage 2"
1744,Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa
1745,A rapid and efficient screening system for neutralizing antibodies and 424 its application for SARS-CoV-2. Front Immunol
1746,CoV-2 IgG II. FDA emergency use authorization instructions manuscript
1747,Single dose vaccination in healthcare workers previously infected with SARS-CoV-2
1748,Glossopharyngeal nerve and vagus nerve palsies associated with influenza vaccination
1749,"FDA, Coronavirus Treatment Acceleration Program (CTAP)"
1750,Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
1751,Five reasons why COVID herd immunity is probably impossible
1752,DNA vaccine protection against SARS-CoV-2 in rhesus macaques
1753,Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network-12 States
1754,"License, supplementary material and copyright"
1755,Age and multimorbidity predict death among COVID-19 patients
1756,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2
1757,Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study
1758,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. 2021. Stockholm: European Centre for Disease Prevention and Control"
1759,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
1760,Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States
1761,Resistance of SARS-CoV
1762,Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry
1763,"Vacunas SARS CoV-2, estudios en fase III"
1764,Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?
1765,Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination
1766,Omicron thwarts some of the world's most-used COVID vaccines
1767,Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis
1768,Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals
1769,MICE: multivariate imputation by chained equations in R
1770,Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
1771,Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine
1772,Efficacy and safety of a COVID-19 inactivated vaccine in health care professionals in Brazil: The PROFISCOV study
1773,Safety and efficacy of the ChAdOx1 nCoV-19 415 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
1774,Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel -33
1775,Disease recognition by infrared and Ramanspectroscopy
1776,Health Am 2021:100025
1777,The improbability of the rapid development of a vaccine for SARS-CoV-2
1778,Subacute thyroiditis after mRNA vaccine for COVID-19
1779,"Retinal, ophthalmic, or ocular migraine"
1780,Oral candidiasis in non-severe COVID-19 patients: Call for antibiotic stewardship. Oral Surg. 2020
1781,Longitudinal analysis of human memory T-cell response according to the severity of illness up to 8 months after SARS-CoV-2 infection
1782,Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. The Lancet Infectious Diseases
1783,"Seasonal characteristics, formation mechanisms and source origins of PM<sub>2.5</sub> in two megacities in Sichuan Basin"
1784,Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature
1785,The Ministry of Health of Turkey Health Statistics Yearbook 2019; General Directorate of Health Information Systems
1786,Children and adolescents in African countries should also be vaccinated for COVID-19 Commentary Handling editor Seye Abimbola
1787,•• Study which evaluated antibody development in cancer patients after COVID-19 infection
1788,Interrupted time series regression for the evaluation of public health interventions: a tutorial
1789,The Hong Kong society of rheumatology consensus recommendations for COVID-19 vaccination in adult patients with autoimmune rheumatic diseases
1790,Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
1791,COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
1792,Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
1793,Modern epidemiology
1794,Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. U.S. Food and Drug Administration
1795,Alarming COVID variants show vital role of genomic surveillance
1796,Regeneron Reports Positive Interim Data With REGEN-COVTM Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19
1797,Essential medical statistics. 2 nd ed. Massachusetts: Blackwell Science
1798,"Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management"
1799,Clinical manifestations of COVID-19 in the general population: systematic review
1800,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to CO-VID-19 vaccines"
1801,"Immunogenicity and reactogenicity of bnt162b2 booster in chadox1-s-primed participants (combivacs): A multicentre, open-label, randomised, controlled, phase 2 trial"
1802,"Students' views towards sarscov-2 mass asymptomatic testing, social distancing and selfisolation in a university setting during the COVID-19 pandemic: a qualitative study"
1803,World Health Organization. Considerations for evaluation of Covid-19 vaccines
1804,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
1805,Citation
1806,Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron variant of concern
1807,The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States
1808,Transmission dynamics and 720 epidemiological characteristics of Delta variant infections in China
1809,Prevalence and drivers of COVID-19 vaccine hesitancy among Czech University Students: national cross-sectional study
1810,Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv
1811,"What Scientists Know about New, Fast-Spreading Coronavirus Variants"
1812,Análise da ocorrência de evento adverso pós-vacinação decorrente de erro de imunização
1813,Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
1814,"The last major outbreak of smallpox (Yugoslavia, 1972): The importance of historical reminders"
1815,COVID-19 Vaccines Safety Tracking (CoVaST): protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines' side effects
1816,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks
1817,Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv
1818,International Consensus (ICON): allergic reactions to vaccines
1819,Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
1820,Title Page: Heterologous prime-boost immunization with CoronaVac and Convidecia
1821,"SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster"
1822,SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas
1823,SARS-CoV-2 variants and vaccines
1824,Clinical characteristics of hospitalized COVID-19 patients who received at least one dose of COVID-19 vaccine
1825,World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11
1826,American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
1827,Sporadic hemiplegic migraine with permanent neurological deficits
1828,Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel)
1829,Multimorbidity and adverse events of special interest associated with CoronaVac (Sinovac) and Comirnaty
1830,"Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern Alpha, Delta, Beta) in Thai Healthcare Workers"
1831,Optimism and caution for an inactivated COVID-19 vaccine
1832,Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study
1833,Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines medRxiv
1834,"Boosting with heterologous vaccines effectively improves protective All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
1835,COVID-19 seroprevalence among hospital staff and preprocedural patients in thai community hospitals: A cross-sectional study
1836,Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
1837,Epidemiology and Infection Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival
1838,Engineering attenuated virus vaccines by controlling replication fidelity
1839,Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
1840,Novavax offers first evidence that COVID vaccines protect people against variants
1841,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial"
1842,Immunological considerations for COVID-19 vaccine strategies
1843,"Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada"
1844,mRNAbased COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
1845,Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil
1846,Escape of SARS-CoV-2 501Y.V2 438 from neutralization by convalescent plasma
1847,Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
1848,Discusses the immunogenicity of mRNA vaccines in cancer patients
1849,Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis
1850,World Health Organization. Coronavirus (COVID-19) dashboard
1851,COVID-19 vaccine development pipeline gears up
1852,An mRNA vaccine against SARS-CoV-2-preliminary Report
1853,"Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly"
1854,Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
1855,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
1856,mRNA vaccine-elicited 817 antibodies to SARS-CoV-2 and circulating variants
1857,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
1858,"Shortterm immune response after inactivated SARS-CoV-2 (CoronaVac ® , Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria ® , Oxford-AstraZeneca) vaccinations in health care workers"
1859,WHO. Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7
1860,"Epidemic Spread of SARS-CoV-2 Lineage, B.1.1.7 in Brazil"
1861,Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required
1862,Hong Kong authorises Sinovac Covid vaccine for children aged 3 to 17
1863,Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials
1864,COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
1865,Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness
1866,Brief History of Pandemics (Pandemics Throughout History). In Psychiatry of Pandemics
1867,A systematic review of COVID-19 vaccine efficacy and 17 effectiveness against SARS-CoV-2 infection and disease
1868,Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
1869,Concerns about sars-cov-2 evolution should not hold back efforts to expand vaccination
1870,Mass psychogenic response to human papillomavirus vaccination. The 333
1871,The REDCap consortium: Building an international community of software platform partners
1872,Coronavirus vaccine tracker
1873,Flu -Severe respiratory syndrome notifications
1874,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients
1875,Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States
1876,Immunogenicity of 981 a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. 982 JAMA
1877,Comparative safety of vaccine adjuvants: a summary of current evidence and future needs
1878,Predictors for and coverage of influenza vaccination among HIV-positive patients: A cross-sectional survey
1879,Decreased vaccine antibody titers following exposure to multiple metals and metalloids in e-waste-exposed preschool children
1880,Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome
1881,Severe allergic reactions to the COVID-19 vaccine-Statement and practical consequences
1882,Prevention of COVID-19 by 671 mRNA-based vaccines within the general population of California
1883,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses
1884,SARS-CoV-2 detection by nasal strips: A superior tool for surveillance of paediatric population
1885,Weekly Epidemiological Update on COVID-19 -31
1886,"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials"
1887,Secondary cases of Delta-variant COVID-19 among vaccinated healthcare workers with breakthrough infections is rare
1888,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv 2021"
1889,Characterizing genomic variants and mutations in SARS-CoV-2 proteins from Indian isolates
1890,"Bern aldez A, Rodr ıguez-Jim enez P. Varicella zoster virus reactivation and mRNA vaccines as a trigger"
1891,"Co-variance nexus between COVID-19 mortality, humidity, and air quality index in Wuhan, China: new insights from partial and multiple wavelet coherence"
1892,Evidence for antibody as a protective correlate for COVID-19 632 vaccines
1893,Tracking changes in SARS-CoV-2 spike: evidence that 395 D614G increases infectivity of the COVID-19 virus
1894,Effects reported by Jordanian healthcare workers who received COVID-19 vaccines
1895,Vaccination against COVID-19 and inequalities -avoiding making a bad situation worse. Public Health Pract (Oxf) 2:100101
1896,Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
1897,Comparing COVID-19 Vaccine Schedule Combinations-Com-COV
1898,Comparative reactogenicity of enhanced influenza vaccines in older adults
1899,Cerebral perfusion changes in hemiplegic migraine: illustrated by Tc-99m ECD brain perfusion scan
1900,Vaccine Hesitancy Survey Questions Related to SAGE Vaccine Hesitancy Matrix
1901,Investigating the relationship between occupation and SARS-CoV2
1902,"BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, 414 phase 2 trial"
1903,"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy"
1904,The New England journal of medicine
1905,Barré Syndrome following ChAdOx1
1906,Omicron-fuelled COVID-19 surge in African plateaus
1907,"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance -VISION Network, 10 States"
1908,GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)
1909,International Vaccine Access Center's. COVID-19 Vaccine Effectiveness Forest Plots
1910,Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey
1911,AdviseDx SARS-CoV-2 IgG II package insert
1912,Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
1913,"C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents"
1914,What can countries learn from Hong Kong's response to the COVID-19 pandemic?
1915,"Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"
1916,An mRNA 273 vaccine against SARS-CoV-2 -Preliminary Report
1917,Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection
1918,Randomized Trial of a 989 Third Dose of mRNA-1273 Vaccine in Transplant Recipients
1919,Nanomaterial Delivery Systems for mRNA Vaccines
1920,Vaccine xxx (xxxx) xxx
1921,Pseudo-anaphylactic reactions to pfizer bnt162b2 vaccine: report of 3 cases of anaphylaxis post pfizer bnt162b2 vaccination
1922,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv
1923,"Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience"
1924,COVID-19 in the elderly people and advances in vaccination approaches
1925,COVID-19 vaccine breakthrough infections reported to CDC-United States
1926,"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
1927,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
1928,Critical revision of the article for important intellectual content
1929,Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions
1930,TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
1931,Cigarette smoke exposure exacerbates lung inflammation and compromises immunity to bacterial infection
1932,COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
1933,CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
1934,Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong
1935,Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients
1936,"vaccine (CoronaVac) in healthy adults aged 60 years and older: a 491 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
1937,Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines (Basel)
1938,"SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls"
1939,Occurrence of Subacute Thyroiditis following Influenza Vaccination
1940,A spatial scan statistic
1941,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
1942,Risk and Course of SARS-CoV-2 Infection in Patients Treated for Hypothyroidism and Hyperthyroidism
1943,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine"
1944,10 States
1945,Public Health England. SARS-CoV-2 variants of concern and variants under investigation
1946,Sample size for binary logistic prediction models: Beyond events per variable criteria
1947,Possible triggering effect of influenza vaccination on psoriasis
1948,Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
1949,Safety and immunogenicity of SARS-CoV-2 1003 variant mRNA vaccine boosters in healthy adults: an interim analysis
1950,"Systematic Review Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review"
1951,Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept
1952,"two randomised, double-blind, placebo-controlled, phase 1 and 2 trials"
1953,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
1954,"Journal Pre-proofs Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Be- ta) in Thai Healthcare Workers Comparison of Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV- 2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers"
1955,"Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean"
1956,Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults
1957,Current state of the first covid-19 vaccines
1958,Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine
1959,Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
1960,The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus
1961,Adjuvantation helps to optimise COVID-19 vaccine candidate
1962,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
1963,"Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?"
1964,A novel coronavirus outbreak of global health concern
1965,Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases
1966,"The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress"
1967,Republic of Turkey Ministry of Health. T.C. Saglık Bakanlıgı Bilimsel Araştırma Platformu
1968,TA B L E 1 Demographic characteristics and outcomes for the 3 participants Demographic and background clinical information Post-dose 1 Pre-dose 2 testing Post-dose 2 Post-dose 2 7-day electronic diary of symptoms Participants Age (Yrs) Sex Ethnicity Medical history Time to urticaria a Duration of urticaria Basophil activation test results a
1969,SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
1970,mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
1971,World Health Organization. Living guidance for clinical management of COVID-19: living guidance
1972,Covid-19: what new variants are emerging and how are they being investigated?
1973,Complex regional pain syndrome and 313 functional neurological disorders -time for reconciliation
1974,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
1975,Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
1976,Dynamic of humoral response to SARS-CoV-2 anti-nucleocapsid and spike proteins after CoronaVac vaccination
1977,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 472 variant of concern
1978,Coronavirus vaccine -weekly summary 1044 of Yellow Card reporting
1979,"RHH-001 study team. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
1980,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
1981,"Clinical course and outcomes of critically ill patients with sars-cov-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study"
1982,"Science in 5. Episode #31-Vaccines, variants & doses"
1983,Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine
1984,International Nonproprietary Names Programme. Messenger RNA Encoding the Full-Length SARS-CoV-2 Spike Glycoprotein. World Health Organization (2020)
1985,The Government of the Hong Kong Special Administrative Region. Secretary for Food and Health approves lowering age limit for receiving Comirnaty vaccine
1986,"Neutralization of SARS-CoV-2 spike 791 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
1987,WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. Geneva: WHO; 2021
1988,The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
1989,What do we know about India's Covaxin vaccine?
1990,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
1991,"COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women"
1992,Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
1993,Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
1994,Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant
1995,BBIP-CorV vaccine effectiveness for preventing infection and death of health workers
1996,T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals
1997,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study"
1998,A new SARS-CoV-2 dual-purpose serology test: Highly accurate infection tracing and neutralizing antibody response detection
1999,Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention
2000,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
2001,Between immunomodulation and immunotolerance: the role of IFNgamma in SARS-CoV-2 disease
2002,Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. Infectious Diseases (except HIV/AIDS)
2003,Vaxzevria (Previously COVID-19 Vaccne AstraZeneca)
2004,DMID 21-0012 Study Group
2005,"Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape"
2006,"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status"
2007,Covid-19 breakthrough infections in vaccinated health care workers
2008,Ghana: FDA authorizes Pfizer vaccine for 15 to 17-year-olds
2009,Long-Term Care Facilities in England
2010,"Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses"
2011,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy"
2012,Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
2013,Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
2014,A country-by-country guide to coronavirus vaccine booster plans. POLITICO; 2021
2015,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study
2016,Acute Idiopathic Blind Spot Enlargement Syndrome: A Review of 27 New Cases
2017,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis annrheumdis-2021-220503
2018,Twitter as a Tool for Health Research: A Systematic Review
2019,Plan Nacional Actualizado contra la COVID-19
2020,Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
2021,Live attenuated vaccines: historical successes and current challenges
2022,"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine"
2023,Collection and assembly of data
2024,Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo
2025,Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis
2026,Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model
2027,Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
2028,Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
2029,Psychogenic illness following vaccination: exploratory study of 335 mass vaccination against pandemic influenza A (H1N1) in 2009 in South Korea. Clinical and experimental 336 vaccine research
2030,Cellular immunity in COVID-19 convalescents with PCR-470 confirmed infection but with undetectable SARS-CoV-2-specific IgG
2031,Update i. a systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for covid-19
2032,Efficacy and Safety of the 454 mRNA-1273 SARS-CoV-2 Vaccine
2033,Neutralizing antibody levels are highly 405 predictive of immune protection from symptomatic SARS-CoV-2 infection
2034,"Immunogenicity, safety, and reactogenicity of heterologous COVID19 primary vaccination incorporating mRNA, viralvector, and proteinadjuvant vaccines in the UK (ComCOV2): a singleblind, randomised, phase 2, noninferiority trial"
2035,"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay"
2036,Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study
2037,COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population
2038,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study"
2039,Immunogenicity of pneumococcal vaccination in HIV infected individuals: a systematic review and meta-analysis
2040,"Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years -VISION Network, 10 States"
2041,ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
2042,Phosphorylation regulates the subcellular localization of Cucumber Mosaic Virus 2b protein
2043,COVID-19 pathophysiology: a review
2044,A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
2045,COVID-19 vaccination coverage in adults 18 years (any type of vaccines) during
2046,Review: ischemia reperfusion injury-A translational perspective in organ transplantation
2047,COVID-19 dynamics after a national immunization program in Israel
2048,DNA vaccines-how far from clinical use?
2049,Adverse effect after COVID-19 vaccination in Thailand
2050,World Health Organization 2020 guidelines on physical activity and sedentary behaviour
2051,SARS-CoV-2 variants of concern exhibit reduced sensitivity to 598 live-virus neutralization in sera from CoronaVac vaccinees and naturally infected 599 COVID-19 patients
2052,Sex differences in vaccine-induced humoral immunity
2053,BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans
2054,Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol
2055,Historical Cohort Study
2056,"Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the Delta variant: real world study and evidence -China"
2057,Considerations for fair prioritisation of COVID-19 vaccine and its mandate among healthcare personnel
2058,"Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Ensanut 2020 Covid-19"
2059,Menos de 7% das áreas quilombolas no Brasil foram tituladas. Agência Brasil
2060,COVID-19 vaccines: should we fear ADE
2061,Mucosal Immunity in COVID-19: A Neglected But Critical Aspect of SARS-CoV-2 Infection
2062,AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
2063,The Cost per Jab of Covid-19 Vaccine Candidates
2064,China authorises CoronaVac Covid-19 vaccine for children above 3 years
2065,"Immunogenic potential of DNA vaccine candidate, zycov-d against SARS-CoV-2 in animal models"
2066,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x2013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases"
2067,Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial
2068,Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa
2069,Sex differences in autoimmune disease
2070,"Migraine, obesity and body fat distribution -a population-based study"
2071,General Data Protection Regulation (GDPR) Compliance Guidelines
2072,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the Severe acute respiratory syndrome coronavirus 2 501Y Variant 1 and Variant 2
2073,Infection in Adults: A Randomized Clinical Trial
2074,SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron
2075,Indonesia begins to give third COVID-19 shots to 1.5 million health workers. Jakarta Post
2076,Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis
2077,Turkish Journal of Biology CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometrics
2078,Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
2079,Antibody evasion by the P.1 strain of SARS-CoV-2
2080,"Rcommendation for an Emergency Use Listing of COVID-19 Vaccine (Vero Cell), Inactivated Submitted by Sinovac"
2081,"Morphology, Genome Organization, Replication, 421 and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"
2082,"COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead"
2083,Comparative Effectiveness of Moderna
2084,Adaptive immunity to SARS-CoV-2 and COVID-19
2085,"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden"
2086,Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus
2087,Review of early immune response to SARS-CoV-2 vaccination among patients with CKD
2088,The British variant of the new coronavirus-19 (SARS-CoV-2) should not create a vaccine problem
2089,IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)
2090,Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology
2091,"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"
2092,COVID-19 vaccine safety in cancer patients: a single centre experience
2093,Surveillance for adverse events after COVID-19 mRNA vaccination
2094,BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype
2095,Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy
2096,SARS and MERS: recent insights into emerging coronaviruses
2097,Psychobehavioral responses and likelihood of receiving COVID-19 vaccines during the Pandemic
2098,The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
2099,A summary of the SARS-CoV-2 vaccines and technologies available or under development
2100,Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
2101,COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
2102,"Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes"
2103,A study on the effects of meteorological and climatic factors on the COVID-19 spread in Canada during 2020
2104,A systematic review of quasiexperimental study designs in the fields of infection control and antibiotic resistance
2105,Efficacy and Safety of the mRNA-1273 SARS-CoV-2
2106,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: a test-negative case-control study. medRxiv
2107,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study
2108,The socio-economic implications of the coronavirus pandemic (COVID-19): a review
2109,SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune 468 escape
2110,Lineage Assignment in An Emerging Pandemic as An Epidemiological Tool
2111,The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
2112,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines. Vaccines (Basel)
2113,Correlates of protection 523 against symptomatic and asymptomatic SARS-CoV-2 infection
2114,SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse
2115,Tutorial in biostatistics: the self-controlled case series method
2116,Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers
2117,"COVID-19 Attributable Deaths on Longevity, Premature Mortality and DALY: Estimates of"
2118,Thailand sticks with Sinovac vaccine after cases of 'stroke-like' side effects. Reuters
2119,"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
2120,Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men
2121,A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
2122,COVID-19 vaccine tracker and landscape [Internet]Ginebra:Organización Mundial de Salud
2123,"Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey"
2124,"Vaccine hesitancy: definition, scope and determinants"
2125,Suppression of normal immune responses after treatment with rituximab
2126,Covid-19: Vaccine roll out could take a year and will require difficult prioritisation decisions
2127,Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil
2128,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type5 vectored COVID19 vaccine: a doseescalation, openlabel, nonrandomised, firstinhuman trial"
2129,Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms and Possible Responses
2130,"Immunologic aspects of characteristics, diagnosis, and treatment of coronavirusdisease 2019 (COVID-19)"
2131,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States
2132,Boletim completo SP contra o coronavirus
2133,Vaccine Breakthrough Infections with SARS-CoV-2 Variants
2134,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
2135,Clin Infect Dis (2021) Epub ahead of print
2136,COVID-19 vaccine safety update
2137,COVID-19 vaccination followed by activation of 289 glomerular diseases: does association equal causation?
2138,COVID-19 vaccine and myocarditis
2139,"Journal Pre-proof Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 1 SARS-CoV-2 and variants of concern: A narrative review 2 3"
2140,Suspected COVID-19 case definition: a narrative review of the most frequent signs and symptoms among confirmed cases
2141,Serological Response to mRNA and Inactivated COVID-19 Vaccine in Healthcare Workers in Hong Kong: Preliminary Results
2142,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
2143,Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested casecontrol study
2144,International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. Milbank Q. 2021
2145,Efficacy of Antiviral Agents against the 401
2146,COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates
2147,Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a Hif-1a/Glycolysis Dependent Axis
2148,Effectiveness of the CoronaVac vaccine in the elderly population during a gamma variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
2149,SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time
2150,Turkey: 85% of new COVID-19 cases due to UK variant
2151,WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic [Internet]. Nature. Nature
2152,Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
2153,Vaccine 657 effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term 658 care facility residents and healthcare workers -a Danish cohort study
2154,The Covid-19 Candidate Vaccine Landscape and Tracker
2155,Protection of BNT162b2 vaccine booster against COVID-19 in Israel
2156,"Pathogenesis of Behçet's syndrome: genetic, environmental and immunological factors"
2157,"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia"
2158,Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences
2159,"Nutrition, diet and immunosenescence"
2160,Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant
2161,Immunization guidelines. Dubai Health Authority Department of Public Health & safety
2162,The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
2163,Principles for designing an optimal mRNA lipid nanoparticle vaccine
2164,"BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced"
2165,Duration of Antibody Responses after Severe Acute Respiratory Syndrome
2166,"Infectious diseases society of America. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the infectious diseases society of America"
2167,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial
2168,1.617.2 and B.1.351 by BNT162b2 vaccination
2169,COVID-19 vaccine type and humoral immune response in patients receiving dialysis
2170,A systematic review assessing the under-representation of elderly adults in COVID-19 trials
2171,The epidemiology of Sjögren's syndrome
2172,SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment
2173,Brazilian Ministry of Health. Definition of COVID-19 cases and recommendations for COVID-19
2174,Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy
2175,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
2176,Respirology Epub ahead of print
2177,A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome
2178,Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
2179,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2180,Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
2181,SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
2182,Ebola vaccine trials: progress in vaccine safety and immunogenicity
2183,COVİD-19 breakthrough ınfections in vaccinated health care workers
2184,Tracking SARS-CoV-2 Variants
2185,Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
2186,Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19
2187,The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic
2188,Global Rheumatology Alliance physician-reported registry
2189,Data source: Ministry of Health of Indonesia)
2190,Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
2191,Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination
2192,CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients
2193,How bharat biotech's vaccine works. The New York Times
2194,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial"
2195,SARS-CoV-2 variants and ending the COVID-19 pandemic
2196,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
2197,Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
2198,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel"
2199,US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination
2200,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
2201,Prevalence and risk factors of CoronaVac side effects: an independent crosssectional study among healthcare workers in Turkey
2202,"Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS)"
2203,World Health Organization. Coronavirus Disease (COVID-19) Dashboard
2204,Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
2205,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
2206,"Oxford University Hospitals Staff Testing, G, 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers"
2207,Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data
2208,Low case numbers enable long-term stable pandemic control without lockdowns. medRxiv
2209,Effectiveness of COVID-19 vaccines: From clinical trials to real life
2210,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings"
2211,Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
2212,Vaccines Against RNA Viruses
2213,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study
2214,Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
2215,Tuberculosis vaccine: a journey from BCG to present
2216,Brazilian Ministry of Health. Campanha Nacional de Vacinação contra a Covid-1. Décimo oitavo informe técnico
2217,Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
2218,SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
2219,SARS-CoV-2 surrogate virus neutralization test (sVNT) kit (RUO)
2220,Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine Through 6 Months
2221,"Coronavirus disease exposure and spread from nightclubs, South Korea"
2222,"Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial"
2223,COVID-19 mRNA vaccination generates greater immunoglobulin g levels in women compared to men
2224,"Time to re-evaluate. SN Compr Clin Med:1, 1-2. Advance online publication"
2225,Title: Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal 1 route among adult who had received CoronaVac 2 3 Authors: 4
2226,World Health Organization. COVID-19 Vaccine Tracker and Landscape
2227,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial"
2228,COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines
2229,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
2230,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older"
2231,Myocarditis and pericarditis after mRNA COVID-19 vaccination
2232,"doi: medRxiv preprint 10. Pietsch, B. Hundreds of Thais inoculated with Sinovac are infected as cases spike in Southeast Asia. The Washington Post"
2233,Progress and prospects on vaccine development against sars-cov-2
2234,Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19
2235,Evaluation of antibody response after COVID-19 vaccination of healthcare workers
2236,Considerations for evaluation of COVID19 vaccines
2237,Centers for Disease Control and Prevention What to do if you had an allergic reaction after getting a COVID-19 vaccine
2238,A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination
2239,Occurrence of severe COVID-19 in vaccinated transplant patients
2240,Covid-19 Latest News: Sinopharm Virus Vaccine Safe in Testing-Bloomberg
2241,Molecular Determinants and Mechanism for Antibody Cocktail Preventing SARS-CoV-2 Escape
2242,"all blood donors, vaccinated individuals, and SARS-CoV-2 patients who provided clinical specimens for this study"
2243,Virological assessment of hospitalized patients with COVID
2244,Antibody titres decline 3-month post-vaccinationwith BNT162b2
2245,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2246,Different mutations in SARS-CoV-2 associate with severe and mild outcome
2247,Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: is inactivated vaccine effective? Ther Apher Dial
2248,Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials
2249,BÜHLMANN Laboratories AG. Flow CAST® Basophil Activation Test (BAT) Flow Cytometry
2250,Vaccination and induction of autoimmune diseases
2251,"Safety and immunogenicity of coronavac and chadox1 against the SARS-CoV-2 circulating variants of concern (alpha, delta, beta) in thai healthcare workers"
2252,COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making
2253,No evidence for increased 747 transmissibility from recurrent mutations in SARS-CoV-2
2254,Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
2255,SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
2256,"COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review"
2257,Leveraging the United States Epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus
2258,Immune system and COVID-19 by sex differences and age. Women's Health
2259,"convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?"
2260,Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
2261,Recombinant vaccines for COVID-19
2262,Enhanced SARS-CoV-2 neutralization by dimeric IgA
2263,Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine Somporn Chantra a Pareena Chaitanuwong a Kasem Seresirikachorm a Keywords COVID-19 vaccine · Ocular surface erosion · Skin rash · Health worker · Case report
2264,Genomic epidemiology of hCoV-19. 2021). www.gisaid.org (accessed
2265,Differential contributions of central and effector memory T cells to recall responses
2266,Department of Health
2267,Evidence for antibody as a protective correlate for COVID-19 vaccines
2268,"mRNA vaccines for COVID-19: What, why and how"
2269,Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants
2270,The World Health Organzation. COVD-19 vaccine tracker
2271,Vaccination against SARS-CoV-2. Vaccines
2272,Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates
2273,CTFFIND4: fast and accurate defocus estimation from electron micrographs
2274,Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
2275,2%) COVID-19 admissions in adults with incomplete vaccination and/or <14 days of last dose at COVID-19 diagnosis; these patients were not eligible for the study CCU: Critical Care Unit
2276,BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting
2277,Guideline on risk management systems for medicinal products for human use
2278,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
2279,Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
2280,The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development
2281,"COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations"
2282,COVID-19 Vaccination Programme
2283,Antibody response of BNT162b2 and CoronaVac platforms in recovered individuals previously infected by COVID-19 against SARS-CoV-2 wild type and delta variant
2284,The nature and extent of COVID-19 vaccination hesitancy in healthcare workers
2285,The plight of essential workers during the COVID-19 pandemic
2286,An updated meta-analysis on the association between HIV infection and COVID-19 mortality
2287,Role of Immunoglobulin M and A Antibodies in the 202
2288,"CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
2289,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination-A systematic review and meta-analysis
2290,Clinical Characteristics of Coronavirus Disease
2291,Zydus's 3-dose ZyCoV-D approved
2292,Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. The Lancet Rheumatology
2293,COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium
2294,Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials
2295,The reproductive number of COVID-19 is higher compared to SARS coronavirus
2296,"Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac"
2297,Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
2298,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
2299,Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination
2300,Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study
2301,Neutralisation of SARS-CoV-2 Lineage P.1 by Antibodies Elicited Through Natural SARS-CoV-2 Infection or Vaccination With an Inactivated SARS-CoV-2 Vaccine: An Immunological Study
2302,Structure analysis of the receptor binding of 2019-nCoV
2303,Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
2304,Transmission of
2305,Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: a case report
2306,Nanotechnology shows promise for nextgeneration vaccines in the fight against COVID-19
2307,The genomic landscape of sars-cov-2: Surveillance of variants of concern
2308,Effectiveness of an inactivated SARS-CoV-2 vaccine in chile
2309,"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open- label, single-centre trial"
2310,Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
2311,Salivary glands are a target for SARS-CoV-2: a source for saliva contamination
2312,Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution
2313,Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
2314,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
2315,"Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years-COVID-NET, 13 States"
2316,Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern
2317,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study
2318,An evaluation of universal vouchers as a demand-side subsidy to change primary care utilization: a retrospective analysis of longitudinal services utilisation and voucher claims data from a survey cohort in Hong Kong
2319,SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys
2320,SARS-CoV-2 vaccines: a triumph of science and collaboration
2321,Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive?
2322,Toll-like receptor sensing of human herpesvirus infection
2323,Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis
2324,This phase 3 clinical trial conducted in healthcare professionals in Brazil demonstrated that the inactivated CoronaVac vaccine has a good safety profile and is efficacious against any symptomatic SARS-CoV-2 infections and highly protective against moderate and severe COVID-19
2325,New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination. Case Rep Rheumatol
2326,Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors
2327,Effectiveness of an inactivated SARS-CoV-2 vaccine
2328,Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
2329,Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants
2330,Social contacts and mixing patterns relevant to the spread of infectious diseases
2331,Effectiveness of CoronaVac in the setting of high SARS
2332,CoVariants: SARS-CoV-2 Mutations and Variants of Interest
2333,SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer
2334,• Study which evaluated the mRNA vaccine BNT162b2 in cancer patients
2335,Mexico -COVID-19 -Vaccines administered
2336,Plasma metabolomic and lipidomic alterations associated with COVID-19
2337,Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine. Vaccines (Basel)
2338,Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells
2339,World medical association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
2340,WHO remarks at the media briefing on COVID-19 -11
2341,Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States
2342,Infectivity and immune escape of the new sars-cov-2 variant of interest lambda. medRxiv
2343,"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022"
2344,Immunological memory cells
2345,Dexamethasone in hospitalized patients with covid-19
2346,COVID-19 Weekly Epidemiological Update Edition 68
2347,SARS-CoV-2 variants of concern and variants under investigation in England
2348,The unequal scramble for coronavirus vaccines -by the numbers
2349,Coronavirus y realidad: los imposibles costos de internarse en una clínica privada
2350,"Pagnano: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Membership on an entity's Board of Directors or advisory committees"
2351,Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
2352,Lymphadenopathy associated with the COVID-19 vaccine
2353,Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
2354,First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
2355,A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
2356,1042 Disponible sur
2357,Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients
2358,A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac
2359,"COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies"
2360,Royal College of Physicians. National Early Warning Score (NEWS) 2. 2021. Available online
2361,Guidelines for the Management of Children and Adolescent with COVID-19: Protocol for an update
2362,Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
2363,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
2364,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A 537 systematic review and meta-analysis
2365,BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
2366,Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
2367,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states"
2368,Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing
2369,"World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Geneva: World Health Organization"
2370,Coronary hypersensitivity disorder: the Kounis syndrome
2371,IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2
2372,Neutralizing Response 822 against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
2373,"Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey"
2374,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of longterm care facilities in England (VIVALDI): a prospective cohort study
2375,Governo do Estado
2376,Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
2377,Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review
2378,MatchIt: Nonparametric Preprocessing for Parametric Causal Inference
2379,The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
2380,COVID-19 Vaccines vs. Variants-Determining How Much Immunity Is Enough
2381,Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
2382,The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
2383,Chinese COVID-19 vaccine candidate the first to start phase 3 clinical trials worldwide-Global Times
2384,Plan Nacional de Vacunación contra el SARS-CoV-2. 2021;Bogóta: Ministerio de de Salud y Protección Social
2385,High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients
2386,Air pollution exposure and COVID-19: a look at mortality in Mexico City using individual-level data
2387,Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses
2388,D614G mutation of SARS-CoV-2 spike protein enhances 408 viral infectivity. bioRxiv
2389,"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-covidnet, 14 states"
2390,"Adrees AO, Side. effects and perceptions following Sinopharm COVID-19 vaccination"
2391,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar
2392,COVID-19) Dashboard with vaccination data
2393,"Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?"
2394,The dependent variable is the delta of antibodies. Time and personal variability are 602 random effects. Reference group BNT162b2 mRNA
2395,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil"
2396,Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
2397,DATASUS -TabNet Win32 3.0: CNES -Recursos Humanos -Profissionais -Indivíduos -segundo CBO 2002 -Brasil
2398,"Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines"
2399,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
2400,Myopericarditis in a Previously Healthy Adolescent Male Following COVID-19 Vaccination: A Case Report
2401,Covid Performance Index: Deconstructing pandemic responses -Methodology
2402,A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
2403,Quantitation of antibodies against SARS-CoV-2 spike proteinafter two doses of CoronaVac in healthcare workers
2404,Hospital Authority. Hospital Authority Statistical Report
2405,The dual nature of type I and type II interferons
2406,Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies. Vaccines (Basel)
2407,Russia's fast track coronavirus vaccine draws outrage over safety
2408,Interleukin-21 is a critical cytokine for the generation of virus-specific longlived plasma cells
2409,"Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. Stockholm: European Centre for Disease Prevention and Control"
2410,Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland
2411,RDP4: Detection and analysis of recombination patterns in virus genomes
2412,Vaccine in Israel
2413,COVID-19: protecting health-care workers
2414,Evaluation of the BNT162b2
2415,Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and Risk at different exposure periods before and after symptom onset
2416,"COVID-19 and postinfection immunity: limited evidence, many remaining questions"
2417,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule"
2418,COVID-19) Dashboard
2419,Statistical analysis was performed by
2420,Cell Memory and Plasma Cell Development
2421,"Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial"
2422,Social Science Research Network; 2021 févr
2423,Strategies for addressing vaccine hesitancy-A systematic review
2424,Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
2425,Childhood vaccination: implications for global and domestic public health
2426,Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus
2427,Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
2428,Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (basel)
2429,World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects
2430,Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
2431,JBI Manual for Evidence Synthesis
2432,Correlates of protection from SARS-CoV-2 infection
2433,World Health Organization. Tracking SARS-CoV-2 Variants
2434,Diagnostic value of nuclear medicine imaging and ultrasonography in subacute thyroiditis
2435,Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
2436,Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
2437,National Guiding Policy for Vaccination Against SARS-CoV-2 for the Prevention of COVID-19 in Mexico
2438,Covid-19 vaccine over 6 months
2439,Twelve-month specific IgG response to SARS-CoV-2 receptor-binding 467 domain among COVID-19 convalescent plasma donors in Wuhan
2440,"The novel coronavirus, 2019-ncov, is highly contagious and more infectious than initially estimated"
2441,Anti-Spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
2442,SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 14
2443,"SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential"
2444,Maternal immunological adaptation during normal pregnancy
2445,Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States
2446,Antigen presentation and adaptive immune responses in skin
2447,Vaccines highly effective against hospitalisation from Delta variant
2448,Phaser crystallographic software
2449,Immune phenotyping based on the Neutrophil-to-Lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19
2450,Under the COVID-19 lockdown: rapid review about the unique case of north Cyprus
2451,Regulation and Prequalification: Emergency Use Listing (EUL)-COVID-19 Vaccines
2452,Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
2453,"The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome"
2454,Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines
2455,FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
2456,"Oxford COVID vaccine trial group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
2457,Redistribution or horizontal equity in Hong Kong's mixed public-private health system: a policy conundrum
2458,Novavax vaccine delivers 89 % efficacy against COVID-19 in U.K.-but is less potent in South Africa
2459,B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes
2460,"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China"
2461,Association between short-term exposure to air pollution and COVID-19 infection: evidence from China
2462,Duration of protection against mild and severe disease by Covid-19 vaccines
2463,A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
2464,Treatment of Kounis syndrome
2465,Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
2466,A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation Between Neutralizing Antibodies and COVID-19 Severity
2467,Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
2468,Incidencia de casos nuevos de enfermedad por grupos de edad Estados Unidos Mexicanos
2469,Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines
2470,Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal
2471,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant -National Healthcare Safety Network
2472,Waning antibody levels after vaccination with mrna bnt162b2 and inactivated coronavac covid-19 vaccines in hong kong blood donors
2473,Genomic Surveillance of SARS-CoV-2 in Brazil
2474,Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants
2475,Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients
2476,Model-420 based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
2477,"Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals"
2478,Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction
2479,Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
2480,Linhagens do SARS-CoV-2 Em Circulacão
2481,Thermo Fisher Scientific for provision of an EVOS inverted microscope for the biosafety level 3 facility at the Emerging Viruses Laboratory; the National Institute of Science and Technology of Photonics Applied to Cell Biology for confocal microscopy analysis; UNICAMP-Task-Force against COVID-19
2482,The SARS-CoV-2 outbreak: What we know
2483,A beacon for the COVID-19 epidemic control in Brasil: seroepidemiological population-based surveys
2484,Simultaneous inference in general parametric models
2485,During Mild Versus Severe COVID-19
2486,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
2487,Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients
2488,Remembrance of things past: long-term b cell memory after infection and vaccination
2489,Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
2490,Comparison of antibody and T cell responses elicited 14 by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in 15 healthy adult humans
2491,Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
2492,Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
2493,"Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples"
2494,"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides"
2495,Effectiveness of COVID-19 vaccines against omicron or delta infection
2496,Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: 499 A Systematic Review and Meta-analysis
2497,Laboratory diagnosis of COVID-192021
2498,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variantassociated epidemic of COVID-19 in Brazil: a test-negative casecontrol study
2499,Development of mRNA Vaccines: Scientific and Regulatory Issues. Vaccines
2500,Interleukin 17 is a chief orchestrator of immunity
2501,Dexamethasone in hospitalized patients with Covid-19
2502,COVID-19 Vaccines for Moderately or Severely Immunocompromised People
2503,Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA
2504,Early alterations in myocardia and vessels of the diabetic rat heart :An FTIR microspectroscopic study
2505,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): A double-blind, randomised"
2506,"World Health Organization. Interim Recommendations for Use of the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2, under Emergency Use Listing: Interim Guidance, First Issued"
2507,Severe acute respiratory coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
2508,Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. MA Pediatr
2509,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action 2021
2510,Ferritin as prognostic marker in COVID-19: the FerVid study
2511,mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal
2512,Comparison of four SARS-CoV-2 Neutralization Assays
2513,Rational Vaccine Design in the Time of COVID-19
2514,"39) Body mass index: kg/m 2 (median, IQR)"
2515,Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-Saharan African countries
2516,63rd ASH Annual Meeting Abstracts POSTER ABSTRACTS 642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
2517,Antiviral activities of type I Interferons to SARS-CoV-2 infection
2518,COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
2519,Homologous and heterologous COVID-19 booster vaccinations
2520,"5′-TCGTTTCGGAAGAGA-CAGGT-3′; reverse primer, 5′-GCGCAGTAAGGATGGCTAGT-3′. gradient centrifugation, and peripheral blood mononuclear cells (PBMCs) were isolated using conventional Ficoll-Hypaque density-gradient centrifugation (GE Healthcare"
2521,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
2522,Spread of a Variant SARS-CoV-2 in
2523,Fomites and the environment did not have an important role in COVID-19 transmission in a Brazilian mid-sized city
2524,Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis
2525,"Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. West Valley Road, Suite 2500"
2526,Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv
2527,Vaccine sideeffects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
2528,"Balazs, mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant"
2529,A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine 587
2530,Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report
2531,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study
2532,Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
2533,Coronavirus Disease
2534,"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak"
2535,"Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion"
2536,Development of low-cost serological immunoassay to detect antiviral antibodies to SARSars-Cov-2 Spike protein
2537,Intradermal vaccination: a potential tool in the battle against the COVID-19 pandemic? Risk Manag
2538,A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
2539,"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States"
2540,Thrombosis after covid-19 vaccination
2541,Male sex identified by global COVID-19 metaanalysis as a risk factor for death and ITU admission
2542,Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
2543,Sequential IgG antibody monitoring for virusinactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers
2544,Transverse myelitis
2545,Indonesia (Data source: Ministry of Health of Indonesia)
2546,"Vaccine efficacy, effectiveness and protection"
2547,SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments
2548,mRNA CO-VID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
2549,Two cases of Graves' disease following SARS-CoV-2 vaccination: An autoimmune/inflammatory syndrome induced by adjuvants
2550,VACCINES CANDIDATES BY TRIAL PHASE. 2021
2551,The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate
2552,Role of nanotechnology behind the success of mRNA vaccines for COVID-19
2553,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series"
2554,Emerging vaccine delivery systems for COVID-19: functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine
2555,Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
2556,Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle
2557,COVID-19 Vaccine AstraZeneca package leaflet
2558,A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic
2559,Associations between air pollution and COVID-19 epidemic during quarantine period in China
2560,Personalized medicine case report a rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration
2561,Rede Genômica Fiocruz. Presença das linhagens por estado
2562,The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews. Checklist for Qualitative Research
2563,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines. medRxiv
2564,Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
2565,Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
2566,Chimpanzee-origin adenovirus vectors as vaccine carriers
2567,"Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, BBIBP-Corv, in People Younger Than 18 Years: A Randomised, Double-Blind, Controlled, Phase 1/2 Trial"
2568,Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
2569,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
2570,"SARS-CoV-2 in municipal wastewater treatment plant, collection network, and hospital wastewater"
2571,How to discover antiviral drugs quickly
2572,Development of Neutralizing Antibody Responses Against SARS-CoV-2 in COVID-19 Patients
2573,"Particulate air pollution and respiratory Haemophilus influenzae infection in Mianyang, southwest"
2574,SARS-CoV-2 Spike P681R Mutation Enhances and Accelerates Viral Fusion
2575,SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
2576,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial (2021) https:// trial siten ews. com/ indon esia-testi ng-locat ion-forchinas-sinov ac-phase-3-clini cal-trial/. Accessed 30 Mar 2021 Investigating a Vaccine Against COVID-19-Full Text View-Clini-calTrials.gov
2577,Plan Estratégico Para La Vacunación Contra La Covid-19 En La república de Argentina
2578,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases"
2579,COVID-19 and non-communicable diseases
2580,mRNA-1273 vaccine 829 induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
2581,Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2582,Five things to know about: Mixing and Matching Coronavirus Vaccines
2583,Medical studies during the COVID-19 pandemic; the impact of digital learning on medical students' murnout and metal health
2584,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
2585,Enhanced readiness for Omicron (B.1.1.529): technical brief and priority actions for member states
2586,Waning antibody levels after vaccination with mRNA BNT162b2 and inactivated CoronaVac COVID-19 vaccines in Hong Kong blood donors
2587,REFERENCES 1. WHO Health Emergency Dashboard.WHO (COVID-19). Homepage; 2021. Accessed
2588,COVID-19 vaccines: modes of immune activation and future challenges
2589,SARS-CoV-2 seroprevalence and risk factors among health care workers: estimating the risk of COVID-19 dedicated units
2590,Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
2591,"HPV vaccine confidence and cases of mass 327 psychogenic illness following immunization in Carmen de Bolivar, Colombia. Human vaccines & 328 immunotherapeutics"
2592,Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients
2593,The impact of COVID-19 on kidney transplantation and the kidney transplant recipient -One year into the pandemic
2594,Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients
2595,An mRNA Vaccine against SARS-CoV-2-Preliminary Report
2596,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving twodose inactivated vaccines in healthy adults
2597,Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) during pregnancy and the risk for autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in the offspring: A true effect o
2598,Age-specific mortality and immunity patterns of SARS-CoV-2
2599,Commentary: SARS-CoV-2 vaccines and cancer patients
2600,Journal Pre-proofs Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
2601,COVID-19: Imbalanced Immune Responses and Potential Immunotherapies
2602,Serological responses to COVID-19 Comirnaty booster vaccine
2603,Looking Beyond COVID-19 Vaccine Phase 3 Trials
2604,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the"
2605,AdviseDx SARS-CoV-2 IgG II
2606,Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
2607,Abbott SARS-CoV-2 IgG II Quant for Use with ARCHITECT
2608,COVID-19 Response in Thailand and Its Implications on Future Preparedness
2609,Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2
2610,Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273
2611,Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine. Emerg Infect Dis
2612,Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
2613,Subacute thyroiditis after SARS-CoV-2 infection
2614,Mutations of SARS-CoV-2-What Do They Mean?
2615,COVID-19 in kidney transplant recipients: a multicenter experience in Istanbul
2616,Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
2617,Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications
2618,Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines
2619,SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
2620,Safety and efficacy of singledose Ad26.COV2.S vaccine against covid-19
2621,Aluminum and vaccines: current state of knowledge
2622,Sex and Gender Differences in the Outcomes of Vaccination Over the Life Course
2623,Safety and immunogenicity of two RNA-based covid-19 vaccine candidates
2624,First case of 2019 novel coronavirus in the United States
2625,The importance of advancing SARS-CoV-2 vaccines in children
2626,e vaccine-elicited immunoglobulin profile in milk after COVID-19 mRNA-based vaccination is IgGdominant and lacks secretory antibodies
2627,Arterial hypertension as a risk comorbidity associated with covid-19 pathology
2628,Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials
2629,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial"
2630,Socioeconomic inequalities associated with mortality for COVID-19 in Colombia: a cohort nationwide study
2631,Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
2632,Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines
2633,"Type I and type III interferons-induction, signaling, evasion, and application to combat COVID-19"
2634,Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
2635,Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice
2636,An unusual presentation of pemphigus foliaceus following COVID-19 vaccination
2637,COVID-19 and cancer: current challenges and perspectives
2638,Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
2639,Evidence refuting the existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)
2640,Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector
2641,Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
2642,"Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: a multicenter, prospective, observational study. Thorac Cancer"
2643,Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis
2644,Why promoting a COVID-19 vaccine booster dose?
2645,COVID-19 vaccination in kidney transplant recipients
2646,Genomic evidence for reinfection with SARS-CoV-2: a case study
2647,Ambient fine particulate matter inhibits innate airway antimicrobial activity in preschool children in e-waste areas
2648,"World Health Organization, Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE Working Group on COVID-19 Vaccines. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
2649,Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines
2650,Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant 593 spreads
2651,Acceptability of vaccination against COVID-19 among healthcare workers in the Democratic Republic of the Congo. Pragmatic and Observational Research
2652,Effectiveness of an inactivated sars-cov-2 vaccine in chile
2653,Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations
2654,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
2655,A Novel Coronavirus From Patients With Pneumonia in China
2656,Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay
2657,Relational ethical approaches to the COVID-19 pandemic
2658,"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv"
2659,Predictors for severe COVID-19 infection
2660,Clinical vaccine development
2661,Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio
2662,Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic
2663,World Health Organization. Coronavirus disease (COVID-19) pandemic
2664,World Health Organization. COVID-19 Vaccines WHO EUL Issued
2665,Neutralizing antibodies against the sars-cov-2 omicron variant following homologous and heterologous coronavac or bnt162b2 vaccination
2666,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
2667,Characterizing SARS-CoV-2 mutations in the United States
2668,Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
2669,Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
2670,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
2671,"Articles Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study"
2672,•• Study which evaluated the efficacy and safety profile of CoronaVac
2673,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 Anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Re"
2674,Rapid generation of neutralizing antibody responses in COVID-19 patients
2675,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant
2676,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
2677,"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study"
2678,"Pregnancy, viral infection, and COVID-19"
2679,Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis
2680,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses
2681,Impact of SARS-CoV-2 variants on the
2682,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adult
2683,Neutralizing antibody levels are highly predictive of immune 624 protection from symptomatic SARS-CoV-2 infection
2684,Multicentre Prospective Cohort Study (the SIREN Study)
2685,Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan
2686,Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
2687,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults"
2688,"Hong Kong Special Administrative Region, China k Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Govern-ment of the Hong Kong Special Administrative Region"
2689,"COVID-19 incidence was higher in the CML than in the MPN population, probably because MPN patients were less exposed, and the older pts were the rst to receive vaccines"
2690,The impact of the COVID-19 pandemic on cancer patients
2691,An infectious cDNA clone of SARS-CoV-2
2692,SARS-CoV-2 B. 1.1. 529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals
2693,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries
2694,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a 505 systematic review and meta-analysis
2695,Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status
2696,Emergency use ICD codes for COVID-19 disease outbreak
2697,Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers With and Without Prior SARS-CoV-2 Infection
2698,Unequal Impact of
2699,Serum neutralizing activity elicited by mRNA-1273 vaccine
2700,Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR -Product information (updated). (2021)
2701,"REACT-1 round 13 final report: 674 exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with 675 Delta variant in England during"
2702,Air pollution by NO 2 and PM 2.5 explains COVID-19 infection severity by overexpression of angiotensinconverting enzyme 2 in respiratory cells: a review
2703,COVID-19 and Older Adults: What We Know
2704,Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity
2705,Is there a link between the pathogenic human coronavirus envelope protein and immunopathology? A review of the literature
2706,Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization
2707,Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses
2708,SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
2709,Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia Ankaravectored Ebola vaccines: a randomized clinical trial
2710,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
2711,Inactivated COVID-19 vaccines to make a global impact
2712,Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients
2713,Evolution of the COVID-19 vaccine development landscape
2714,"Anaphylaxis: clinical patterns, mediator release, and severity"
2715,A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice
2716,Journal Pre-proof Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta- analysis
2717,Landscape of COVID-19 Candidate Vaccines
2718,Adaptive value of high mutation rates of RNA viruses: Separating causes from consequences
2719,Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
2720,Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors
2721,Clinical Infectious Diseases BRIEF REPORT • cid 2021:XX (XX XXXX) • 1 Clinical Infectious Diseases ® 2021;XX(XX):0-0 False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine
2722,Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and 251 necessary measures for global immunity
2723,A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation
2724,Protection against COVID-19 by BNT162b2 booster across age groups
2725,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
2726,"Interim report: Safety and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
2727,Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
2728,Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report
2729,Philippines approves emergency use of Moderna's COVID-19 vaccine for 12-17 year olds
2730,Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health
2731,Immunogenicity and efficacy of heterologous ChAdox1-BNT162b2 vaccination
2732,Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection. Vaccine
2733,Antigenic minimalism of SARS-CoV-2 is
2734,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
2735,Bladder cancer diagnosis from bladder wash by Fourier transform infrared spectroscopy as a novel test for tumor recurrence
2736,Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants
2737,Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
2738,Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial
2739,Longer intervals and extra doses of ChAdOx1 188 nCoV-19 vaccine
2740,Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19/bnt162b2 vaccination
2741,Antibody neutralization to SARS-CoV-2 and variants after one year 470 in Wuhan
2742,World Health Organization.WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
2743,Epidemiology of diabetes mellitus in Mexico
2744,Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
2745,et als for the COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
2746,HIV-positive gay men's knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study
2747,World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance
2748,Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine
2749,Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination
2750,Erythema multiforme after CoronaVac vaccination
2751,Cost-effectiveness and budget impact analysis
2752,Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
2753,The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
2754,Immunosenescence and Human Vaccine Immune Responses
2755,Forward-looking serial intervals correctly link epidemic growth to reproduction numbers
2756,COVID-19 vaccines: Breaking record times to first-in-human trials
2757,Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
2758,Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage
2759,What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
2760,COVID-19 antibody tests and their limitations
2761,COVID-19 Outbreak Associated with Air Conditioning in Restaurant
2762,Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2763,"Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases systems**, n (%) 17564 (25.4) 11866 (17.2) and RT-PCR testing, median (p25-p75)"
2764,Diagnosis and management of pemphigus: Recommendations of an international panel of experts
2765,European Centre for Disease Prevention and Control. Types of seasonal influenza vaccine
2766,Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural
2767,"Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States"
2768,mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
2769,Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
2770,A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus
2771,Phase 1-2 trial of a SARSCoV-2 recombinant spike protein nanoparticle vaccine
2772,Mrna-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-Cov-2 Omicron Variant
2773,Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv
2774,Herd immunity: understanding COVID-19
2775,Airborne or droplet precautions for health workers treating COVID-19?
2776,Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
2777,Lessons learned one year after SARS-CoV-2 emergence leading to COVID-19 pandemic
2778,Minist erio da Sa ude. SIM. sistema de informações de mortalidade
2779,"Serological testing for COVID-19, immunological surveillance, and exploration of protective antibodies"
2780,Viral coagulopathy in patients with COVID-19: Treatment and care
2781,Infectious optic neuropathies: a clinical update
2782,Adenovirus vector-based vaccine for infectious diseases
2783,Carditis Risk After Messenger RNA and Inactivated Virus Vaccination a population-based cohort study
2784,"Immunogenicity and safety of two-visit, intradermal preexposure rabies prophylaxis simultaneously administrated with chimeric liveattenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country"
2785,Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine
2786,New tools for automated high-resolution cryo-EM structure determination in RELION-3
2787,CoronaVac (2x) DR + Pfizer (1x) DR
2788,SARS-CoV-2 neutralizing antibodies: A network meta-analysis across vaccines
2789,Durable Humoral and Cellular Immune Responses 8
2790,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet"
2791,PMCID:PMC7447111)
2792,SARS-CoV-2 spike L452R variant evades 440 cellular immunity and increases infectivity
2793,"COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variants, spike mutations and immune escape"
2794,Antibody responses to SARS-CoV-2 in patients with COVID-19
2795,Xinhuanet News. Namibia to start vaccinating teens against COVID-19
2796,"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment"
2797,Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
2798,Defining clinical improvement in adult and juvenile myositis
2799,E.a. The COVID-19 pandemic and global environmental change: emerging research needs
2800,COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration
2801,Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
2802,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial"
2803,COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider
2804,Reduced 882 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
2805,Comparative immunogenicity of 232 mRNA and inactivated vaccines against COVID-19
2806,Behcet's disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature
2807,International Expansion of a Novel SARS-CoV-2 Mutant
2808,mRNA vaccination boosts cross-variant 397 neutralizing antibodies elicited by SARS-CoV-2 infection
2809,Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-458 elicited antibodies
2810,Sinovac: Coronavac. Inactivated Vaccine. Available online
2811,"A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2812,Cytomegalovirus-specific CD4 T cells are Cytolytic and mediate vaccine protection
2813,Estimativas da população residente no Brasil e unidades da federação com data de referência em 1º de julho de 2019. Rio de Janeiro: IBGE
2814,"Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity"
2815,Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis
2816,Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults
2817,Republic of Turkey Ministry of Health. COVID-19 Vaccination Information Platform
2818,Assessing Immune Response to SARS-CoV-2 Infection
2819,A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
2820,SES/SP; 2021
2821,AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 476 at interim analysis
2822,Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil. medRxiv
2823,"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients"
2824,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: A prospective cohort study. medRxiv 2021"
2825,Coagulation cascade and fibrinolysis in patients with multipledrug allergy syndrome
2826,Effect of physical activity on the production of specific antibody in response to the 1998-99 influenza virus vaccine in older adults
2827,Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
2828,Molecular basis of receptor binding and antibody neutralization of Omicron
2829,A Predictive Model and Risk Factors for Case Fatality of COVID-19
2830,Using the Internet for Surveys and Health Research
2831,History of vaccination
2832,Omicron variant neutralization after mRNA-1273 booster vaccination
2833,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid
2834,"Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway"
2835,Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2
2836,Current Concepts in 311 Diagnosis and Treatment of Functional Neurological Disorders
2837,Risking further COVID-19 waves despite vaccination. The Lancet Infectious Diseases
2838,VIVALDI): a prospective cohort study. The Lancet Infectious Diseases
2839,Siemens Healthcare Diagnostics Atellica IM SARS-CoV-2 total (COV2T) ELISA assay for the detection of total antibodies to SARS-CoV-2
2840,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
2841,Evidence for antibody as a protective 230 correlate for COVID-19 vaccines
2842,"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines"
2843,Motor cortical 321 activity during motor tasks is normal in patients with complex regional pain syndrome
2844,Cross-Presentation by dendritic cells
2845,Michos A SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
2846,Autoimmune hepatitis after COVID-19 vaccination
2847,Turkey begins mass COVID-19 vaccination with Sinovac's jabs. 2021
2848,"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv"
2849,Safety and efficacy of the ChAdOx1
2850,Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia
2851,Clover's COVID19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
2852,Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
2853,Distribution of total cases of COVID-19 in the United States as of
2854,CoV-2 in convalescent individuals
2855,Mapping neutralizing and immunodominant sites on the 402 SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
2856,The clinical development process for a novel preventive vaccine: An overview
2857,Uveitis and other ocular complications following COVID-19 vaccination
2858,Spike in pollution to ignite the bursting of COVID-19 second wave is more dangerous than spike of SAR-CoV-2 under environmental ignorance in long term: a review
2859,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
2860,Bell's Palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study
2861,BNT162b2 643 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary 644 report
2862,Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
2863,Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples
2864,Heterologous prime-boost strategies for COVID-19 vaccines
2865,Open data on Malaysia's National COVID-19 Immunisation Programme
2866,Is It Lawful and Ethical to Prioritise Racial Minorities for COVID-19 Vaccines?
2867,"India's Coronavirus Death Toll Tops 400,000 as the Delta Variant Spreads Globally, Including in the United States-The Washington Post"
2868,SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19
2869,Effectiveness of an Inactivated SARS-CoV-2 Vaccine 11 in Chile
2870,World Health Organization. Considerations for Evaluation of COVID-19 Vaccines
2871,Emerging SARS-CoV-2 variants of 455 concern evade humoral immune responses from infection and vaccination
2872,"Monitoring incidence of COVID-19 cases, and deaths, by vaccination status 13 US jurisdictions"
2873,Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset
2874,Adverse reactions to COVID-19 vaccines: a practical approach
2875,seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
2876,Antigen-presenting cells in the skin
2877,Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
2878,Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
2879,"M on behalf of the VIPER (Vaccines IdP, and Epidemiology Research) group COVID-19 vaccine development and approvals tracker team, COVID-19 vaccine development and approvals tracker"
2880,"No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
2881,"Secretaria Extraordinário de Enfrentamento à COVID-19, Secovid. In Plano de Operacionalização da Vacinação Contra a COVID-19, 11 a ; Brasil. Ministério da Saúde: Brasília, Brazil"
2882,The role of air pollution (PM and NO2) in COVID-19 spread and lethality: a systematic review
2883,"CIs) with binary data was used for frequency of seroconversion rates of total anti-SARS-Cov-2 S1/S2 IgG (SC) and neutralizing antibodies (NAb) positivity. Tobit regression was used for natural log transformed GMT, FI-GMT and neutralizing activity. *P<.05, **P<.01, ***P<.001. Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination"
2884,Cutaneous reactions reported after Moderna 432 and Pfizer COVID-19 vaccination: A registry-based study of 414 cases
2885,Retrieved
2886,Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS
2887,The manuscript was written by Valéria O. Silva and Luís F. de Macedo Brígido
2888,secured funds and supervised the project
2889,"Vacunas contra sars-cov-2 utilizadas en chile mantienen altos niveles de efectividad para evitar hospitalización, ingreso a uci y muerte"
2890,Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
2891,SARS-CoV-2 breakthrough infections in fully vaccinated individuals
2892,WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination
2893,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
2894,Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases
2895,Dynamics of inactivated SARS-CoV-2 vaccine antibody response in SARS-CoV-2-seropositive autoimmune rheumatic disease patients
2896,COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
2897,SARS-CoV-2 variant classifications and definitions
2898,Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222)
2899,Time course of cerebral perfusion changes in children with migraine with Aura mimicking stroke
2900,Turkey Begins Administering Sinovac Shot to Health Workers
2901,SARS-CoV-2 Vaccine
2902,"The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations"
2903,Plano Nacional de Operacionalização da Vacinação contra a COVID-19. 2021. Ministério da Saúde website
2904,"SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: what is the connection?"
2905,Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine
2906,Institute for Public Health (IPH); National Institutes of Health; Ministry of Health Malaysia
2907,Allergic acute coronary syndrome (Kounis syndrome)
2908,I mmunosenescence and inflammaging: risk factors of severe COVID-19 in older people
2909,Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
2910,What other countries can learn from Italy during the COVID-19 pandemic
2911,Flare of rheumatoid arthritis after COVID-19 vaccination
2912,Epitopes for a 2019-nCoV vaccine
2913,Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against omicron variant
2914,Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
2915,Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults
2916,Coronavirus Vaccine -Weekly Summary of Yellow Card Reporting
2917,COVID-19 Vaccine Janssen: Guillain-Barré Syndrome Listed as a Very Rare Side Effect. European Medicines Agency
2918,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
2919,Correlates of protection against symptomatic and 170 asymptomatic SARS-CoV-2 infection
2920,Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection
2921,Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong
2922,Th17 cytokines and vaccineinduced immunity
2923,Skeletal muscle cells: from local inflammatory response to active immunity
2924,Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus? Front Immunol
2925,Omicron escapes the majority of existing SARS-CoV-2 386 neutralizing antibodies
2926,Threat Assessment Brief: Emergence of SARS CoV 2 B. 1.617 Variants in India and Situation in the EU/EEA
2927,SARS-CoV-2 antibody response in persons with past natural infection
2928,Mutation D614G increases SARS-CoV-2 transmission
2929,booster doses are considered third and fourth doses after the 2-dose primary COVID-19 vaccination series vaccines
2930,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19
2931,Estimating the effect of social inequalities on the mitigation of covid-19 across communities in santiago de chile
2932,Multiple Evanescent White Dot Syndrome
2933,Youtube'daki Aşılarlaİlgili Türkçe Videolar Neler Söylüyor? Birİçerik Analizi
2934,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
2935,Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer
2936,Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 8)
2937,Human Neutralizing Antibodies Against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection
2938,Extended interval 972 BNT162b2 vaccination enhances peak antibody generation in older people
2939,Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses
2940,COVID-19 dashboard
2941,CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
2942,Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong
2943,Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
2944,WHO coronavirus (COVID-19) dashboard. 2021
2945,Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness
2946,The cost-effectiveness of universal varicella vaccination in Italy: a model-based assessment of vaccination strategies
2947,Immunogenicity and safety of a SARS-CoV-2
2948,"2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
2949,R: A language and environment for statistical computing
2950,Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
2951,Virology Subject_term_id: sars-cov-2;virology
2952,Thailand cites positive results from Sinovac-AstraZeneca vaccine formula. Reuters
2953,Measures of multimorbidity and morbidity burden for use in primary care and community settings: A systematic review and guide
2954,Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong
2955,COVID-19: a review of therapeutic strategies and vaccine candidates
2956,Pathogenesis of the antiphospholipid syndrome
2957,What is an adequate sample size? Operationalising data saturation for theory-based interview studies
2958,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
2959,World Health Organization Draft Landscape of COVID-19 Candidate Vaccines
2960,Heterologous prime-boost immunization with CoronaVac and Convidecia
2961,Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects
2962,Reduced neutralization of 811 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
2963,Strategy to achieve global COVID-19 vaccination by mid-2022
2964,Vaccination drive against coronavirus begins with health care workers in Turkey
2965,Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant
2966,"Secretaria de Atenção Primária à Saúde, Departamento de Açõe Programáticas Estratégicas. Nota Técnica Nº 1/2021-DAPES/SAPS/MS. Recomendações referentes a administração de vacinas covid 19 em gestantes, puérperas e lactantes, incluindo os esclarecimentos que devem ser fornecidos para tomada de decisão"
2967,Susceptibility of circulating SARS-CoV-2 variants to neutralization
2968,Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial
2969,A systematic review of SARS-CoV-2 vaccine candidates
2970,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
2971,COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs
2972,2021. 2. WHO. Draft Landscape and Tracker of COVID-19 Candidate Vaccines
2973,Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions
2974,"A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? Vaccines 2020, 8, 220"
2975,Arthritis Foundation. ACR COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases
2976,but the intention of immediate vaccination declined substantially due to concerns about the vaccine's safety. The results implied that information about vaccination safety was important in addressing vaccine hesitancy and promoting successful herd immunity for the general population in China
2977,"No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups ınfected with SARS-CoV-2 delta variant"
2978,Immunosenescence and human vaccine immune responses
2979,mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
2980,Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
2981,Monitor da COVID: Vacinação. Lagom Data
2982,Biochemical characterization of SARS-CoV-2 nucleocapsid protein
2983,Interim national immunization technical advisory group for covid-19 vaccines resolution no
2984,COVID-19 Vaccines: Special Considerations for the Obese Population
2985,Interpretation of the Protocol for Prevention and Control of COVID-19 in China
2986,Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines. medRxiv
2987,"Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study Summary Background"
2988,Allocation of COVID-19 vaccination: when public prioritisation preferences differ from official regulations
2989,Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
2990,Antibody Response in Persons with Past Natural Infection
2991,13-Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel
2992,Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: a randomized controlled trial
2993,COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy
2994,Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers
2995,The variant gambit: COVID's next move
2996,Clinical and prognostic characteristics of 573 cases of primary Sjögren's syndrome
2997,Nonviral delivery of self-amplifying RNA vaccines
2998,Reduced neutralisation of 860 the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
2999,"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil"
3000,Molecular basis of COVID-19 relationships in different species: a one health perspective
3001,Agência Brasil -Vacinação contra COVID-19 começa em todo país
3002,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection-Full Text View-ClinicalTrials.gov. (2021)
3003,"Lymphocyte count, cells/L, median (IQR)"
3004,Vaccine hesitancy of the COVID-19 by health care personnel
3005,COVE Study Group (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
3006,Safety Monitoring of COVID-19 Vaccines in Hong Kong
3007,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: Aprospective, single-centre, longitudinal cohort study in health-care workers"
3008,Comparative effectiveness of COVID-19 vaccines against the Delta variant
3009,despite high seroprevalence
3010,Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina
3011,The immunogenicity and safety of different COVID-19 512 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
3012,vaccine for preventing severe outcomes in Israel: an observational study
3013,Prevalence of anti-platelet factor 4/ polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais
3014,Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
3015,Should We Mandate a COVID-19 Vaccine for Children?
3016,Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study
3017,World Health Organization. WHO coronavirus (COVID-19) dashboard 2021
3018,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial"
3019,Is prime boost strategy a promising approach in HIV vaccine development?
3020,Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
3021,Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
3022,"The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines"
3023,Comunicado de sochinf sobre variante delta en chile
3024,Distribution of SARS-CoV-2 variants of concern (VOCs) in samples examined during 632
3025,COVID-19 Vaccine Hesitancy in Canada: Content Analysis of Tweets Using the Theoretical Domains Framework
3026,"Neutralization of Alpha, Gamma, and D614G SARS-CoV-2 Variants by CoronaVac Vaccine-Induced Antibodies"
3027,The Turkish Ministry of Health Covid19 information page
3028,The COVID-19 vaccine development landscape
3029,"Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization; US Department of Health and Human Services, Food and Drug Administration: Silver Spring"
3030,COVID-19 vaccines in healthy adults
3031,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
3032,Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis
3033,Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y. V2 (B.1.351)
3034,Vaccination with 714 BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
3035,"Indonesia 2 Centre for Research and Development on Biomedical and Basic Health Technology, National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia"
3036,Psoriasiform disorders. Fitzpatrick's Dermatology
3037,"CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and 639"
3038,Períodico el Contribuyente México. Éstos son los costos de atención médica en el IMSS en
3039,Impact of yellow fever vaccine on patients with psoriasis: preliminary results
3040,Confronting the Delta Variant of SARS-CoV-2
3041,Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients with Autoimmune Rheumatic Diseases
3042,Effectiveness of the coronavac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: a test-negative case-control study
3043,At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis
3044,SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity
3045,Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent 1 and vaccinated sera 2 Running Title: SARS-CoV-2 B.1.617 variant exhibits neutralization resistant
3046,The epidemiology of infectious 568 gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study
3047,Boletim do Observatório Covid-19 -semanas epidemiológicas 16 e 17 de 2021
3048,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
3049,A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2
3050,MMWR 611 Morb Mortal Wkly Rep
3051,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind"
3052,Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study
3053,SARS-CoV-2 variant B.1.1.7 is 845 susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
3054,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial"
3055,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
3056,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines (Basel)
3057,Comparing the COVID-19 vaccines: how are they different
3058,Sinovac says a booster shot for COVID-19 would increase antibody response tenfold within one week
3059,COVID-19 vaccine development: a pediatric perspective
3060,The different types of COVID-19 vaccines
3061,"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial"
3062,Experience of 1089 COVID-19 Vaccination of Healthcare Workers in a Hospital Setting
3063,A SARS-CoV-2 antibody curbs viral nucleocapsid proteininduced complement hyperactivation
3064,SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 11. SARS-CoV-2 Variants of Concern and Variants under Investigation in England
3065,Algorithm AS 136 A K-Means Clustering Algorithm
3066,Effectiveness of BNT162b2 vaccine against omicron variant in South Africa
3067,Moradi-Asl E (2021b) Investigation of SARS-CoV-2 virus on nozzle surfaces of fuel supply stations in North West of Iran
3068,Development of the ClinESSDAI: a clinical score without biological domain A tool for biological studies
3069,Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
3070,Interim findings from first-1083 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a 1084 national prospective cohort study
3071,"SARS-CoV-2, COVID-19 and the Ageing Immune System"
3072,"Mitigating Covid-19 in the Face of Emerging Virus Variants, Breakthrough Infections and Vaccine Hesitancy"
3073,"A Third Dose of Inactivated Vaccine Augments the Potency, Breadth, and Duration of Anamnestic Responses Against"
3074,Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis
3075,"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial"
3076,Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine
3077,Increased risk of stroke after a herpes zoster attack
3078,An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
3079,"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence"
3080,COVID-19 outbreak associated with a SARS-CoV-2 P.1 lineage in a longterm care home after implementation of a vaccination program -Ontario
3081,Rayyan-a web and mobile app for systematic reviews
3082,"Ministério da Saúde: Brazilia, Brazil"
3083,Sjögren's syndrome: a systemic autoimmune disease
3084,RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
3085,Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study
3086,"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"
3087,Real-time analysis of a mass vaccination effort confirms the safety of FDAauthorized mRNA COVID-19 vaccines
3088,Case Report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination
3089,CoronaVac induces lower neutralising activity against variants of concern than natural infection. The Lancet Infectious Diseases
3090,Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine-United States
3091,"SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, 192 placebo-controlled, phase 1/2 clinical trial"
3092,CanSino's COVID-19 Vaccine Candidate Approved for Military use in China
3093,"Neutralising antibody activity against SARS-CoV-2 VOCs, B.1.617.2 and B.1.351 by BNT162b2 vaccination"
3094,Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
3095,COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
3096,Covaxin shot recommended for children in India
3097,World Health Organization. Polio vaccines: WHO position paper
3098,A leading coronavirus vaccine trial is on hold: scientists react
3099,Coronavirus diseases (COVID-19) Dashboard (2022) Updated on 5:13pm CET
3100,Clinical characteristics of subacute thyroiditis is different than it used to be -current state based on 15 years own material
3101,Positivity for NAb was defined as a neutralizing activity ≥ 30% (cPass sVNT Kit
3102,Initial report of 693 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
3103,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
3104,CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes
3105,The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach
3106,Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature
3107,Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
3108,Infection and Vaccine-871 Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
3109,How important is the vaccine for someone who has already had COVID-19? Not important Not very important I don´t know Important Very important
3110,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis
3111,Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study
3112,"World Health OrganizationInterim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac: Interim Guidance"
3113,"Vaccination status, acceptance, and knowledge toward a COVID-19 vaccine among healthcare workers: a cross-sectional survey in China"
3114,US Anti-Vaxxers Aim to Spread Fear Over Future Coronavirus Vaccine
3115,"Thailand to mix Sinovac, AstraZeneca vaccine doses"
3116,"A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv"
3117,1 variant transmission in Brazil: a test-negative case-control study
3118,"Optic Neuritis Complicating Measles, Mumps, and Rubella Vaccination"
3119,Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein
3120,Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients
3121,"Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States"
3122,Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet Respiratory medicine 2021
3123,El virus se adaptó para transmitirse rápidamente
3124,"Multimorbidity in middle age predicts more subsequent hospital admissions than in older age: A nine-year retrospective cohort study of 121,188 discharged in-patients"
3125,COVID-19 vaccine trials in Africa
3126,Multivariate Data Analysis: In Practice: an Introduction to Multivariate Data Analysis and Experimental Design
3127,Why the immune system fails to mount an adaptive immune response to a COVID-19 infection
3128,Questionnaire sur les effets secondaires des vaccins anti-COVID-19 chez le staff médical en Algérie −19 . Google Forms
3129,Carditis following Covid-19 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a case-control study
3130,Disponible sur: 925
3131,Single-domain antibodies make a difference. Science (80-)
3132,How to cite this article: Hadj Hassine I. Covid-19 vaccines and variants of concern: A review
3133,Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
3134,Homologous and Heterologous Covid-19 Booster Vaccinations
3135,T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
3136,Causal diagrams in systems epidemiology
3137,The influence of sex and gender on the immune response
3138,Austria: R Foundation for Statistical Computing
3139,Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv : the preprint server for health sciences
3140,Study of SH-SY5Y cancer cell response to treatment with polyphenol extracts using FT-IR spectroscopy
3141,Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
3142,Tanzania refuses COVID-19 vaccines
3143,National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
3144,"Eficácia global da Coronavac é de 50,38%, anuncia governo paulista"
3145,Prenatal antidepressant use and risk of attention-deficit/ hyperactivity disorder in offspring: population based cohort study
3146,Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
3147,Clinical Characteristics of Coronavirus Disease 2019 in China
3148,Immunology of COVID-19: Current state of the science
3149,"Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 2021"
3150,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"
3151,Disponible en: www.globaltradealert.org/reports 35. ForoALC2030. Cuarta reunión virtual del Foro de los Países de América Latina y el Caribe sobre el Desarrollo Sostenible
3152,Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA
3153,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in 574 Brazilian elderly
3154,Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
3155,World alliance for patient safety: WHO draft guidelines for adverse event reporting and learning systems: from information to action. Geneva: World Health Organization
3156,Risk for SARS-CoV-2 infection in healthcare workers
3157,Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
3158,The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction
3159,COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States
3160,Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine
3161,Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2
3162,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial"
3163,Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months 473 following primary infection
3164,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (Coronavacâ) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3165,Lessons for COVID-19 Immunity from Other Coronavirus Infections
3166,Evaluation of COVID-19 Vaccine Effectiveness: Interim Guidance
3167,COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses
3168,Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea
3169,N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
3170,Safety and Efficacy of the BNT162b2
3171,Obesity and COVID-19: The Two Sides of the Coin
3172,Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers
3173,Boosting with heterologous vaccines effectively improves protective 612 immune responses of the inactivated SARS-CoV-2 vaccine
3174,Hospital 784 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared 785 with alpha (B.1.1.7) variants of concern: a cohort study
3175,Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results
3176,SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe
3177,"Aging, cancer, and antitumor immunity"
3178,The differential impact of pediatric COVID-19 between high-income countries and low-and middle-income countries: a systematic review of fatality and ICU admission in children worldwide
3179,Secretaria de Vigilância em Saúde
3180,Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine
3181,Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. medRxiv
3182,e epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
3183,Expert suspects causal link between AstraZeneca jab and rare blood clots
3184,SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
3185,Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey
3186,Data. Coronavirus (COVID-19) Vaccinations -Statistics and Research
3187,Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
3188,Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
3189,Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
3190,Emergence of SARS-CoV-2 Variants in the World: How Could This Happen? Life
3191,Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation
3192,Sex-based biology and the rational design of influenza vaccination strategies
3193,COVID-19 and myositis -unique challenges for patients
3194,MMWR Morb Mortal 640 Wkly Rep
3195,The clinical development process for a novel preventive vaccine: an overview
3196,Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
3197,The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States
3198,COVID-19 vaccination in developing nations: challenges and opportunities for innovation
3199,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines
3200,COVID-19 vaccine tracker and landscape
3201,An overview of COVID-19
3202,WHO. The Sinovac-CoronaVac COVID-19 vaccine: what you need to know. 2021
3203,Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays
3204,Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study
3205,Access to vaccines in brazil and the global dynamics of the health economic-industrial complex
3206,Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
3207,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals-Full Text View-ClinicalTrials.gov
3208,Structures and distributions of SARS-CoV-2spike proteins on intact virions
3209,"Progress of the COVID-19 365 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
3210,Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
3211,Hospitalizations Among Adults Without Immunocompromising Conditions -United States
3212,"Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study"
3213,Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
3214,"Centers for Disease Control and Prevention, 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel"
3215,Effects of COVID-19 and mRNA vaccines on human fertility
3216,Updates on COVID-19 Variants of Concern
3217,Comparing the clinical efficacy of 461 COVID-19 vaccines: a systematic review and network meta-analysis
3218,Virological assessment of hospitalized patients with COVID-2019
3219,Non-alcoholic fatty liver disease among patients with sleep 575 disorders: a Nationwide study of Taiwan
3220,Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
3221,Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. medRxiv 2021
3222,The challenges of containing SARS-CoV-2 via test-trace-and-isolate
3223,Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes
3224,Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B
3225,FDA Briefing Document-Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. US Food and Drug Administration
3226,Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients
3227,Effectiveness of COVID-19 vaccines against the B. 1.617.2 (Delta) variant
3228,Computation and analysis of multiple structural change models
3229,Accurate spliced alignment of long RNA sequencing reads
3230,Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
3231,Effectiveness of a nation-wide COVID-19 vaccination program in Mexico
3232,Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations
3233,Neutralizing antibodies against the SARS-CoV-2 Delta and 580
3234,"Guillain-Barre syndrome, influenza, and influenza vaccination: 405 the epidemiologic evidence"
3235,CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection 903 and vaccination. bioRxiv. 5 mai 2021
3236,Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
3237,Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (delta) variant
3238,Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study
3239,Adrenal Vascular Changes in COVID-19 Autopsies
3240,A brief outline of respiratory viral disease outbreaks: 1889-till date on the public health perspectives
3241,A collaborative approach to investigating the risk of 407 thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
3242,Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19
3243,reactive T-and B cell responses in COVID-19 vaccine recipients
3244,Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
3245,Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
3246,Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination -a case report. C Pediatr
3247,Epub ahead of print) future science group
3248,An observational study to identify the prevalence of thrombocytopenia and anti-PF4/ polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
3249,Influence of a COVID-19 vaccine&#x2019;s effectiveness and safety profile on vaccination acceptance
3250,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-Cov-2 in Patients Undergoing Treatment for Cancer
3251,SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration
3252,The Short Time Exposure (STE) test for predicting eye irritation potential: intra-laboratory reproducibility and correspondence to globally harmonized system (GHS) and EU eye irritation classification for 109 chemicals
3253,Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis
3254,Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
3255,Global prevalence and drivers of dental students' COVID-19 vaccine hesitancy
3256,Journal Pre-proof Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature reviewAIBDs and SARS-Cov-2 vaccination Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of pemphigus vulgaris and a literature review
3257,Neutralizing antibodies against the SARS-CoV-2 Omicron variant 577
3258,Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
3259,Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients
3260,Available at
3261,"000 (82) 2,751,916/3,443,000 (80) 171,899/3,443,000 (5.0) 30-39 889"
3262,Disposable face masks and reusable face coverings as non-pharmaceutical interventions (NPIs) to prevent transmission of SARS-CoV-2 variants that cause coronavirus disease (COVID-19): Role of new sustainable NPI design innovations and predictive mathematical modelling
3263,Prevention of Dabigatran-Related Gastrointestinal 440
3264,Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study
3265,Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing
3266,Coronavirus disease (covid-19) associated mucormycosis (CAM): case report and systematic review of literature
3267,BNT162b2 mRNA COVID-19 caccine in a nationwide mass vaccination setting
3268,Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination. US Food and Drug Administration website
3269,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
3270,Heterologous prime-boost vaccination
3271,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3272,Association between short-term exposure to air pollution and COVID-19 infection: Evidence from China
3273,booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
3274,Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries
3275,Article
3276,Safety and Immunogenicity of
3277,An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey
3278,Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
3279,"Documento técnico: campanha de vacinação contra a COVID-19: 23 de julho de 2021, 18ª atualização"
3280,"COVID-19 vaccine anaphylaxis : IgE, complement or what else ? A reply to"
3281,Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom
3282,Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience
3283,A cross-country database of COVID-19 testing
3284,Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers-A Danish cohort study
3285,Features and development of Coot
3286,Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi
3287,Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong
3288,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv
3289,Serum antibody profile of a patient with coronavirus disease 2019 reinfection
3290,Comprehensive integration of single-cell data
3291,"History of the COVID-19 pandemic: origin, explosion, worldwide spreading"
3292,mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern
3293,Effectiveness of Mrna COVID-19 Vaccines Against SARS-Cov-2 Infection in a Cohort of Healthcare Personnel
3294,Inflammation in hypertension
3295,A Primer on Effectiveness and Efficacy Trials
3296,STROBE 432 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 433 statement: guidelines for reporting observational studies
3297,A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
3298,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial"
3299,Reduced threshold for cortical spreading depression in female mice
3300,Sanctioned countries in the global COVID-19 vaccination campaign: the forgotten 70
3301,Saúde do idoso em tempos de pandemia COVID-19
3302,COVID-19: travel into the EU. Brussels: European Council 2022
3303,Our World in Data
3304,Immunology of COVID-19: current state of the science
3305,What you always needed to know about electroporation based DNA vaccines
3306,Limited resources of genome sequencing in developing countries: challenges and solutions
3307,Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants
3308,Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
3309,Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry
3310,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
3311,Wilson IA (2020) A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
3312,"Heterologous versus homologous covid-19 booster vaccination in previous recipients of two doses of coronavac covid-19 vaccine in brazil (rhh-001): A phase 4, non-inferiority, single blind, randomised study"
3313,Months after Ad26.COV2.S Vaccination
3314,"The Government of the Hong Kong Special Administrative Region. Together we fight the virus. Hong Kong, China: The Government of the Hong Kong Special Administrative Region"
3315,FTIR spectroscopy of whole cells for the monitoring of yeast apoptosis mediated by p53 over-expression and its suppression by Nigella sativa extracts
3316,Vascular wall imaging in reversible cerebral vasoconstriction syndrome -a 3-T contrast-enhanced MRI study
3317,Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies
3318,Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
3319,Rapid COVID-19 vaccine development
3320,MMWR Morb Mortal Wkly Rep
3321,Técnicos da anvisa recomendam uso emergencial da vacina de oxford
3322,Glyceryl trinitrate triggers premonitory symptoms in migraineurs
3323,Plano Nacional da Operacionalização da Vacinação Contra a COVID-19
3324,Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems
3325,BNT162b2 vaccine booster dose protection: A nationwide study from Israel. medRxiv
3326,Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
3327,Immunogenicity of a third 165 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in 166 healthy adults
3328,Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
3329,Delayed production of neutralizing antibodies correlates with fatal COVID-19
3330,COVID-19 mRNA Vaccine Induced Antibody Responses and Neutralizing Antibodies Against Three SARS
3331,Graves' disease following acute (subacute) thyroiditis
3332,Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes
3333,BR). e-SUS Notifica
3334,Joint investigation of 2-month post-diagnosis IgG antibody levels and psychological measures for assessing longer term multi-faceted recovery among COVID-19 cases in northern Cyprus
3335,"Brasileiro perdeu quase 2 anos de expectativa de vida na pandemia, e 2021 deve ser pior, diz demógrafa de Harvard. BBC News Brasil"
3336,Aspectos demográficos e socioeconômicos dos adultos brasileiros e a covid-19: uma análise dos grupos de risco a partir da pesquisa nacional de saúde
3337,"Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn"
3338,Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages
3339,T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire
3340,"Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1"
3341,Interim Public Health recommendations for fully vaccinated people
3342,Immunogenicity of the Ad26.COV2.S vaccine for COVID-19
3343,Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach
3344,Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
3345,"Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis"
3346,Vaccines (Basel) 2020
3347,World Health Organization. Draft landscape of COVID-19 candidate vaccines
3348,Considerable escape of SARSCoV2 Omicron to antibody neutralization
3349,"COVID-19 coagulopathy, thrombosis, and bleeding"
3350,All rights reserved. No reuse allowed without permission. perpetuity
3351,Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group
3352,"Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population"
3353,A thermostable mRNA vaccine against COVID-19
3354,Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently
3355,Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults
3356,"Safety and immunogenicity of an rAd26 and rAd5 vector-based 587 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-588 randomised phase 1/2 studies from Russia"
3357,Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis
3358,Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer
3359,Understanding the most important facilitators and barriers for online education during COVID-19 through online photovoice methodology
3360,Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland
3361,China COVID vaccine reports mixed results-what does that mean for the pandemic?
3362,The Effects of Heterologous Immunization with Prime-Boost
3363,Exhaled particles and small airways
3364,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States
3365,Short and longterm effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome
3366,"Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study"
3367,Reduced neutralization of SARS-CoV-2 B.1.617 449 by vaccine and convalescent serum
3368,Centers for Disease Control and Prevent. Interim clinical considerations for use of COVID-19 vaccines currently approved and authorized in the United States
3369,Early evidence of the effect of SARS-CoV-2 vaccine at one medical center
3370,Antibody responses to the BNT162b2 mRNA vaccine in individuals 485 previously infected with SARS-CoV-2
3371,Drug-induced interstitial lung disease: a systematic review
3372,BioNTech Product Monograph including Patient Medication Information Comirnaty(R) COVID-19 Vaccine
3373,ANA investigates: neurological complications of COVID-19 vaccines
3374,Spectroscopy as a tool for detection and monitoring of Coronavirus (COVID-19)
3375,Vaccines against the B.1.617.2 (Delta) Variant
3376,National strategy for test-trace-and-isolate (COVID-19
3377,Adenoviruses as vaccine vectors
3378,"Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud Recomendaciones basadas en consenso de expertos e informadas en la evidencia"
3379,An overview of vaccine development for COVID-19
3380,"Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors-A prospective community cohort study (Virus Watch)"
3381,mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants
3382,SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion
3383,Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
3384,Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2
3385,Prevention of host-to-host transmission by SARS-CoV-2 vaccines
3386,Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14
3387,"COVID-19 in patients with sickle cell disease: A single center experience from Ohio, United States"
3388,Development of an inactivated vaccine candidate for SARS-CoV-2
3389,COVID-19 vaccination: initial reactogenicity data. The Lancet
3390,Multilateral leaders task force on COVID-19. Data. Available at
3391,"Heterogeneity: I 2 = 0%, Q = 1.65, P ="
3392,"Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways"
3393,Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals
3394,Biphasic neurovascular changes in prolonged migraine aura in familial hemiplegic migraine type 2
3395,Throat wash as source of SARS-CoV-2 RNA to monitor community spread of COVID-19
3396,The US Regulatory System and COVID-19 Vaccines
3397,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial
3398,Impact of COVID-19 Pandemic on Flu and COVID-19 Vaccination Intentions among University Students
3399,Association between mRNA vaccination and COVID-19 hospitalization and disease severity
3400,Open Data on COVID-19 in Malaysia
3401,Statement -Older People are at Highest Risk From COVID-19
3402,The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States
3403,SARS-CoV-2 Post vaccinated adverse effects and efficacy in the Egyptian population
3404,Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
3405,"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial"
3406,"Efficacy and safety of an inactivated wholevirion SARS-CoV-2 vaccine (CoronaVac): interim results of a doubleblind, randomised, placebo-controlled, phase 3 trial in Turkey"
3407,Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies
3408,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
3409,Current advances in the development of SARS-CoV-2 vaccines
3410,Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients
3411,Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
3412,Maintaining Safety with SARS-CoV-2 Vaccines
3413,World Health Organization. COVID-19 vaccine Tracker and landscape
3414,Evidence assessment: Sinopharm/BBIBP COVID-19 vaccine
3415,Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States
3416,The Spike D614g Mutation Increases Sars-Cov-2 Infection of Multiple Human Cell Types
3417,Covid-19 Vaccines
3418,Cerebral venous sinus thrombosis
3419,Effectiveness of COVID-19 vaccines against Delta variant (B.1.617.2): a metaanalysis
3420,Clinical features of patients infected with 2019 novel coronavirus in
3421,Infectivity and Immune Escape of the New SARS-CoV-2 Variant of Interest Lambda
3422,Vaccine Hesitancy and Building Confidence in COVID-19 Vaccination | GOARN
3423,Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
3424,"Safety and Immunogenicity of the Vi-DT Typhoid Conjugate Vaccine in Healthy Volunteers in Nepal: An Observer-Blind, Active-Controlled, Randomised, non-Inferiority, Phase 3 Trial"
3425,Routine COVID-19 Testing may Not be Necessary for Most Cancer Patients
3426,Considering how biological sex impacts immune responses and COVID-19 outcomes
3427,Do vaccines protect against long COVID? What the data say
3428,"Safety, tolerability, and immunogenicity of an 486 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a 487 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
3429,COVID-19 vaccine hesitancy in a representative working-age population in France: A survey experiment based on vaccine characteristics
3430,"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort"
3431,COVID-19 in children and young people
3432,Vaccines: Correlates of vaccine-induced immunity
3433,COVID-19 vaccines for moderately to severely immunocompromised people. Cdc.gov; 2021
3434,SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3
3435,Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
3436,Systemic sclerosis and the COVID-19 pandemic: world Scleroderma Foundation preliminary advice for patient management
3437,Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
3438,COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
3439,"Guillain-Barré syndrome following the first dose of 428 SARS-CoV-2 vaccine: A temporal occurrence, not a causal association"
3440,"Mask up to keep it up"": Preliminary evidence of the association between erectile dysfunction and COVID-19"
3441,The Government of the Hong Kong Special Administrative Region. Government expands scope of priority groups and opens more CVCs
3442,BNT162b2 Vaccine 652 Effectiveness in Preventing Asymptomatic Infection with SARS-CoV-2 Virus: A Nationwide 653
3443,Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
3444,"Safety and immunogenicity of seven COVID19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
3445,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case-control study
3446,"Rapid increase in circulation of the SARS-CoV-2, B. 1.617. 2 (Delta) variant-Mesa County"
3447,Evaluation of a commercially-available surrogate virus neutralization test for severe acute 599 respiratory syndrome coronavirus-2 (SARS-CoV-2)
3448,Clinical Characteristics of 30 Medical Workers Infected With New Coronavirus Pneumonia
3449,Factsheet on COVID-19 Vaccination for Persons with Prior COVID-19 Infection
3450,Kawasaki disease and 13-valent pneumococcal conjugate 557 vaccination among young children: A self-controlled risk interval and cohort study with null results
3451,Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
3452,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
3453,2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
3454,Omicron escapes the majority of existing SARS-CoV-2 403 neutralizing antibodies
3455,Acute transverse myelitis -A rare clinical manifestation of Lyme neuroborreliosis
3456,Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
3457,Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
3458,Longitudinal analysis shows durable and broad immune memory after 475
3459,Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study
3460,Validation and 595 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
3461,SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
3462,"AstraZeneca vaccine: blood clots are ""extremely rare"" and benefits outweigh risks, regulators conclude"
3463,CoV-2) lineage with multiple spike mutations in South Africa
3464,Evidence of SARS-Cov-2-942 specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine
3465,"Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome"
3466,Fundação de Vigilância em Saúde do Amazonas. BOLETIM DIÁRIO COVID-19 NO AMAZONAS
3467,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted"
3468,"Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city"
3469,Small-area Deprivation Measure for Brazil: Data Documentation. University of Glasgow
3470,Notice of the state food and drug administration on issuing the guidelines for the grading standards for adverse events in clinical trials of prophylactic vaccines
3471,An mRNA Vaccine against SARS-CoV-2 -Preliminary Report
3472,Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
3473,Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study
3474,"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape"
3475,dos que não tomaram segunda dose. Agência Brasil
3476,"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial"
3477,Increased Risk of SARS-CoV-2 Reinfection Associated with Emergence of the Omicron Variant in South Africa
3478,The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV. Clinical Infectious Diseases
3479,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant ınfections among ıncarcerated persons in a federal prison-Texas
3480,"Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, japan, 2020"
3481,324 Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV 325 vaccination in Rio Branco
3482,Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis
3483,Vaccinating Children against Covid-19-The Lessons of Measles
3484,International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples
3485,A novel coronavirus from patients with pneumonia in China
3486,Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
3487,Protection 999 of BNT162b2 Vaccine Booster against Covid-19 in Israel
3488,Thrombosis and COVID-19 pneumonia: the clot thickens!
3489,Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 464
3490,ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
3491,Safety and immunogenicity of the third booster dose with inactivated
3492,Covid-19 vaccines: where we stand and challenges ahead
3493,Health system accounts in the international accountability perspective: Brazil
3494,Immune system and COVID-19 by sex differences and age
3495,The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
3496,Coronavirus vaccine trials have delivered their first results-But their promise is still unclear
3497,Effectiveness of 602 the Single-Dose Ad26.COV2.S COVID Vaccine
3498,Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase
3499,"Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia. Front. Med. 2021, 8, 644300"
3500,Safety and 162 immunogenicity of heterologous and homologous inactivated and adenoviral
3501,"Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina"
3502,Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
3503,The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
3504,Emergence and rapid spread of a new severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
3505,"Emotional, behavioral, and psychological impact of the COVID-19 pandemic"
3506,Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates
3507,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
3508,Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine
3509,Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant-2021
3510,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
3511,Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
3512,Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv
3513,SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
3514,Immunogenicity and safety of the coronavac vaccine in patients with cancer receiving active systemic therapy
3515,Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases
3516,Barriers to Vaccination for COVID-19 Control-Experience from the United States
3517,Mass psychogenic illness in nationwide in-school vaccination 330 for pandemic influenza A (H1N1)
3518,COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee
3519,Bell's palsy following vaccination with mRNA 421 (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-422 control study
3520,COVID-19 Map-Johns Hopkins Coronavirus Resource Center
3521,"Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how?"
3522,Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance
3523,Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
3524,"SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection"
3525,Safety and immunogenicity of ChAdOx1
3526,Evaluation of the safety profile of COVID-19 vaccines: a rapid review
3527,"Children and adolescents with SARS-CoV-2 Infection: epidemiology, clinical course and viral loads"
3528,SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months 556 after the infection
3529,Safety and immunogenicity of anti-sars-cov-2 messenger RNA vaccines in recipients of solid organ transplants
3530,COVID-19: Medical community split over vaccine interval policy as WHO recommends six weeks
3531,Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant
3532,SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts
3533,BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants
3534,History and recent advances in coronavirus discovery
3535,One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19
3536,Structural and functional analysis of a potent sarbecovirus neutralizing antibody
3537,Rapid displacement of SARS-CoV-2 variant B.1.1.7 447 by B.1.617.2 and P.1 in the United States. medRxiv
3538,Overview of SARS-CoV-2 infection in adults living with HIV
3539,"Myocarditis following mRNA vaccination against SARS-CoV-2, a case series"
3540,Reduced neutralization of SARS-CoV-2 B.1.617 401 by vaccine and convalescent serum
3541,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 14"
3542,CLINICAL EXPERIMENTAL VACCINE RESEARCH
3543,COVID-19) vaccination information for public health professionals
3544,Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons
3545,COVID-19 vaccine: critical questions with complicated answers
3546,Available online at: https:// www.gatesfoundation.org/Media-Center/Press-Releases/2020/04/Gates-Foundation-Expands-Commitment-to-COVID-19-Response-Calls-for-International-Collaboration
3547,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults 20 in England: test negative case-control study"
3548,Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
3549,Automated electron microscope tomography using robust prediction of specimen movements
3550,The changing acceptance of COVID-19 vaccination in different epidemic phases in china: a longitudinal study
3551,Herd Immunity and Implications for SARS-CoV-2 Control
3552,Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients
3553,Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals
3554,COVID-19 and comorbidities in the Americas: Hands-on tool to estimate the population at increased and high risk of severe COVID-19 due to underlying health conditions for the Americas
3555,COVID-19) in the UK. Updated Wednesday 27
3556,COVID-19-associated ophthalmoparesis and hypothalamic involvement
3557,A case of severe interstitial lung disease after COVID-19 vaccination
3558,Elicits Potent Immune Responses in a Mouse Model
3559,Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
3560,CoV-2 nAb FIA
3561,CD8+ T cells clear influenza virus by perforin or Fas-dependent processes
3562,Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
3563,Clinical and Experimental Dermatology Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination
3564,Coronavirus Disease (COVID-2019) Situation Reports. 2020. Available online
3565,"RWYC Writing -original draft: SL, JYC, RWYC Writing -review & editing"
3566,Efficacy of Antibodies and Antiviral 399 Drugs against Covid-19 Omicron Variant
3567,Final analysis of efficacy and safety of single-dose Ad26.COV2.S
3568,Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
3569,China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine | Reuters
3570,Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
3571,Transverse myelitis after vaccination
3572,Diagnostic accuracy of serological tests for Covid-19: systematic review and metaanalysis
3573,Online ahead of print
3574,SARS-CoV-2 1001 Neutralization with BNT162b2 Vaccine Dose 3
3575,Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
3576,Cell-Mediated Immune Response to Respiratory Coronaviruses
3577,Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
3578,Immunogenicity and Safety of the COVID-19 Vaccines Compared With 458 Control in Healthy Adults: A Qualitative and Systematic Review
3579,Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: Results from a cross-sectional survey among staff of a large Italian teaching hospital
3580,Ultrarapid on-site detection of sars-cov-2 infection using simple atr-ftir spectroscopy and an analysis algorithm: high sensitivity and specificity
3581,Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 21/2021-CGPNI/DEIDT/SVS/MS. Orientações referentes aos erros de imunização relacionados às vacinas COVID-19
3582,Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
3583,"Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021"
3584,Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization
3585,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273
3586,COVID-19: is it just a lung disease? A casebased review
3587,Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics
3588,Department of Disease Control MoPH. Thailand. a guide to COVID-19 vaccines in Thailand
3589,"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine"
3590,Is one vaccine dose enough if you've had COVID? What the science says
3591,Pathogenesis of HIV infection: what the virus spares is as important as what it destroys
3592,Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers
3593,Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
3594,Sex differences in immune responses
3595,"Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate using CKD EPI Formula"
3596,Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine
3597,Global public health COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs
3598,Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
3599,Medidas de distanciamento social no controle da pandemia de COVID-19: potenciais impactos e desafios no Brasil
3600,"COVID-19 vaccines: production, affordability, allocation, and deployment"
3601,Análise da qualidade das estatísticas vitais brasileiras: a experiência de implantação do SIM e do SINASC. Ciência & Saúde Coletiva
3602,Challenges to vaccination against SARS-CoV-2 in patients with immune-mediated diseases
3603,"Familial hemiplegic migraine: follow-up findings of diffusion-weighted magnetic resonance imaging (MRI), perfusion-MRI and [99mTc] HMPAO-SPECT in a patient with prolonged hemiplegic aura"
3604,"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
3605,Autorização de Uso Emergencial de Vacinas contra a COVID-19
3606,An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
3607,"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study"
3608,Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
3609,Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
3610,FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations
3611,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
3612,"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?"
3613,Vaccine hesitancy: The next challenge in the fight against COVID-19
3614,A simple protein-based surrogate neutralization assay for SARS-CoV-2
3615,"BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data"
3616,High-definition optical coherence tomography findings in acute idiopathic blind spot enlargement (AIBSE) syndrome
3617,Amsterdam: European Medicine Agency
3618,Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
3619,Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
3620,Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
3621,Antibody titres decline 3-month post-vaccination with BNT162b2
3622,BA. 2 and BA. 3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative 394
3623,Evaluation of postintroduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization
3624,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers"
3625,Our World in Data: Statistics and Research-Cornavirus (COVID-19) Vaccinations
3626,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV
3627,The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity
3628,A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations
3629,Antibody response to COVID-19 vaccination in adults with hematologic malignant disease
3630,Fast model selection for accurate phylogenetic estimates
3631,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
3632,Vpr is required for efficient replication of human 422 immunodeficiency virus type-1 in mononuclear phagocytes
3633,Divergent SARS CoV-2 Omicron-421
3634,COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination
3635,Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
3636,Moderate exercise improves antibody response to influenza immunization in older adults
3637,Definition of COVID-19 cases and recommendations for COVID-19 surveillance in Brazil
3638,Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic
3639,WHO. Interim statement on heterologous priming for COVID-19 vaccines
3640,Safety and efficacy of single-dose Ad26COV2S vaccine against covid-19
3641,Has a family member died or been admitted to ICU for COVID-19? Yes No
3642,Inference of COVID-19 epidemiological distributions from Brazilian hospital data
3643,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
3644,BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant
3645,Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice
3646,BNT162b2-elicited neutralization of 880 B.1.617 and other SARS-CoV-2 variants
3647,"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated SARS-CoV-2 vaccine in patients with sle: A case series"
3648,Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine
3649,Efficacy and Safety of the mRNA-1273
3650,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised
3651,"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -eight U.S. locations"
3652,SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients
3653,SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
3654,"Pandemic inequity in a megacity: a multilevel analysis of individual, community and health care vulnerability risks for COVID-19 mortality in Jakarta"
3655,Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
3656,COVID-19 Weekly Epidemiological Update Global overview
3657,Structural insights into coronavirus entry
3658,Current and innovative methods for the diagnosis of COVID19 infection (Review)
3659,Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
3660,Assessing transmissibility 418 of SARS-CoV-2 lineage B.1.1.7 in England
3661,Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern
3662,COVID-19 vaccination acceptance and its associated factors among cancer patients in Tunisia
3663,"Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England"
3664,COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): A prospective cohort study
3665,Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv 2021. preprint
3666,Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases
3667,Prothrombotic immune thrombocytopenia after COVID-19 vaccine
3668,Discusses the immunogenicity of CoronaVac in patients with rheumatological disease receiving immunomodulator drugs
3669,"SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties"
3670,Uganda to start inoculating children under 15 with Pfizer vaccine
3671,"A phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers"
3672,"Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study"
3673,The clinical and laboratory manifestations profile 560 of antiphospholipid syndrome among Saudi Arabia population: Examining the applicability of 561 Sapporo criteria
3674,COVID-19 vaccine-related interstitial lung disease: a case study
3675,Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients
3676,Grading of corneal and conjunctival staining in the context of other dry eye tests
3677,Antibody response of BNT162b2 and CoronaVac platforms in COVID-19 recovered individuals against SARS-CoV-2 wild type and delta variant
3678,COVID-19 Vaccines for Children and Teens
3679,Omicron SARS-CoV-2 variant: what we know and what we don't
3680,The Xs and Y of immune responses to viral vaccines
3681,Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein 1 triggers recent massive expansion of SARS-Cov-2 variants 2
3682,Effectiveness of CoronaVac among healthcare All rights reserved. No reuse allowed without permission. perpetuity
3683,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme opens to persons aged 16 or above
3684,Physician COVID-19 Vaccination Study (Final Report)
3685,A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex
3686,Keeping track of the SARS-CoV-2 vaccine pipeline
3687,Structural and 390 functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
3688,"SAGE Working Group on Vaccine Hesitancy Vaccine hesitancy: Definition, scope and determinants"
3689,COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
3690,ModelFinder: fast model selection for accurate phylogenetic estimates
3691,COVID-19 vaccine efficacy and effectivenessthe elephant (not) in the room
3692,Cord blood antibodies following maternal COVID-19 vaccination during pregnancy
3693,Sleeping when the world locks down: Correlates of sleep health during the COVID-19 pandemic across 59 countries
3694,Reactive arthritis after COVID-19 vaccination
3695,The potential danger of suboptimal antibody responses in COVID-19
3696,"Anti-PF4/polyanionic antibodies were positive in five participants in the ChAdOx1 nCoV-19, and four participants in the CoronaVac group by ELISA. The highest OD was 0.9. OD of >0.3 indicates positive result. Black dots indicate OD after first-dose vaccination, and red diamonds indicate OD after second-dose vaccination. Gray shading indicates negative range. OD; optical density"
3697,Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison -Texas
3698,Mental health and the covid-19 pandemic
3699,Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis
3700,"Transmission, 908 infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California 909 carrying a L452R spike protein mutation"
3701,"Efficacy and safety of an inactivated whole-virion sars-cov-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey"
3702,"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study"
3703,SARS-CoV-2 variants: levels of neutralisation required for protective immunity. medRxiv
3704,Threequarters attack rate of sars-cov-2 in the brazilian amazon during a largely unmitigated epidemic
3705,Vaccines in historic evolution and perspective: a narrative of vaccine discoveries
3706,Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
3707,Challenges to the system of reserve medical supplies for public health emergencies: Reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in china
3708,Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
3709,Waning Immune Humoral Response to BNT162b2
3710,A systematic review of factors affecting vaccine uptake in young children
3711,"Aging in COVID-19: Vulnerability, immunity and intervention"
3712,Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19
3713,Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study
3714,Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies
3715,China's COVID vaccines have been crucial-now immunity is waning
3716,Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
3717,Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
3718,"Efficacy and Safety of an Inactivated Whole-Virion SARS-Cov-2 Vaccine (Coronavac): Interim Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in Turkey"
3719,Allergic reactions to CO-VID-19 vaccinations-unveiling the secret(s)
3720,Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies
3721,Brazil: the PROFISCOV study
3722,Effectiveness of an Inactivated SARS-CoV-2
3723,COVID-19 Vaccine Effectiveness
3724,Coronavirus update (live) COVID-19 virus pandemic
3725,Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
3726,rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
3727,Immune Responses Against SARS-CoV-2 Variants After Heterologous and Homologous ChAdOx1 Ncov-19/BNT162b2 Vaccination
3728,On determining the most appropriate test cut-off value: the case of tests with continuous results
3729,-Chile´s Ministry of Health daily official report
3730,S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of 865 concern
3731,MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
3732,Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases
3733,Pipe-Friendly Framework for Basic Statistical
3734,"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study"
3735,Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea
3736,Immunogenicity of a third dose viral-vectored COVID-19 vaccine after 483 receiving two-dose inactivated vaccines in healthy adults
3737,Factors associated with COVID-19-related death using OpenSAFELY
3738,Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2
3739,Malaysia's third COVID-19 wave-a paradigm shift required
3740,Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine
3741,Influenzarelated hospitalizations among children in Hong Kong
3742,Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus
3743,Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects
3744,Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
3745,Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
3746,Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
3747,Oxford Vaccine Group COM-COV Comparing COVID-19 Vaccine Schedule Combinations
3748,Acute exercise enhancement of pneumococcal vaccination response: A randomised controlled trial of weaker and stronger immune response
3749,Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study
3750,Immunogenicity and safety of an intradermal BNT162b2 mRNA 263 vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
3751,Relation between COVID-19 and Guillain-Barré syndrome in adults. Systematic review
3752,"Vaccine hesitancy, vaccine refusal and the anti-vaccine 410 movement: influence, impact and implications"
3753,The self-controlled case series method
3754,Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients
3755,Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
3756,Chile´s Ministry of Health. Effectiveness of the SARS-CoV-2 vaccine program
3757,Self-controlled case series studies: A modelling guide with R
3758,5% de la población objetivo ha recibido la primera o única dosis de la vacuna contra SARS-CoV-2 -Ministerio de Salud -Gobierno de Chile
3759,Boosting immunity to COVID-19 vaccines
3760,COVID-19 vaccination and glomerulonephritis
3761,Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals
3762,The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine
3763,"Swords and Shields"" against COVID-19 for patients with cancer at ""clean"" and ""pandemic"" hospitals: are we ready for the second wave?"
3764,Vaccine booster efficiently inhibits entry of SARS-CoV-2 Omicron variant
3765,Neutralization of SARS-CoV-2 VOC 501Y.V2 848 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD 849 ZF2001 vaccines
3766,"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china"
3767,Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
3768,The Redox-Metabolic Couple of T Lymphocytes: Potential Consequences for Hypertension
3769,Turkey Finds Chinese Vaccine Efficacy Rate of 91.25% in Trial
3770,Food and Drug Administration Rituxan label
3771,Mortality National Information System
3772,Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients
3773,Effectiveness of heterologous ChAdox1 nCov-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study
3774,Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
3775,The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines
3776,Reduced neutralization of SARS-CoV-2 B.1.617 893 variant by inactivated and RBD-subunit vaccine
3777,SARS-CoV-2 infection in patients with systemic autoimmune diseases
3778,Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
3779,O R I G I N A L A R T I C L E Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study
3780,Primary exposure to SARS-CoV-2 protects against reinfection in Rhesus macaques
3781,WHO. Coronavirus disease (COVID19): Vaccines. 2021
3782,Severe COVID-19: what have we learned with the immunopathogenesis?
3783,Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
3784,Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis
3785,Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic EClinicalMedicine
3786,SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
3787,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study
3788,Human IgG and IgA responses to COVID-19 mRNA vaccines
3789,Developing mRNA-vaccine technologies
3790,Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
3791,Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU States
3792,Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
3793,SARS-CoV-2 uses CD4 to infect T helper lymphocytes
3794,SARS-CoV-2 variants: levels of neutralisation required for protective immunity
3795,An assessment of the screening method to evaluate vaccine effectiveness: The case of 7-valent pneumococcal conjugate vaccine in the United States
3796,COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
3797,"Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges"
3798,SARS-CoV-2 variant B.1.617 is resistant to 437 bamlanivimab and evades antibodies induced by infection and vaccination
3799,MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection
3800,What can the world learn from China's response to covid-19?
3801,Are genetic vaccines the right weapon against COVID-19?
3802,Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States
3803,T cell responses to SARS-CoV-2 spike cross-424 recognize Omicron
3804,ANCA glomerulonephritis after the Moderna COVID-19 vaccination
3805,Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
3806,Serologic vaccination response after solid organ transplantation: a systematic review
3807,Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?
3808,Allergy to COVID-19 vaccines: a current update
3809,Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
3810,Effects of a SARS-associated coronavirus vaccine in monkeys
3811,or GMFI (95% CI). n= the number of participants included the intervention modified intention-to-treat cohort. The P values are the results of comparison between the two treatment groups
3812,Available: https:// africacdc.org/download/covid-19-scientific-and-public-healthpolicy-update
3813,Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study
3814,Polyethylene glycol may be the major allergen in depot medroxyprogesterone acetate
3815,Social Science Research Network; 2021 mars 654
3816,"Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants"
3817,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study"
3818,Phyathai 3 Hospital. The. Bangkok
3819,"COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations"
3820,Detection of a SARS-CoV-2 variant of concern in South Africa
3821,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
3822,Evolution and epidemic spread of SARS-CoV-2 in Brazil
3823,Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep
3824,"COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis"
3825,COVID-19 breakthrough infections in vaccinated health care workers
3826,"Health inequity and the effects of COVID-19: assessing, responding to and mitigating the socioeconomic impact on health to build a better future"
3827,COVID vaccine excitement builds as Moderna reports third positive result
3828,New recommendation policies for pathogen surveillance testing of researchers and improved stewardship of diagnostic DNA
3829,Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
3830,Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study
3831,Meta-analysis in clinical trials
3832,Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
3833,Differential impacts of multimorbidity on COVID-19 severity across the socioeconomic ladder in Hong Kong: a syndemic perspective
3834,A simple method to assess and report thematic saturation in qualitative research
3835,European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
3836,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
3837,Vaccination
3838,The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
3839,Interactive spatial data analysis in medical geography
3840,Gender differences in myocarditis: a nationwide study in Finland
3841,"Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers"
3842,GISAID's Role in Pandemic Response
3843,Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3844,Protection of BNT162b2 vaccine booster against Covid-19 in Israel
3845,Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers
3846,Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
3847,Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Practice
3848,"Hazal Cansu Acar, Sumeyye Nur Aydin et al. Vaccine xxx (xxxx) xxx"
3849,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv
3850,Safety and immunogenicity of seven COVID-19 412 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
3851,"TNF inhibitors: infliximab, golimumab, adalimumab, etanercept, certolizumab pegol 2. Other cancers: peritoneum, gastric, liver, ovarium, testicular and small bowel 3. HSC: hematopoietic stem cell transplant"
3852,Discrete SARS-CoV-2 antibody titers track with functional humoral stability
3853,"Molecular sciences mRNA vaccine era-mechanisms, drug platform and clinical prospection"
3854,The hallmarks of COVID-19 disease
3855,Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile
3856,An mRNA vaccine against SARS-CoV-2 -preliminary report
3857,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""EpiVacCorona"" vaccine for the prevention of COVID-19"
3858,Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions
3859,A 'Mix and Match' Approach to SARS-CoV-2 Vaccination
3860,Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans
3861,SARS-CoV-2 vaccines: status report
3862,"nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
3863,data. Coronavirus (COVID-19) Vaccinations. Available online at
3864,Association between IL-10 systemic low level and pain during symptomatic SARS-CoV-2 infection
3865,SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted
3866,Comparative systematic review and meta-analysis of reactogenicity. immunogenicity and efficacy of vaccines against SARS-CoV-2 npj Vaccines
3867,A review of the progress and challenges of developing a vaccine for COVID-19
3868,Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: A systematic review and meta-analysis
3869,SARS-CoV-2 Immunoassays: Advancing diagnostics of COVID-19
3870,COVID-19 vaccine-induced myocarditis: case report with literature review
3871,"Extended Data Table 2 | Patient data: Yale healthcare worker SARS-CoV-2-vaccinated cohort Exact counts for each demographic category are displayed in N cell. Percentages of total, where applicable, are displayed in (%) cell. The mean with accompanying standard deviations for each measurement are displayed in Mean and SD cells respectively"
3872,Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2
3873,"Immunogenicity and safety of a third dose of coronavac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
3874,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-spike Protein-Protein Interaction
3875,"Considerable decrease of antibody titers against measles, mumps, and rubella in preschool children from an e-waste recycling area"
3876,SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front
3877,Emerging SARS-CoV-2 variants of concern and potential 388 intervention approaches
3878,Emergence of Omicron third lineage BA.3 and its importance
3879,"Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
3880,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, Phase 3 trial in Turkey"
3881,Southampton University COV-BOOST Evaluating COVID-19 Vaccine Boosters
3882,mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
3883,PMCID:PMC8632191)
3884,"Reporte COVID-19: Vacuna CoronaVac tiene un 90,3% de efectividad para prevenir el ingreso a UCI"
3885,Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant
3886,"Heterologous prime-boost immunisation in Ebola vaccine development, testing and licensure"
3887,PMCID:PMC8704915)
3888,"Department of Health and Human Services, Food and Drug Administration"
3889,"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26-and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study"
3890,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine
3891,WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
3892,Randomized 597 Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster 598 Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine
3893,Dynamic Igg Seropositivity After Rollout of Coronavac and BNT162b2 COVID-19 Vaccines in Chile: A Sentinel Surveillance Study
3894,"Lastest news, COVID-19 Coronavirus pandamic"
3895,Graves' disease with thyrotoxicosis following subacute thyroiditis
3896,"New COVID-19 cases and hospitalizations among adults, by vaccination status"
3897,Induction of robust neutralizing antibodies 958 against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster 959 following a primary vaccination series with CoronaVac
3898,Correlations of clinical and laboratory characteristics of COVID-19: a systematic review and meta-analysis
3899,Clinical Features of COVID-19 in Elderly Patients: A Comparison With Young and Middle-Aged Patients
3900,"COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study"
3901,Occurrence of subacute thyroiditis following influenza vaccination
3902,1.351 and B.1.1.7 to Antibody Neutralization
3903,Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
3904,Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports
3905,Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong
3906,Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
3907,Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
3908,Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
3909,Prevalence of comorbidities and their association with mortality in patients with COVID-19: a systematic review and metaanalysis
3910,Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
3911,The Impact of Vaccination on
3912,Health prices database
3913,Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
3914,Common risk factors for both arterial and venous thrombosis
3915,COVID-19 vaccines and risks of hematological abnormalities: nested case-control and selfcontrolled case series study
3916,"Features, Evaluation, and Treatment of Coronavirus (COVID-19)"
3917,Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
3918,Revista da Sociedade Brasileira de Medicina Tropical Case Report Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report
3919,Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines 2021
3920,Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations
3921,Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients
3922,Minist erio da Sa ude. COVID-19 painel coronavírus
3923,Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein
3924,Early rate reductions of SARS-CoV-2 1086 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet. 6 mars
3925,"High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in Over 75-Year-Olds, CearáState, Brazil"
3926,Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: The REACT-SCOT case-control study
3927,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study"
3928,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded"
3929,B cell memory and Plasma cell development
3930,Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
3931,Survival Analysis: Techniques for Censored and Truncated Data
3932,SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. medRxiv
3933,Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine
3934,Virological and serological kinetics of 1 SARS-CoV-2 Delta variant vaccine breakthrough infections: A multi-center cohort study
3935,Mounting evidence suggests Sputnik COVID vaccine is safe and effective
3936,"Journal Pre-proof Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report"
3937,Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
3938,Bleeding With Gastroprotective Agents: A Population-Based Study
3939,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
3940,Vaccines and the risk of Guillain-Barré syndrome
3941,COVE study group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
3942,"Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies"
3943,Prediction of long-term kinetics of vaccine-elicitedneutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
3944,Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
3945,mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern
3946,Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
3947,"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)"
3948,Cytokine gene expression in epidermis with biological effects following injection of naked DNA
3949,Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study
3950,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
3951,Inhalable Nanovaccine With Biomimetic Coronavirus Structure to Trigger Mucosal Immunity of Respiratory Tract Against COVID-19
3952,Changes in the humoral immunity response in SARS-CoV-2 418 convalescent patients over 8 months
3953,Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
3954,COVID-19 and air pollution and meteorology-an intricate relationship: a review
3955,Interim Report : Safety and Immunogenicity of an Inactivated Vaccine
3956,a systematic subnational analysis for the global burden of disease study
3957,Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
3958,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet"
3959,Omicron (B. 1.1. 529) variant of concern and its global perspective
3960,Chronic urticaria and autoimmunity: associations found in a large population study
3961,A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
3962,Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health -Europe
3963,Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China
3964,Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion
3965,CoV-2 Variants. bioRxiv. 19 juill 2021
3966,Clinical features of patients infected with 2019 novel coronavirus in Wuhan
3967,Sinovac says its Covid-19 vaccine generated immune responses-STAT
3968,Turkey's national immunization program
3969,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalised Adults Aged ≥65 Years -United States
3970,Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
3971,BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 451 variants
3972,Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway
3973,The Implementation of Mass-Vaccination against SARS-CoV-2: A Systematic Review of Existing Strategies and Guidelines
3974,World Health Organization (2022) Variants of concern (VOC)
3975,Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273
3976,Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19
3977,Single-dose 963 administration and the influence of the timing of the booster dose on immunogenicity and 964 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. 965 The Lancet. 6 mars 2021
3978,Incidence of SARS-CoV-2 Infection in Health Care Workers From Northern Italy Based on Antibody Status: Immune Protection From Secondary Infection-A Retrospective Observational Case-Controlled Study
3979,Incentives for Immunity-Strategies for Increasing Covid-19 Vaccine Uptake
3980,Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination
3981,Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
3982,"Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2"
3983,The Government of Hong Kong Special Administrative Region. Hong Kong vaccination dashboard. Hong Kong: The Government of Hong Kong Special Administrative Region
3984,One year update on the COVID-19 pandemic: where are we now?
3985,Um ano de pandemia da COVID-19: Diversidade genética do SARS-CoV-2 no Brasil
3986,Clinical Medicine Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey
3987,Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium
3988,Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. FDA News Release
3989,The Journal of Headache and Pain
3990,COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers
3991,Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration
3992,Interpreting diagnostic tests for SARS-CoV-2
3993,Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response
3994,Draft landscape and tracker of COVID-19 candidate vaccines-30
3995,Ministry of Health Malaysia. Open data on Malaysia's National COVID-19 Immunisation Programme
3996,"Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 11/2021-CGPNI/DEIDT/SVS/MS. Esclarecimentos sobre eventos adversos supostamente atribuíveis à vacinação contra a covid-19"
3997,Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot
3998,A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
3999,Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
4000,"Situação epidemiológica dos eventos adversos pós-vacinação contra a covid-19, Brasil"
4001,Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum
4002,Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses
4003,Associations between HIV infection and clinical spectrum of COVID-19: A population level analysis based on US National COVID Cohort Collaborative (N3C) data
4004,Interim recommendations for heterologous COVID19 vaccine schedules. Interim guidance
4005,Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study
4006,Public attention; 2021
4007,ARTICLE Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
4008,G-test of goodness-of-fit
4009,Investigation of SARS-CoV-2 virus in environmental surface
4010,Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
4011,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled"
4012,Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women
4013,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study
4014,Establishment of the WHO International standard and reference panel for anti-SARS-CoV-2 antibody
4015,Polyclonal F(ab )2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
4016,Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
4017,SARS-CoV-2 D614G Spike Mutation Increases Entry Efficiency With Enhanced ACE2-Binding Affinity
4018,SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
4019,Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Malignancy
4020,"double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
4021,Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
4022,Generalized linear models. 2 nd ed
4023,Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
4024,Vaccine Clinical Trials
4025,Data. Statistics and Research -Coronavirus (COVID-19) Vaccinations. 2021
4026,Vasovagal episode or anaphylaxis
4027,Clin Infect Dis
4028,SARS Coronavirus Spike Protein-Induced Innate Immune Response Occurs via Activation of the NF-kb Pathway in Human Monocyte Macrophages In Vitro
4029,Actualización Epidemiológica Enfermedad por coronavirus (COVID-19) [Internet] Washington DC: Organización Panamericana de la Salud
4030,Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr Oslo Nor
4031,Cross-reactive memory T cells and herd immunity to SARS-CoV-2
4032,Sexual dimorphism in SARS-COV-2 infection
4033,Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
4034,Hesitant or not? A global survey of potential acceptance of a COVID-19 vaccine
4035,COVID-19 Vacinação Doses Aplicadas
4036,Historical aspects of immunization and vaccine safety communication
4037,CureVac's mRNA-based vaccine candidate against COVID-19. CureVac; 2021
4038,Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines
4039,Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic
4040,Sinovac's Vaccine Approved by Indonesia for Emergency Use
4041,COVID-19) update: FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
4042,Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study
4043,"Safety and immunogenicity of heterologous versus homologous primeboost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a singleblind, randomised, non-inferiority trial"
4044,Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners
4045,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, Phase 1/2 trial"
4046,Comparative Immunogenicity of mRNA and Inactivated Vaccines Against COVID-19
4047,Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
4048,Thyroiditis and SARS-CoV-2 pandemic: a review
4049,Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
4050,Vaccines: correlates of vaccine-induced immunity
4051,Immune responses to SARS-CoV-2 among patients with cancer: what can seropositivity tell us?
4052,"Cerca de 570 mil profissionais de saúde se infectaram e 2,5 mil morreram por COVID-19 nas Américas"
4053,Neutralising capacity 886 against Delta (B.1.617.2) and other variants of concern following Comirnaty
4054,"COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, and other serious comorbid conditions: a cross-sectional internet-based survey"
4055,SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against
4056,COVID-19 vaccines: interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States
4057,"Effects and perceptions following COVID-19 vaccination in Jordan: a randomised, cross-sectional study implementing machine learning for predicting severity of side effects"
4058,COVID-19 vaccines: acting on the evidence
4059,Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials
4060,Myocarditis and pericarditis after vaccination for COVID-19
4061,Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
4062,Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis
4063,Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
4064,Prevalence of anti-platelet factor4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais
4065,Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
4066,Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults
4067,Localized cutaneous reaction to an mRNA COVID-19 vaccine
4068,A Phase III Study to Investigate a Vaccine Against COVID-19
4069,SARS-CoV-2 and viral sepsis: observations and hypotheses
4070,"Nyna Llanovarced-Kawles, and Álvaro Olivera-Nappa. Statistically-based methodology for revealing real contagion trends and correcting delay-induced errors in the assessment of COVID-19 pandemic"
4071,Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches
4072,Pemphigus vulgaris after SARS-CoV-2 vaccination: a case with new-onset and two cases with severe aggravation
4073,Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents
4074,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by 696 Vaccination Status"
4075,Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19
4076,Dynamic of anti-spike receptor binding domain (RBD) levels and short- term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers
4077,"Wię ckiewicz M. Demographic, clinical, laboratory, and genetic risk factors associated with COVID-19 severity in adults: a narrative review"
4078,Neutralizing Antibodies Against SARS-CoV-434 2 Variants After Infection and Vaccination
4079,ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
4080,MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
4081,Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children
4082,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: Test negative design study"
4083,Accelerating development of SARS-CoV-2 vaccines -the role for controlled human infection models
4084,Considerations in boosting COVID-19 vaccine immune responses
4085,Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
4086,Spike Is the Most Recognized Antigen in the Whole-Blood Platform in Both Acute and Convalescent COVID-19 Patients
4087,Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
4088,SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review
4089,The state of vaccine safety science: Systematic reviews of the evidence
4090,Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19
4091,Department of Health and Human Services NIH National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.0
4092,Migraine headache is present in the aura phase: a prospective study
4093,A Tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates
4094,"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers, israel"
4095,"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India-NC-ND license. EClini-calMedicine"
4096,Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine
4097,Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
4098,Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
4099,Will SARS-CoV-2 become endemic?
4100,"Transverse myelitis: pathogenesis, diagnosis and treatment"
4101,Inflammation and Arterial Hypertension-Pathophysiological Links and Clinical Aspects
4102,Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse
4103,mRNA vaccines -a new era in vaccinology
4104,Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological
4105,"Correlation Between SARS-Cov-2 Vaccination, COVID-19 Incidence and Mortality: Tracking the Effect of Vaccination on Population Protection in Real Time"
4106,COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics
4107,Sex and Gender Differences in the Outcomes of Vaccination over the Life Course
4108,Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2
4109,A Genomic Perspective on the Origin and Emergence of SARS-CoV-2
4110,Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia
4111,Symptoms and Symptom Clusters Associated With SARS-CoV-2 Infection in Communitybased Populations: Results From a Statewide Epidemiological Study
4112,"Dynamics of 553 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. and Salvador, Natalia and Franco"
4113,Population Ages 0-14 (% of Total Population)
4114,Plan Nacional de Vacunacion Covid
4115,Alter G. (2021) Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
4116,"Optimization, comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich ELISA for measurement of human IL-23"
4117,Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
4118,"Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls"
4119,"Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines (Basel) 2020"
4120,"Safety, mucosal and systemic immunopotency of an aerosolized adenovirusvectored vaccine against SARSCoV2 in rhesus macaques"
4121,Infectivity of asymptomatic versus symptomatic covid-19
4122,COVID-19 vaccines and decreased transmission of SARS-CoV-2
4123,COVID-19: insight into the asymptomatic SARS-CoV-2 infection and transmission
4124,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia
4125,Efficacy and safety of COVID-19 vaccines: A systematic review
4126,Cell Immunometabolism and Redox Signaling in Hypertension
4127,"World Health Organization. GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2. Geneva: WHO; 2021"
4128,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
4129,The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
4130,SARS-CoV-2 was already spreading in France in late
4131,A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria
4132,BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
4133,Ten months of COVID-19 in metropolitan region of Curitiba: the pandemic in the territory and the mitigation damage public policies in 2020
4134,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 510 2021:2021.07.27.21261116
4135,"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2"
4136,Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
4137,IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection
4138,Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel)
4139,The Special Committee for Ensuring Access to COVID-19 Vaccine
4140,Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection
4141,Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report
4142,SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons
4143,Structural Health Determinants and Comorbidity on COVID-19 Severity and Lethality in Older Mexican Adults: Considerations Beyond Chronological Aging
4144,Projeto S: imunização em serrana faz casos de covid-19 despencarem 80% e mortes
4145,Indonesia: Coronavirus Pandemic Country Profile
4146,Intradermal covid-19 vaccination could solve supply problems
4147,Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
4148,Geographical distribution of genetic variants and lineages of sars-cov-2 in chile
4149,"Transmission, Infectivity, and Neutralization of a Spike L452R SARS-CoV-2 Variant"
4150,Immunosenescence: Influenza Vaccination and the Elderly
4151,"High seroprevalence of SARS-CoV-2 (COVID-19)-Specific antibodies among healthcare workers: a cross-sectional study in guilan, Iran"
4152,Serum Antibody Profile of a Patient With Coronavirus Disease
4153,The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children
4154,"A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association With Severity"
4155,A global survey of potential acceptance of a COVID-19 vaccine
4156,Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients
4157,Immune-Mediated Disease Flares or New-Onset 437 Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
4158,Opendatasus. campanha nacional de vacinação contra COVID-19
4159,The SARS-CoV-2 spike glycoprotein as a drug and vaccine target: structural insights into its complexes with ACE2 and antibodies
4160,"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines"
4161,"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-Sprimed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial"
4162,Director-General's opening remarks at the media briefing on COVID-19 -11
4163,"Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show"
4164,Heterologous AD5nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
4165,Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type
4166,Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel)
4167,COVID-19 exacerbating inequalities in the US
4168,"COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV"
4169,SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
4170,"Department of Health, the Government of Hong Kong Safety monitoring of COVID-19 vaccines in Hong Kong"
4171,"Lessons from the ""Euro-Phospholipid"" project"
4172,COVID-19 vaccines for low-and middle-income countries
4173,Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
4174,Aurisicchio L (2020) Are genetic vaccines the right weapon against COVID-19?
4175,Is the host viral response and the immunogenicity of vaccines altered in pregnancy? Antibodies (Basel)
4176,"Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections"
4177,Systematic review of studies to determine factors affecting vaccine rejection/instability/contrast
4178,"Title Safety and efficacy of two immunization schedules with an inactivated SARS- 2 CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. Affiliations Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el Short running title: CoronaVac ® safety and efficacy in adults by two immunization"
4179,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac"
4180,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months
4181,The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety
4182,The Policy Institute. Coronavirus: Vaccine Misinformation and the Role of Social Media
4183,Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model
4184,Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
4185,NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO's COVID-19 Vaccine ConvideciaTM
4186,"Public Health Scotland and the EAVE 410 II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital 411 admission, and vaccine effectiveness"
4187,"Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France"
4188,The COVID-19 Outbreak and Oncology Centers in Iran
4189,Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants
4190,Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit
4191,COVID-19 data in Brazil
4192,27 WHO. EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody
4193,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
4194,"Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older"
4195,Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
4196,Science Task Force
4197,The acute stressinduced immunoenhancement hypothesis
4198,Brazil's unified health system: the first 30 years and prospects for the future
4199,mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.3.5.1 variants and severe COVID-19 disease in Qatar
4200,Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice
4201,"TAG-VE), classification of omicron (B.1.1.529): SARS-CoV-2 variant of Concern"
4202,"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus"
4203,Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
4204,Ambient air heavy metals in PM2.5 and potential human health risk assessment in an informal electronic-waste recycling site of China
4205,CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study
4206,"Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 delta VOC in Guangzhou. China EClinicalMedicine"
4207,An Interactive Web-Based Dashboard to Track COVID-19 in Real Time
4208,"Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis"
4209,The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
4210,Recurrence of subacute thyroiditis over 10 years after the first attack in three cases
4211,"Th1 cytokines, true functional signatures for protective immunity against TB?"
4212,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, doubleblind, and placebo-controlled phase 2 clinical trial"
4213,World Health Organization. The Sinovac COVID-19 vaccine: What you need to know
4214,Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study
4215,WHO SAGE values framework for the allocation and prioritization of COVID-19
4216,Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Frontline Workers Before and During B. 1.617. 2 (Delta) Variant Predominance-Eight US Locations
4217,SINOVAC科兴. 2021. 为人类消除疾病提供疫苗. Accessed
4218,CDC. Interim guidelines for COVID-19 antibody testing
4219,The protective and pathogenic roles of IL-17 in viral infections: friend or foe?
4220,Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine
4221,SARS-CoV-2 IgG Antibody Response after Immunization of Healthcare Workers with Inactivated COVID-19 Vaccine
4222,Brasil receberá as primeiras vacinas contra COVID-19 por meio do Mecanismo COVAX neste domingo
4223,Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
4224,Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
4225,Estimating Individual and Household Reproduction Numbers in an Emerging Epidemic
4226,FT-IR spectroscopy in diagnosis of diabetes in rat animal model
4227,Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: a systematic review and meta-analysis
4228,Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease
4229,Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years-United States
4230,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4231,Erythema multiforme after Corona-Vac vaccination
4232,"Mapping the Dutch vaccination debate on Twitter: Identifying communities, narratives, and interactions"
4233,Vaccine allergies
4234,The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?
4235,Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated 2 vaccine
4236,Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
4237,Turkey OKs emergency use of Sputnik-V vaccine
4238,"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses"
4239,Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants
4240,"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler"
4241,Intention to Receive the COVID-19 Vaccination in China: Application of the Diffusion of Innovations Theory and the Moderating Role of Openness to Experience
4242,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
4243,Recognizing vaccine-induced immune thrombotic thrombocytopenia
4244,A review on the effectivity of the current COVID-19 drugs and vaccines: are they really working against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants?
4245,Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein
4246,Inequalities in 571 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
4247,"Correlation of the units (U) of the Elecsys® Anti-SARS-CoV-2 S assay to the ""binding antibody units"" (BAU) of the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin"
4248,Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
4249,Threat assessment brief: emergence of SARS CoV 2 B. 1.617 variants in India and situation in the EU/EEA
4250,Moderna 2Q 2021 Earnings Call
4251,COVID-19) Vaccinations. Our World in Data
4252,Covid-19: Global Attitudes towards a COVID-19 Vaccine
4253,Breakthrough 256 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
4254,Hyperinflammatory shock in children during COVID-19 pandemic
4255,Inflammation and hypertension: new understandings and potential therapeutic targets
4256,Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study
4257,Overview of Variants/Mutations
4258,Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention
4259,Relaxing restrictions at the pace of vaccination increases freedom and guards against further covid-19 waves
4260,Content Themes and Influential Voices within Vaccine Opposition on Twitter
4261,Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep
4262,CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
4263,World Health Organization. Tracking SARS-CoV-2 variants
4264,Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS-CoV-2 Delta variant dominant period and their clinical characteristics
4265,Global Health Observatory|By category|Sex distribution of health workers
4266,How Much is the Cost of Each Covid-19 Patient? Available online
4267,"Transmission, infectivity, and neutralization of a 474 spike L452R SARS-CoV-2 variant"
4268,Draft landscape of COVID-19 candidate vaccines
4269,Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study
4270,"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study"
4271,Acute idiopathic blind spot enlargement syndrome following influenza vaccination
4272,"A comparative study between the severe acute respiratory syndrome-coronavirus-2, severe acute respiratory syndrome coronavirus, and the Middle East respiratory syndrome coronavirus"
4273,AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
4274,Screening for SARS-CoV-2 Antibodies in Convalescent Plasma in Brazil: Preliminary Lessons From a Voluntary Convalescent Donor Program
4275,Asia syndrome and endocrine autoimmune disorders
4276,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
4277,Clinical characteristics and risk profile of patients with elevated baseline serum tryptase
4278,Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis
4279,Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers 472 Previously Infected With SARS-CoV-2
4280,"Effects of Regular Physical Activity on the Immune System, Vaccination and Risk of Community-Acquired Infectious Disease in the General Population: Systematic Review and Meta-Analysis"
4281,Effectiveness of the first component of
4282,Structural basis for the recognition of the SARS-CoV-2 by full length human ACE-2
4283,SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
4284,Current understanding of Kounis syndrome
4285,Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
4286,Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant
4287,Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
4288,Vaccine Following Two CoronaVac Shots: A Case Report
4289,"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents"
4290,WHO. WHO Coronavirus Disease (COVID-19) Dashboard
4291,"Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia"
4292,WHO. Interim statement on COVID-19 vaccine booster doses 2021
4293,"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study"
4294,The arrival of Sputnik V
4295,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients
4296,An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile
4297,The biological and clinical significance of emerging SARS-CoV-2 variants
4298,Unfolding the mild to moderate shortterm side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study
4299,BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting
4300,Effectiveness of an Inactivated SARS-CoV-2 196
4301,Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
4302,Is there a role for childhood vaccination against COVID-19? Pediatr
4303,Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine
4304,Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
4305,SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women
4306,Behçet's-like adverse event or inaugural Behçet's disease after SARS-CoV-2 mRNA-1273 vaccination?
4307,Update of the guidelines for lupus anticoagulant detection
4308,BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
4309,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"
4310,Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults
4311,Correlation of Side Effects and Neutralizing Antibody mSphere
4312,Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
4313,Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
4314,COVID-19 Vaccine: Promoting Vaccine Acceptance
4315,T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine | 1
4316,"Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)"
4317,"Brown CM. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough 700 Infections"
4318,Sociodemographic moderation of the association between depression and stroke incidence in a retrospective cohort of 0.4 million primary care recipients with hypertension
4319,Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
4320,Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. medRxiv
4321,Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
4322,Categorical variables reported as number (%)
4323,A Minimal Common Outcome Measure Set for COVID-19 Clinical Research
4324,"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to ""potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"
4325,Risk of 425 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort 426 study
4326,Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose
4327,Virus isolation and quantitation
4328,Extrafollicular responses in humans and SLE
4329,"Covid-19: Herd immunity is ""unethical and unachievable, "" say experts after report of 5% seroprevalence in Spain"
4330,"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data"
4331,Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. Front. Public Health
4332,High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
4333,Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis
4334,Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series
4335,Endocrine significance of SARS-CoV-2's reliance on ACE2
4336,The COVID-19 pandemic: major risks to healthcare and other workers on the front line
4337,Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination -A systematic review and meta-analysis
4338,Interim Recommendations for Heterologous COVID-19 Vaccine Schedules
4339,The Use of Nanobiotechnology in Immunology and Vaccination
4340,"Covid-19: WHO declares pandemic because of ""alarming levels"" of spread, severity, and inaction"
4341,Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey
4342,Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
4343,COVID-19 Vaccine Tracker: Latest Updates -The New York Times. The New York Times
4344,Interpreting vaccine effectiveness trial results for infection and transmission
4345,SARS-CoV-2 breakthrough infections in vaccinated kidney transplant recipients: an issue of concern
4346,nsus_ inter im_ recom menda tions_ on_ the_ use_ of_ covid 19_ vacci nes_ inhk
4347,Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method-experience across the 2010/11 season
4348,Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks-Connecticut
4349,Immunological mechanisms of vaccination
4350,BioNTech/Pfizer) vaccination in health care workers
4351,Antibody responses to COVID-19 vaccines in older adults
4352,The Tribune. India gets its 1st vaccine for children above 12
4353,Heterologous ChAdOx1 nCoV-19 and mRNA-1273
4354,The antibody response to SARS-CoV-2 infection persists over at least 448 8 months in symptomatic patients
4355,Influenza vaccines in immunosuppressed adults with cancer
4356,Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
4357,Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
4358,Duration of Humoral Immunity to Common Viral and Vaccine Antigens
4359,Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2
4360,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Eng
4361,Estimated 757 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
4362,First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
4363,A Novel Coronavirus from Patients with Pneumonia in China
4364,Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China
4365,Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?
4366,COVID-19 Vaccines: a review of the safety and efficacy of current clinical trials
4367,Anomalous COVID-19 tests hinder researchers
4368,CoronaVac induces lower neutralising activity against variants of concern than natural infection
4369,Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report
4370,COVID-vaccine booster shot shows promise in Israeli study
4371,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study"
4372,The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
4373,"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments"
4374,"Sinovac is the most used vaccine in the world, with 943M doses delivered"
4375,Surveillance for Adverse 1041
4376,Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
4377,A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report
4378,Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
4379,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster
4380,Aluminiuminduced granulomas after inaccurate intradermal hyposensitisation injections of aluminium-adsorbed depot preparations
4381,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sarscov-2)
4382,Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach
4383,Brazilian Ministry of Health. COVID-19 vaccination applied doses
4384,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
4385,"Polio vaccination: past, present and future"
4386,Interim statement on COVID-19 vaccination for children and adolescents
4387,The race to a COVID-19 vaccine: opportunities and challenges in development and distribution
4388,"Coronavac has overall efficacy of 50.4 percent, says butantan"
4389,AZD1222 US Phase III primary analysis confirms safety and efficacy
4390,Short Term Reduction in 994 the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three 995 doses of the BNT162b2 Vaccine
4391,SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
4392,Strategic Advisory Group of Experts on Immunization -SAGE (WHO). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
4393,/BNT162b2 vaccination
4394,Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults-United States
4395,Fluoroquinolones and cardiovascular risk: a systematic review Meta-analysis and Network Meta-analysis
4396,Humoral immune response to SARS-CoV-2 in Iceland
4397,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Reagent Pack
4398,Transmission of Omicron (B.1.1.529) -SARS-CoV-2 variant of concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
4399,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant -national healthcare safety network
4400,How generation intervals shape the relationship between growth rates and reproductive numbers
4401,Rapid SARS-CoV-2 antigen detection assay in comparison with realtime RT-PCR assay for laboratory diagnosis of COVID-19 in ailand
4402,"Report on Evaluation of Safety, Efficacy and Quality of Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection"
4403,"Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera"
4404,Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications
4405,China's single-dose COVID vaccine has efficacy similar to Johnson & Johnson's. Fortune
4406,Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19
4407,Clinical Performance of a Standardized SARS-CoV-2 Interferon-g Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination
4408,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
4409,Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
4410,Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review
4411,Neutralization of UK-834 variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv
4412,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis
4413,"Covid-19: Algeria receives US donation of 604,800 doses of J&J vaccine"
4414,Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
4415,A novel concept for treatment and vaccination against Covid-19 with an inhaled chitosan-coated DNA vaccine encoding a secreted spike protein portion
4416,Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2
4417,Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households. medRxiv
4418,A one-shot COVID-19 vaccine
4419,Policy notes: interpretation of the protocol for prevention and control of COVID-19 in China
4420,Cultivation of viruses from a high proportion of patients with colds
4421,Multiple forms of mass anxiety in coronavirus disease-2019 pandemic
4422,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster
4423,Is the vaccine´s country of origin important in the decision to vaccinate? Yes No
4424,Evaluating and managing severe headache in the emergency department
4425,Overview of the Main Anti-SARS-CoV-429 2 Vaccines: Mechanism of Action
4426,WHO. 2022. WHO Coronavirus (COVID-19) Dashboard
4427,Non-viral COVID-19 vaccine delivery systems
4428,A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2
4429,Multi-Omics Resolves a Sharp Disease-State Shift Between Mild and Moderate COVID-19
4430,The full spectrum of COVID-19 development and recovery among kidney transplant recipients
4431,Advisory Committee on Immunization Practices -United States
4432,Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19
4433,COVID-19 vaccines in children: research to guide your news coverage
4434,Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
4435,Concise report SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
4436,ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses 491 among Health Care Workers. Vaccines (Basel) 2021
4437,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18−59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4438,Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
4439,an Inactivated SARS-CoV-2 Vaccine
4440,HLA common and well-documented alleles in China. HLA
4441,"COVID-19) Dashboard, Overview of all Countries"
4442,Rapid Measurement of SARS-Cov-2 Spike T Cells in Whole Blood From Vaccinated and Naturally Infected Individuals
4443,"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment"
4444,Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen
4445,"doi: medRxiv preprint workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study"
4446,Lira diz que inclusão de pessoas com comorbidades diminuiu ritmo de vacinação no Brasil. Valor Econômico
4447,Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients
4448,Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
4449,Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
4450,Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial
4451,Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
4452,Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys
4453,SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
4454,Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection
4455,Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre
4456,Análisis de impacto presupuestal de la vacunación contra COVID-19 en América Latina
4457,Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
4458,ESMO statements for vaccination against COVID-19 in patients with cancer
4459,"Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins"
4460,Covid-19. Draft Landscape of COVID-19 Candidate Vaccines
4461,World Health Organization. Covid-19 vero cell inactivated
4462,Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection
4463,Seoul metropolitan government COVID-19
4464,Oral pemphigus after COVID-19 vaccination
4465,"Safety and immunogenicity of CpG 1018 and aluminium hydroxideadjuvanted SARSCoV2 S2P protein vaccine MVCCOV1901: interim results of a large scale, doubleblind, randomised, placebocontrolled phase 2 trial in Taiwan"
4466,Introducing COVID-19 vaccination: Guidance for determining priority groups and microplanning. Version 1
4467,Genomic Survey of SARS-CoV-2 Vaccine Breakthrough Infections in Healthcare Workers From Kerala
4468,CDC Centre for Disease Control and Prevention. Adjuvants and Vaccines
4469,"Antibody response to the inactivated sars-cov-2 vaccine among healthcare workers, indonesia"
4470,Efficacy and safety of highdose influenza vaccine in elderly adults: a systematic review and meta-analysis
4471,COVID-19 vaccine response in pregnant and lactating women: a cohort study
4472,Journal Pre-proof Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine
4473,SARS-CoV-2 reinfection and implications for vaccine development
4474,SARS-CoV-2 viral load is associated with increased disease severity and mortality
4475,"Centre for Health Protection, Hong Kong Department of Health. Interim Guidance Notes On Common Medical Diseases and COVID-19 Vaccination In Primary Care Settings"
4476,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv
4477,Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
4478,Early-stage trial data on AstraZeneca COVID-19 vaccine due Monday -Lancet. Race for a cure
4479,Have deaths from COVID-19 in Europe plateaued due to herd immunity?
4480,Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
4481,COVAX anuncia un nuevo acuerdo y previsiones sobre las primeras entregas de vacunas
4482,"Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children"
4483,Inactivated Viral Vaccines
4484,Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up
4485,CMMID COVID-19 Working Group
4486,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
4487,Can a COVID-19 vaccine live up to Americans' expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions
4488,How Much Will a Covid-19 Vaccine Cost? The Financial Times
4489,Impaired humoral response in renal
4490,Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus
4491,Strengthened health systems are needed to tackle COVID-19 in Africa
4492,An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
4493,Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv
4494,One dose of 443 SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from 444 symptomatic COVID-19
4495,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial"
4496,WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
4497,COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey
4498,"Understanding the epidemiology, diagnosis and management of"
4499,data. Coronavirus (COVID-19) Vaccinations. Available online
4500,"Origin, evolution and global spread of SARS-CoV-2"
4501,Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals. Hum Vaccines Immunother
4502,EMA commissions independent research to prepare for real-world monitoring of COVID-19 vaccines
4503,Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
4504,Subacute thyroiditis following the H1N1 vaccine
4505,Thrombotic events and COVID-19 vaccines
4506,"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape"
4507,Respiratory support for adult patients with COVID-19
4508,62% dos indígenas na Amazônia estão vacinados contra COVID; AC e PA têm aldeias com baixa adesão. G1 Globo/ Instituto Socioambiental
4509,An interactive web-based dashboard to track COVID-19 in real time
4510,Characterization of the Second Wave of COVID-19 in India
4511,"which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder"
4512,The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
4513,ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
4514,Efficacy of ChAdOx1 nCoV-465 19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an 466 exploratory analysis of a randomised controlled trial. The Lancet [Internet]. 30 mars 2021
4515,Poor 1019 antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-1020 experienced individuals
4516,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection during a Delta variant epidemic surge in Multnomah County
4517,Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
4518,A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
4519,Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
4520,Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
4521,Evaluation of masks' internal and external surfaces used by health care workers and patients in coronavirus-2 (SARS-CoV-2) wards
4522,Global manual on surveillance of adverse events following immunization
4523,SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients
4524,Morbidity and Mortality Weekly Report COVID-19 Mortality and Vaccine Coverage -Hong Kong Special Administrative
4525,Projeções populacionais por sexo e idade para pequenas áreas no Brasil
4526,SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
4527,CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
4528,Vaccines against COVID-19
4529,Introduction to vibrational spectroscopy in diagnosis and screening
4530,Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in new jersey
4531,A new framework and software to estimate time-varying reproduction numbers during epidemics
4532,The role of IgA in COVID-19
4533,Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic
4534,Development of cell-based Pseudovirus entry 428 assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
4535,Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
4536,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against SARS-CoV-2 in Healthy Chilean Adults in a Phase 3 Clinical Trial. medRxiv
4537,Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
4538,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial"
4539,COVID-19 Vaccine Tracker. Sinovac: CoronaVac. Available online
4540,World Health Organization. Clinical management of COVID-19
4541,COVID-19 vaccine adverse reactions bring patients to emergency departments
4542,Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature
4543,safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine -United States
4544,Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
4545,Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
4546,Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
4547,SAHPRA update on section 21 Authorisation for Pfizer Comirnaty vaccine
4548,"Asymptomatic and presymptomatic sarscov-2 infections in residents of a long-term care skilled nursing facility-king county, washington"
4549,Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine
4550,SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
4551,"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models"
4552,Short-term immunogenicity profiles and predictors for suboptimal immune responses in patients with end-stage kidney disease immunized with inactivated SARS-CoV-2 vaccine
4553,"Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273"
4554,A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection
4555,Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
4556,SARS-CoV-2 variants B.1.351 and P.1 escape 466 from neutralizing antibodies
4557,"Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens"
4558,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. www. thela ncet"
4559,"The Fcmediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody"
4560,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers"
4561,Hong Kong Special Administrative Region. CHP Local Situation Dashboard
4562,SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
4563,"Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil"
4564,Lastest news. COVID-19 Coronavirus pandemic
4565,Covid-19 vaccination rollout: A commentary from England
4566,Diagnostic Snibe MAGLUMI 2019-nCoV IgM/IgG Immunoassay 2020
4567,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted"
4568,The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
4569,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial"
4570,"Convergent evolution of SARS-CoV-2 spike mutations L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra"
4571,"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants"
4572,"Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants"
4573,The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting
4574,Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
4575,COVID-19) Outbreaks in the United States
4576,Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
4577,Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
4578,Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
4579,Antibody 733 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
4580,Efficacy and Safety of BNT162b2 Vaccination in Patients With Solid Cancer Receiving Anticancer Therapy -A Single Centre Prospective Study
4581,The Role of Cost-Effectiveness in U.S. Vaccination Policy
4582,Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19
4583,The prime-boost strategy: exciting prospects for improved vaccination
4584,COVID-19 mortality among Indigenous people in Brazil: a nationwide register-based study
4585,"Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 14 de agosto de"
4586,The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay
4587,"First-dose ChAdOx1 and BNT162b2 COVID-19 418 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"
4588,Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant
4589,"A randomized, double-blind, placebocontrolled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial"
4590,Phase I/II study of intracutaneous inoculation of COVID-19 DNA vaccine (AG0302-COVID19)
4591,Depression and Anxiety in Hong Kong during COVID-19
4592,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers
4593,A Retrospective observational survey of 1058 adverse events following immunization comparing tolerability of covishield and covaxin 1059 vaccines in the real world
4594,"The brazilian health system: history, advances, and challenges"
4595,Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
4596,Longterm Specific IgG Response to SARS-CoV-2 Nucleocapsid Protein in Recovered COVID-19 Patients
4597,Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports
4598,Case Study of Two Post Vaccination SARS-CoV-2 Infections With P1 Variants in Coronavac Vaccinees in Brazil
4599,Waning of BNT162b2 vaccine protection against SARS-CoV-2 ınfection in Qatar
4600,ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
4601,Decreased blood hepatitis B surface antibody levels linked to ewaste lead exposure in preschool children
4602,Will COVID-19 Vaccinations End Discrimination against COVID-19 Patients in China?
4603,"High prevalence of syphilis, HBV, and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital"
4604,Aluminum treatment induces nitric oxide synthase in the rat brain
4605,Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
4606,All things equal? heterogeneity in policy effectiveness against covid-19 spread in chile
4607,• Comment about seropositivity in cancer patients
4608,Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
4609,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021
4610,Approval letter-Comirnaty. Accessed atwww.fda.gov/media/151710/download on 10
4611,Summary of Product Characteristic CoronaVac
4612,Transmission of SARS-CoV-2 variant B. 1.1. 7 among vaccinated health care workers
4613,SARS-CoV-2 IgG antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (CoronaVac) at Phyathai 3 Hospital
4614,New Zealand Ministry of Health
4615,Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health
4616,• Study which evaluated the efficacy and safety profile of CoronaVac in cancer patients
4617,The SARS-CoV-2 as an instrumental trigger of autoimmunity
4618,Perfil da Enfermagem no Brasil: relatório final. Rio de Janeiro: Fiocruz/COFEN
4619,Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
4620,Coronavirus Vaccine Developers Wary of Errant Antibodies
4621,Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variantdependent manner
4622,Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
4623,Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response
4624,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2:e423
4625,Evaluation of antibody response after COVID-19 vaccination of healthcare workers | 1
4626,Safety of SARS-CoV-2 436 vaccines: a systematic review and meta-analysis of randomized controlled trials
4627,Association of SARS-CoV-2 seropositive antibody test with risk of future infection
4628,"Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety"
4629,Plan Nacional De Vacunacioń
4630,Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera
4631,To appear in: Vaccine
4632,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in Sao Paulo, Brazil"
4633,Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label
4634,Omicron variant showed lower neutralizing sensitivity than 159 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
4635,Coronavirus Pandemic (COVID-19)
4636,Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review
4637,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study
4638,Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province
4639,Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients
4640,Safety and immunological response following heterologous primary series of COVID-19 vaccination: the preliminary report focusing on the delta variant
4641,SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study
4642,A pneumonia outbreak associated with a new coronavirus of probable bat origin
4643,"Inflammation, Immunity, and Oxidative Stress in Hypertension-Partners in Crime?"
4644,International Society of Hypertension global hypertension practice guidelines
4645,Guillain-Barré syndrome and influenza vaccines: A meta-analysis
4646,Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of ireland
4647,C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
4648,Effects of mRNA-based COVID-19 vaccine: nationwide phase iv study among healthcare workers in Slovakia
4649,Adverse events reported from COVID-19 vaccine trials: a systematic review
4650,Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review
4651,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 476 against Covid-19
4652,Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-reactive antibodies
4653,"Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil)"
4654,A new coronavirus associated with human respiratory disease in China
4655,Antigen-specific adaptive immunity to
4656,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioN-Tech mRNA COVID-19 vaccine
4657,Convalescent plasma anti-sars-cov-2 spike protein ectodomain and receptor-binding domain igg correlate with virus neutralization
4658,Strong humoral 967 immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 968 sixteen-week interval between doses
4659,ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
4660,CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 751 medRxiv
4661,"Kidney transplantation in the time of COVID-19: dilemmas, experiences, and perspectives"
4662,"Guidelines on diagnosis, treatment and prevention of Covid-19 in hospitals, the revised version"
4663,RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types
4664,World Health Organization. COVID-19 Weekly Epidemiological Update-Edition 64
4665,Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study
4666,WHO (2022) WHO director-general's opening remarks at the media briefing on COVID-19
4667,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial"
4668,Spread and dynamics of the covid-19 epidemic in italy: Effects of emergency containment measures
4669,"The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant"
4670,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
4671,"COVID-19: vaccine brands can be mixed in ""extremely rare occasions,"" says Public Health England"
4672,The Coronavirus Disease
4673,Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant
4674,mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2-preliminary report
4675,Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays
4676,World Health Organization. COVID-19 in Malaysia Situation Report 45
4677,Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv
4678,Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
4679,Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies
4680,Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
4681,"Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race"
4682,Publisher's Note
4683,Pfizer en personas ya vacunadas con una dosis de AstraZeneca
4684,WHO. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems
4685,Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
4686,Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots
4687,T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe
4688,A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine
4689,Molecular Diagnosis of a Novel Coronavirus (2019-Ncov) Causing an Outbreak of Pneumonia
4690,On the heterogeneous spread of covid-19 in chile
4691,Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study Background: Case reports of carditis after BNT162b2 vacci
4692,Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
4693,"Present variants of concern (VOC) and variants of interest (VOI) of SARS-CoV-2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape, and vaccines activity"
4694,"Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy)"
4695,Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study
4696,Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools
4697,IQ-TREE: A fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies
4698,V2 escapes neutralization by South African COVID-19 donor plasma
4699,Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in elderly people over 85 years of age in Greece
4700,Anti-SARS-CoV-2 antibody levels measured by the AdviseDx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing ımmunity
4701,MMR vaccine and idiopathic thrombocytopaenic purpura
4702,Correlates of protection against symptomatic and 185 asymptomatic SARS-CoV-2 infection
4703,Mouse and human FcR effector functions
4704,"Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis"
4705,COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals)-A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)
4706,Immediate-type systemic hypersensitivity reactions after the inactivated Sars-Cov-2 vaccine in healthcare workers
4707,"Soodeh Hooshmandi, Behrooz Ataei, and Shaghayegh Haghjooy Javanmard. Novel and emerging mutations of SARS-CoV-2: Biomedical implications"
4708,"Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis"
4709,Guidance for Industry: Clinical data needed to support the licensure of pandemic influenza vaccines. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research
4710,Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
4711,Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
4712,Emergence 753 and rapid spread of a new severe acute respiratory syndrome
4713,"COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity"
4714,Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
4715,Prime-boost vaccine strategy against viral infections: mechanisms and benefits
4716,Pathophysiology of migraine: a disorder of sensory processing
4717,Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination
4718,Strength and durability of antibody responses to
4719,Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination
4720,"Alter, A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus"
4721,World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022
4722,The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
4723,"Lamon-Fava S (2021) EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study"
4724,COVID-19 Vaccine Spikevax Approved for Children Aged 12 to 17 in EU
4725,A SARS-CoV-2 surrogate virus 497 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 498 interaction
4726,the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak
4727,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
4728,"Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine"
4729,COVID-19-neutralizing antibodies predict disease severity and survival
4730,Systemic and Mucosal Antibody Responses Specific to SARS
4731,Understanding neutralizing antibodies against SARS-CoV-2 and their implications in clinical practice
4732,"Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by Lselectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways"
4733,"Probable Inference, the Law of Succession, and Statistical Inference"
4734,"Safety, reactogenicity, and immunogenicity of All rights reserved. No reuse allowed without permission. perpetuity"
4735,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: Test negative case-control study
4736,micron extensively but incompletely escapes Pfizer BNT162b2 neutralization
4737,Eong Ooi E (2020) A single dose of self-transcribing and replicating RNA based SARS-CoV-2 1 vaccine produces protective adaptive immunity
4738,1.429 and B.1.351
4739,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial"
4740,Vaccine breakthrough ınfections with SARS-CoV-2 variants
4741,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
4742,NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
4743,SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
4744,"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the ""Epi-VacCorona"" vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II)"
4745,Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
4746,view points on SARS-CoV-2 vaccination in patients with RMDs
4747,Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example
4748,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial"
4749,"Association of SARS-CoV-2 Vaccinations with SARS-CoV-2 Infections, ICU Admissions and Deaths in Greece. Vaccines (Basel)"
4750,Optic neuritis
4751,The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial
4752,Hydroxychloroquine inhibits the trained innate immune response to interferons
4753,Considerations in boosting COVID-19 vaccine immune 4 responses
4754,Antibodies in the breast milk of a maternal woman with COVID-19. Emerg Microbes Infect
4755,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. Epub ahead of print
4756,"COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to -COVID-19 vaccine anaphylaxis -PEG or not?"
4757,"Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge"
4758,COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
4759,Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom
4760,"CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico"
4761,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 33
4762,Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy
4763,Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine
4764,How can a global pandemic affect vaccine hesitancy?
4765,Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
4766,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
4767,hk * Total persons vaccinated divided by total population in the age group
4768,A flare of Still's disease following COVID-19 vaccination in a 34-year-old patient
4769,Analysis of vascular event risk after herpes zoster from 2007 to 2014 US insurance claims data
4770,Evaluation of COVID-19 vaccination strategies with a delayed second dose
4771,"Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines (Basel) 9"
4772,Coronavirus Pandemic (COVID-19): Our World in Data
4773,WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 2021
4774,"Sitting Time, Physical Activity, and Risk of Mortality in Adults"
4775,Genomic characterization of an emergent SARS-CoV-2 lineage in Manaus: Preliminary findings
4776,Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorVvaccinated individuals compared with homologous BNT162b2 vaccination: results of a pilot prospective cohort study from Lebanon
4777,Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. The Lancet Microbe
4778,"Combined toxicity of outdoor air pollution on kidney function among adult women in Mianyang City, southwest China"
4779,Unilateral axillary adenopathy in the setting of COVID-19 vaccine
4780,Optimal governance and implementation of vaccination programmes to contain the COVID-19 pandemic
4781,Multiple evanescent white dot syndrome following influenza immunization -A multimodal imaging study
4782,"Epidemiological and clinical characteristics of 99 cases of 2019 novel 595 coronavirus pneumonia in Wuhan, China: a descriptive study"
4783,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
4784,Expert Committee on COVID-19 Vaccination: Updated Recommendation on Use of COVID-19 Vaccines
4785,Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a postvaccination cross-sectional survey
4786,"Vygen-Bonnet, S. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B. 1.617. 2) variant: Second interim results of a living systematic review and meta-analysis"
4787,Estimation of the asymptomatic ratio of novel coronavirus infections (covid-19)
4788,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study"
4789,Multivalue ethical framework for fair global allocation of a COVID-19 vaccine
4790,Heterogeneity: I 2 = 0%
4791,e cytokine storm and COVID-19
4792,Russia announces positive COVID-vaccine results from controversial trial
4793,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4794,Immunogenicity of heterologous prime/booster-inactivated and 629 adenoviral-vectored COVID-19 vaccine: real-world data
4795,Sinovac reports positive data from Phase I/II trials of CoronaVac
4796,Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans
4797,World Health Organization. WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell
4798,Effectiveness of BNT162b2 vaccine against Delta variant in adolescents
4799,Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic
4800,ANCA-associated vasculitis following pfizer-BioNTech COVID-19 vaccine
4801,Interim estimates of COVID-19 vaccine effectiveness in a mass vaccination setting: data from an Italian province. Vaccines (Basel)
4802,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
4803,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled phase 1/2 clinical trials. medRxiv"
4804,Digital 2021: Turkey. Available online
4805,T cell-oriented strategies for controlling the COVID-19 pandemic
4806,Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
4807,Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread
4808,Inflammation and coagulation
4809,"Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19"
4810,"Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine-United States"
4811,American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1
4812,Mental health outcomes of the CoViD-19 pandemic
4813,Sinovac COVID-19 vaccine: What are the side effects?
4814,BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2) variant in Qatar
4815,Vaccines for 9
4816,BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms
4817,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study
4818,Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
4819,Optic Neuritis After Influenza Vaccination
4820,Performance of a surrogate SARS-CoV-2-neutralizing antibody assay in natural infection and vaccination samples
4821,Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study
4822,Vaccine Boosts Immune Response In Pigs
4823,Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
4824,"s first COVID-19 vaccine for those above 12, gets nod. The Hindu"
4825,Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
4826,"efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
4827,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
4828,mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
4829,Herd immunity or suppression strategy to combat COVID-19
4830,"Histological appearance of second renal biopsy. (A) Normal histological appearance of glomeruli (haematoxylen & eosin, Â200). (B) Interstitial inflammation composed predominantly of lymphocytes"
4831,"Autoimmune bullous skin diseases, pemphigus and pemphigoid"
4832,Increased risk of SARS-CoV-2 390 reinfection associated with emergence of Omicron in South Africa
4833,"Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context"
4834,SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
4835,China: an observational cohort study
4836,"New mutations raise specter of ""immune escape"
4837,"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?"
4838,Covid-19 vaccination hesitancy
4839,"Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Dynamic of humoral response to SARS-CoV-2 anti Nucleocapsid and Spike proteins after CoronaVac vaccination Running title: Antibodies response after CoronaVac vaccine Technology and Innovation, Brazil Institutional Network, Project: Laboratories for"
4840,Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
4841,Special features of SARS-CoV-2 in daily practice
4842,Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
4843,Fouriertransform infrared spectroscopy coupled with a classification machine for the analysis of blood plasma or serum: a novel diagnostic approach for ovarian cancer
4844,mRNA vaccination 1006 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
4845,Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly
4846,Vacina adsorvida covid-19 (inativada)
4847,"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance"
4848,"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review"
4849,T follicular helper cells in human autoimmunity
4850,Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military
4851,A review on current COVID-19 vaccines and evaluation of particulate vaccine delivery systems
4852,COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform
4853,Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyzes of routinely-collected data on vaccine coverage and mortality
4854,CoronaVac induces lower neutralising activity against variants of concern 484 than natural infection
4855,Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01
4856,Reino Unido comienza vacunación masiva contra la covid-19: cómo es el proceso y qué se puede esperar
4857,"França Acquisition of data: Fernandes, Magliano, Macedo, Padila, Braga Analysis and interpretation of data: Fernandes, Santos, Tura, Macedo, Padila, França Drafting of the manuscript: Fernandes, Magliano, Macedo, Padila, França, Braga Critical revision of the paper for important intellectual content: Fernandes"
4858,Effectiveness of an ınactivated SARS-CoV-2 vaccine in Chile
4859,Analysis of the delta variant B.1.617.2 COVID-19
4860,The 2020 pandemic: current SARS-CoV-2 vaccine development
4861,Generation of influenza A viruses as live but replication-incompetent virus vaccines
4862,Entropy balancing is doubly robust
4863,Dating first cases of COVID-19
4864,Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?
4865,mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
4866,Abdel-Moneim AS (2021) Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective
4867,Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts-what is known so far
4868,"Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
4869,Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms. medRxiv
4870,Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine
4871,Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study
4872,Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria
4873,"Immunization stress-related response: a manual for program managers and 308 health professionals to prevent, identify and respond to stress-related responses following 309 immunization"
4874,A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients
4875,Mucosal Immunology
4876,The burden of seasonal and pandemic influenza in infants and children
4877,S/nCoV-19 Vaccine
4878,Dynamics of SARS-CoV-2 Neutralising Antibody Responses and Duration of Immunity: A Longitudinal Study
4879,Factors associated with early uptake of COVID-19 vaccination among healthcare workers in Azerbaijan
4880,Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
4881,Associations of baseline use of biologic or targeted synthetic DMARDs 16
4882,COVID-19 Vaccine: Critical Questions with Complicated Answers
4883,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B
4884,Durability of mRNA-1273 740 vaccine-induced antibodies against SARS-CoV-2 variants
4885,"COVID-19 in health-care workers: a living systematic review and metaanalysis of prevalence, risk factors, clinical characteristics, and outcomes"
4886,A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis
4887,Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
4888,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase 3 trial in Turkey"
4889,Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature
4890,Exercise and the Regulation of Immune Functions
4891,Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
4892,"Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays"
4893,Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens
4894,CDC's COVID-19 Vaccine Rollout Recommendations | CDC
4895,Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
4896,Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine
4897,Offline: COVID-19 is not a pandemic
4898,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
4899,Draft Landscape and Tracker of COVID-19 Candidate Vaccines
4900,Vacina de Oxford ultrapassa CoronaVac e é a mais usada no Brasil
4901,Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
4902,The severity of COVID-19 among pregnant women and the risk of adverse maternal outcomes
4903,Thailand Guideline for COVID-19 vaccination 2021 second edition
4904,Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment
4905,Multiplex 549 analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot
4906,WHO. WHO coronavirus (COVID-19) dashboard
4907,Sequence and Structural-based Computational Assessment
4908,The Census and Statistics Department of the Hong Kong Government
4909,Diagnostic performance of COVID-19 serology assays
4910,"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron"
4911,Covid-19 vaccines and variants of concern: A review Ikbel Hadj Hassine
4912,Safety and efficacy of singledose Ad26.COV2.S vaccine against COVID-19
4913,New-onset autoimmune phenomena post-COVID-19 vaccination
4914,Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses
4915,Prevention and attenuation of COVİD-19 with the BNT162b2 and mRNA-1273 Vaccines
4916,The manifestation of oral mucositis in COVID-19 patients: A case-series
4917,Commercial serology assays predict neutralization activity against SARS-CoV-2
4918,Phase I/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults
4919,"Comparative systematic review and metaanalysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2"
4920,Mixing COVID-19 Vaccines Appears to Boostİmmune Responses
4921,Janssen Vaccines & Prevention B.V. A Study of Ad26.COV2.S in Adults
4922,Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study
4923,"International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity"
4924,Recent advances in mRNA vaccine technology
4925,CoV-2 variants escape neutralization by vaccine-induced humoral immunity
4926,COVID-19 treatment: Close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
4927,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet"
4928,Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
4929,COVID-19 human challenge studies: ethical issues
4930,Cancer patients' willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea
4931,Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy
4932,Widespread psoriasis flare following influenza vaccination
4933,Frailty: implications for clinical practice and public health
4934,"Neutralization of SARS-CoV-2 Spike 69/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera"
4935,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days. medRxiv
4936,Rapid field determination of SARS-CoV-2 by a colorimetric and fluorescent dual-functional lateral flow immunoassay biosensor
4937,Safety and Immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile
4938,"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 Years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial"
4939,Predictors of willingness to receive COVID-19 vaccine: cross-sectional study of Palestinian dental students
4940,"The Global Epidemic of the SARS-CoV-2 delta variant, 393 key spike mutations and immune escape"
4941,Respiratory mucosal delivery of nextgeneration COVID19 vaccine provides robust protection against both ancestral and variant strains of SARSCoV2
4942,Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
4943,Benign ethnic neutropenia
4944,Looking beyond COVID-19 vaccine phase 3 trials
4945,Nurses' voices matter in decisions about dismissing vaccine-refusing families
4946,Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine
4947,FDA-authorized mRNA COVID-19 vaccines are effective per 21
4948,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
4949,"Department of Health, The Government of the Hong Kong Special 25 Administrative Region"
4950,Heterologous primeboost immunization with CoronaVac and Convidecia
4951,An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
4952,Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: Una guía práctica
4953,Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland
4954,"Sirotkin, B. Field evaluation of vaccine efficacy"
4955,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area"
4956,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/ 2 clinical trial"
4957,Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus
4958,"Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data"
4959,"SARS-CoV-2 variants, spike mutations and immune escape"
4960,"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo"
4961,Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv
4962,Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient
4963,Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
4964,Profile of specific antibodies to SARS-CoV-2: the first report
4965,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
4966,Antigen-specific antibody responses in lupus patients following immunization
4967,Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
4968,Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
4969,Vaccination into the Dermal Compartment: Techniques
4970,Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers
4971,Nota Técnica N° 1/2021-DAPES/SAPS/MS -Vaccination for pregnant and postpartum women with comorbities
4972,Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
4973,"The relationship of COVID-19 vaccine attitude with life satisfaction, religious attitude and COVID-19 avoidance in Turkey. Hum. Vaccines Immunother"
4974,Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
4975,"Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ 2021"
4976,immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv
4977,Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine 1
4978,"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine 1 (BBV152): a, double-blind, randomised"
4979,Projeções da população
4980,Dynamics of antibody response to CoronaVac vaccine
4981,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"
4982,Reactogenicity following receipt of mRNA-Based COVID-19 vaccines
4983,Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
4984,Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil
4985,BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel
4986,Covid-19 Vaccine in Children 5 to 11 Years of Age
4987,Properties of Coronavirus and SARS-CoV-2
4988,Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
4989,A multi-group SEIRA model for the spread of COVID-19 among heterogeneous populations
4990,Plano nacional de operacionalização da vacinação contra a covid-19: 9ª edição
4991,"Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France"
4992,Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant
4993,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
4994,Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
4995,"*Based on adjusted multivariable logistic regression, accounting for age (continuous), sex, district of COVID-19 in adults (aged 18 years), by age group"
4996,Controlled trial prednisolone in acute polyneuropathy
4997,"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study"
4998,ARTICLE Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
4999,A human monoclonal antibody blocking SARS-CoV-2 infection
5000,Intradermal Vaccination: 493 A Potential Tool in the Battle Against the COVID-19 Pandemic?
5001,Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac®)-SINOVAC -Supply Vaccines to Eliminate Human Diseases
5002,"Endocrinology adult and pediatric, 7th edn"
5003,Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without 743 Immunocompromising Conditions -United States
5004,COVID-19 Vaccination: From Interesting Agent to the Patient. Vaccines
5005,Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University hospital
5006,Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and 426 its immune cross-reactivity with SARS-CoV
5007,Cells Found in COVID-19 Patients Bode Well for Long-Term Immunity
5008,Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
5009,"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist"
5010,Fluctuations in environmental pollutants and air quality during the lockdown in the USA and China: two sides of COVID-19 pandemic
5011,Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data
5012,Systemic lupus erythematosus disease activity index
5013,Highlyspecific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA
5014,The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
5015,Maintaining safety with SARS-CoV-2 vaccines
5016,Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
5017,SARS-CoV-2 vaccines: anamnestic response in previously infected recipients
5018,Desafios das Fake News com Idosos durante Infodemia sobre Covid-19: Experiência de Estudantes de Medicina
5019,WHO. Coronavirus disease (COVID-19
5020,Censo 2010 IBGE
5021,Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia
5022,SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse
5023,Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them?
5024,Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
5025,PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
5026,Autoimmune phenomena following SARS-CoV-2 vaccination
5027,Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers
5028,Complete Course COVID-19 Vaccinal Rate in Beijing Exceeded 90%
5029,Approach to the patient with postpartum thyroiditis
5030,Will the COVID-19 pandemic end with the delta and omicron variants? 254
5031,Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
5032,Source apportionment and health risk assessment of air pollution particles in eastern district of Chengdu
5033,Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
5034,European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children
5035,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
5036,Allergic reaction reveals a non-lethal late stent thrombosis. A new subtype of Kounis syndrome?
5037,Targeting skin dendritic cells to improve intradermal vaccination
5038,Occurrence and spontaneous remission of Graves' hyperthyroidism preceded by painless thyroiditis
5039,Preclinical and Clinical Demonstration of Immunogenicity by mRNA 25
5040,Regional variation of Guillain-Barré syndrome
5041,A Case Report to Assess Passive Immunity in a COVID Positive Pregnant Patient
5042,Waiting vaccines. FGV IBRE
5043,COVID-19 and comorbidities: Deleterious impact on infected patients
5044,Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: one or even several swallows do not make a summer
5045,SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
5046,Verification of precision and estimation of bias; approved guideline
5047,Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 585
5048,The effect of estrogen in coronavirus disease 2019
5049,AS03-Adjuvanted Versus Non-Adjuvanted Inactivated Trivalent Influenza Vaccine Against Seasonal Influenza in Elderly People: A Phase 3 Randomised Trial
5050,Importance of efficacy in decision to vaccinate No Yes I don´t understand efficacy data Indifferent
5051,Myocarditis with COVID-19 mRNA vaccines
5052,"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: ORIGINAL RESEARCH"
5053,Measurement of multiple SARS-CoV-2 antibody titer after vaccination represents individual vaccine response and contributes to individually appropriate vaccination schedules. medRxiv
5054,Vaccination in the elderly: The challenge of immune changes with aging
5055,"Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data"
5056,"Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah. medRxiv 2021"
5057,Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years-United States
5058,Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum
5059,The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out
5060,Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers
5061,Changes of Lymphocyte Subsets in Patients With COVID-19 and Clinical Significance: A Case-Control Observational Study
5062,Second wave of COVID-19 in Brazil: Younger at higher risk
5063,Assessment of the immune responses to Treponema pallidum Gpd DNA vaccine adjuvanted with IL-2 and chitosan nanoparticles before and after Treponema pallidum challenge in rabbits
5064,Countries of origin of imported COVID-19 cases into China and measures to prevent onward transmission
5065,Enhanced SARS-CoV-2 neutralization by 205 dimeric IgA
5066,BNT162b2 vaccine 934 induces neutralizing antibodies and poly-specific T cells in humans
5067,The health of the healthcare workers
5068,1 skewed immune response of whole virion inactivated SARS cov 2 vaccine and its safety evaluation
5069,Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination-Kentucky
5070,World Health Organization. Rabies vaccines: WHO position paper
5071,Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance? Eur
5072,COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness
5073,Evidence of 552 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2
5074,Guangzhou Municipal Health Commission. COVID-19 situation update in Guangzhou on 21
5075,Immunology of COVID-19: Current State of the Science
5076,US Centers for Disease Control and Prevention. COVID-19 vaccine booster Shots
5077,"A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients"
5078,NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome
5079,"The Mysterious Disappearance of the First SARS Virus, and Why we need a Vaccine for the Current One But Didn't for the Other"
5080,In-terim guidance for COVID-19 vaccination in children and adolescents
5081,Department of Health. Hong Kong Vaccination Dashboard
5082,GAPSS: the Global Anti-Phospholipid Syndrome Score
5083,The coronavirus is here to stay-here's what that means
5084,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, doubleblind, randomised, placebo-controlled phase 2 clinical trials"
5085,1 strain of SARS-CoV-2. Cell [Internet]. 30 mars 2021
5086,AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
5087,The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). Short Title: Effectiveness of Vaxzevria and CoronaVac vaccines in Brazil
5088,Quinto Informe Estadistico: 1069 ESAVI asociados a la administracion de las vacunas SARS-CoV-2 en Chile
5089,Universal coronavirus vaccines-an urgent need
5090,Tracking Coronavirus Vaccination Around the World
5091,Dominance of alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
5092,Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv
5093,Evaluation of the performance of SARS-CoV--2 antibody assays for the longitudinal population-based study of COVID-19 spread in
5094,Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
5095,An mRNA vaccine against SARS-CoV-2-preliminary report
5096,Coordenação Geral do Programa Nacional de Imunizações. Plano Nacional de Operacionalização da Vacinação contra a Covid-19. Brasil Imunizado Somos Uma Só Nação 2020
5097,Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
5098,Total and IgE antibody levels following booster immunization with aluminum absorbed and nonabsorbed tetanus toxoid in humans
5099,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
5100,Differential Kinetics of Immune Responses Elicited by COVID-19 Vaccines
5101,SARS-CoV-2 Vaccine Effectiveness in a High-Risk 669 National Population in a Real-World Setting
5102,Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
5103,"Bases técnicas para decisão do uso emergencial, Em caráter experimental de vacinas contra a COVID-19. ANVISA, Relatório"
5104,China approves emergency use of Sinopharm COVID-19 vaccine for children aged 3-17
5105,WHO coronavirus (COVID-19) dashboard
5106,Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination
5107,Rapidly declining SARS-CoV-2 antibody titers within 4 months after BNT162b2 vaccination
5108,Rapid epidemic expansion of the SARS-CoV-2
5109,The importance of hydration and DNA conformation in interpreting infrared spectra of cells and tissues
5110,COVID-19 (SARS-CoV-2) variants. GOV.UK; 2021
5111,"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19"
5112,SARS-CoV-2 variants of concern in the United States-challenges and opportunities
5113,COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases 2021
5114,The epidemiology of antiphospholipid syndrome: A populationbased study
5115,Children and COVID-19 vaccinations trends
5116,The typical duration of migraine aura: a systematic review
5117,Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
5118,Delayed second dose versus standard regimen for COVID-19 vaccination
5119,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
5120,Analysis of the Anti-Vaccine Movement in Social Networks: A Systematic Review
5121,Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study
5122,"Evolution of the deaths registry system in Brazil: associations with changes in the mortality profile, under-registration of death counts, and illdefined causes of death"
5123,Halitosis in COVID-19 patients. Spec. Care Dent
5124,BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
5125,COVID-19 in longterm care facilities: an upcoming threat that cannot be ignored
5126,Low dose mRNA-937 1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-938 existing crossreactive T cell memory
5127,"World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac"
5128,"designed, managed and monitored the quality of the epidemiological data collected in the REDCap database"
5129,SARS-CoV-2 Immunoassays: advancing diagnostics of COVID-19
5130,"Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study"
5131,Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
5132,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals
5133,The Bonferonni and `idák corrections for multiple comparisons
5134,Real-time public health communication of local SARS-CoV-2 genomic epidemiology
5135,Introduction to the analysis of survival data in the presence of competing risks
5136,Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
5137,Will SARS-CoV-2 variants of concern affect the promise of vaccines?
5138,Identifying airborne transmission as the dominant route for the spread of COVID-19
5139,Assessing the mechanism of DNA damage induced by lead through direct and indirect interactions
5140,Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
5141,"SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions"
5142,Genetics of healthy aging and longevity
5143,Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
5144,Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2. Vaccine in a Subgroup of Healthy Adults in Chile
5145,Clinical efficacy of antivirals against novel coronavirus (COVID-19): a review
5146,All rights reserved. No reuse allowed without permission
5147,Key residues of the receptor binding motif in the spike protein of SARS-435
5148,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases"
5149,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The"
5150,Comparison of the effects of acute Influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts
5151,Heavily mutated Omicron variant puts scientists on alert
5152,Reduced neutralization of SARS-CoV-2 B.1.1.7 168 variant by convalescent and vaccine sera
5153,Sinopharm Says Second Covid Vaccine Found to Be Safe
5154,"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokinetreated patients with immune-mediated inflammatory diseases"
5155,India's DNA COVID vaccine is a world firstmore are coming
5156,"Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort"
5157,Increased risk of SARS-CoV-2 178
5158,Orofacial adverse effects of COVID-19 vaccines exist but are rare
5159,Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2: a national case-control study
5160,Protection duration after vaccination or infection -Swiss National COVID-19
5161,Connecting clusters of COVID-19: An epidemiological and serological investigation
5162,Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated
5163,"From Oxford to an Italian Lab, One Race for Coronavirus Vaccine is gaining Backers"
5164,Prognostic Factors in Elderly Patients With Guillain-Barré Syndrome: Does Age Matter?
5165,Vaccine in Adolescents
5166,"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS"
5167,Long-term residential exposure to air pollution is associated with hair cortisol concentration and differential leucocyte count in Flemish adolescent boys
5168,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
5169,Hematologic toxicity of sodium valproate
5170,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled"
5171,COVID-19: Significance of Antibodies
5172,Effect of COVID-19 on anti-S antibody response in health care workers six months post-vaccination. Vaccines (Basel)
5173,"Safety and immunogenicity of seven covid-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial"
5174,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, doubleblind, placebo-controlled, phase 1/2 trial"
5175,"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against 1 SARS-CoV-2 across four different countries. 2 3 Running Title: Immunization of 7 vaccines vs SARS.CoV-2 4"
5176,SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
5177,Extended interval BNT162b2 vaccination enhances peak antibody generation
5178,Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales
5179,Does the world need an Omicron vaccine? What researchers say
5180,Direct gene transfer into 443 mouse muscle in vivo
5181,"Drugs prosthesis and procedures -(management system of SUS procedures, drugs, and orthotics, prostheses and materials data). SIGTAP, Management System of Procedures Table"
5182,Vaccination in chronic kidney disease
5183,Pfizer-Biontech announce positive topline results of pivotal COVID-19 vaccine study in adolescents
5184,Relapsing-remitting multiple sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis
5185,Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
5186,A novel coronavirus associated with severe acute respiratory syndrome
5187,Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study
5188,Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
5189,Vírus emergentes e reemergentes
5190,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Artic Lancet Infect Dis"
5191,COVID-19) Situation Report
5192,Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
5193,Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19
5194,Neutralizing activities against the omicron variant after a heterologous booster in healthy 248 adults Receiving Two Doses of CoronaVac Vaccination
5195,A cluster of the new SARS-CoV-2 B1621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
5196,Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
5197,Association between age and clinical characteristics and outcomes of COVID-19
5198,Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
5199,Prevalence and risk factors of coronavac side effects: an independent cross-sectional study among healthcare workers in Turkey
5200,Severe Acute Respiratory Syndrome Coronavirus 2: Vaccine Hesitancy Among Underrepresented Racial and Ethnic Groups with HIV in
5201,Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab
5202,Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals
5203,Emergence of a novel SARSCoV2 variant in southern California
5204,World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection
5205,Impact of the COVID-19 pandemic on surgical oncology in Europe: results of a European survey
5206,Comparative immunogenicity of mRNA and inactivated 7 vaccines against COVID-19
5207,Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two 1093 Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut
5208,Risk of Systemic Lupus Erythematosus in Patients With Anti-566 phospholipid Syndrome: A Population-Based Study
5209,Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies
5210,Robust spike antibody responses and 464 increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA 465 vaccine
5211,Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients
5212,"Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera"
5213,The epidemiology and clinical information about COVID-19
5214,"All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted"
5215,Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low-and middle-income countries
5216,Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection
5217,mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
5218,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial"
5219,Analysis of efficacy of intervention strategies for COVID-19 transmission: a case study of Hong Kong
5220,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature
5221,"Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls"
5222,Efficacy of 457 the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
5223,Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
5224,WHO. WHO coronavirus disease (COVID-19) dashboard. 2020
5225,"Clinical impact, reactogenicity, and immunogenicity after the first coronavac dose in kidney transplant recipients"
5226,Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Res Sq
5227,Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA
5228,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
5229,Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
5230,"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review"
5231,Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
5232,"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) -highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts"
5233,Functional neurological disorder after COVID-341 19 vaccination
5234,diagnostics Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
5235,"World Health Organization. Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization"
5236,Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
5237,The Government of the Hong Kong Special Administrative Region. COMIRNATY COVID-19 mRNA vaccine (BNT162b2) 2021
5238,Effect of Vaccination on 614 Transmission of SARS-CoV-2
5239,COVID-19 Vaccine AstraZeneca
5240,Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
5241,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial"
5242,Covid-19 in Brazil: a sad scenario
5243,The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries
5244,SARS-CoV-2-Immnuoassays
5245,Alkaline
5246,Reporting survey based studies-a primer for authors
5247,"Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum. Vaccines Immunother"
5248,"Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study"
5249,Structure-based development of human antibody cocktails against SARS-CoV-2
5250,Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients
5251,Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
5252,mRNA vaccinesa new era in vaccinology
5253,Betjes MGH. Protective cytomegalovirus (CMV)-Specific T-Cell immunity is frequent in kidney transplant patients without serum anti-CMV antibodies
5254,Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy
5255,Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on Good Research Practices -Budget Impact Analysis. Value Heal
5256,Impact of SARS-CoV-2 Variants on the Total CD4+ and CD8+ T Cell Reactivity in Infected or Vaccinated Individuals
5257,Evaluation of nine commercial SARS-CoV-2 immunoassays
5258,Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
5259,"Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers"
5260,Identification of symptoms prognostic of COVID-19 severity: multivariate data analysis of a case series in Henan Province
5261,Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
5262,Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines
5263,"Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine"
5264,A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection
5265,"Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime. medRxiv preprint"
5266,"Characteristics and factors associated with COVID-19 infection, hospitalization, and mortality across race and ethnicity"
5267,Accessed 28
5268,Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
5269,Male Sex Identified by Global COVID-19 Meta-Analysis as a Risk Factor for Death and ITU Admission
5270,Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study
5271,Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays
5272,The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study
5273,Characteristics of SARS-CoV-2 positive cases beyond health-care professionals or social and health-care facilities
5274,Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac 1 (CoronaVac) followed by AstraZeneca (Vaxzevria) 2 3 Running Title: Heterologous prime-boost with CoronaVac-AZD1222
5275,Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
5276,Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
5277,*Statistical significance (p-value < 0.05) comparing between ChAdOx1 and CoronaVac group
5278,The critical need for pooled data on coronavirus disease 2019 in African children: an AFREhealth call for action through multicountry research collaboration
5279,National COVID-19 vaccination plan: using artificial spatial intelligence to overcome challenges in Brazil
5280,Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications
5281,"Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups"
5282,Supporting Information section at the end of this article. How to cite this article
5283,Kounis Syndrome in a patient after administration of influenza vaccine
5284,Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
5285,Association 1100 Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
5286,Desigualdades regionais na sa ude: mudanças observadas no Brasil de
5287,An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination
5288,Predictors of mechanical ventilation in Guillain-Barré syndrome with axonal subtypes
5289,Varicellazoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
5290,Cardiovascular Exercise Training Extends Influenza Vaccine Seroprotection in Sedentary Older Adults: The Immune Function Intervention Trial
5291,Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
5292,Stratégie de Vaccination Contre Le SARS-CoV-2 -Vaccination Des Personnes Ayant Un Antécédent de Covid-19.; 2021
5293,Evidence for Antibody as a Protective Correlate for COVID-19
5294,Safety of CO-VID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
5295,real-world evidence synthesized across a multi-state health system
5296,Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population
5297,Available online
5298,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study"
5299,"Population Movement, City Closure in Wuhan, and Geographical Expansion of the COVID-19 Infection in China in"
5300,Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect? Hepatology
5301,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv
5302,"Access to COVID-19 vaccines and medicines-a Global Public Good Zur Verfügung Gestellt in Kooperation Mit/ provided in cooperation with: GIGA German Institute of Global and Area Studies Vaccines and Medicines -a Global Public Good. (GIGA Focus Global, 4)"
5303,International consensus (ICON): allergic reactions to vaccines
5304,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
5305,"Impact of COVID-19 pandemic on time series of maternal mortality ratio in Bahia, Brazil: analysis of period 2011-2020"
5306,"Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation"
5307,DNA and mRNA vaccination against allergies
5308,"Correspondence on ""SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"
5309,Myocarditis following COVID-19 vaccination
5310,Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis
5311,Egypt authorizes Pfizer's COVID-19 vaccine for 12 to 15 year-olds
5312,How to cite this article: Fonseca MHG
5313,reinfection associated with emergence of the Omicron variant in South Africa. medRxiv
5314,Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach
5315,BNT162b2 625 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 626
5316,"Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World"
5317,Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer
5318,Prevention is better than the cure: risk management of COVID-19
5319,Criteria for diagnosis of Guillain-Barré syndrome
5320,Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
5321,Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature (PREPRINT)
5322,Virological characteristics of SARS-CoV-2 BA.2 variant.2022. February152022
5323,"Test-negative designs: differences and commonalities with other case-control studies with ""other patient"
5324,Methodological quality and synthesis of case series and case reports
5325,ARTICLE A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE
5326,El COVID-19 como renovado detonador del acaparamiento y la depredación comercial: ¿el multilaterismo en coma? Glob Trade Alert Rep
5327,"To cite: Saygılı ES, Karakilic E"
5328,Spontaneous abortion following COVID-19 vaccination during pregnancy
5329,Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
5330,The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
5331,Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus
5332,Antibody response after second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among health care workers in India: final results of cross-sectional coronavirus vaccine
5333,Harvard Humanitarian Initiative
5334,Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
5335,Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series
5336,Challenges in ensuring global access to 222
5337,"Methylation, sugar puckering and Z-form status of DNA from a heavy metal-acclimated freshwater Gordonia sp"
5338,Polyethylene glycol and polysorbate testing in twelve patients prior to or after COVID-19 vaccine administration
5339,Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity
5340,Angular cheilitis of COVID-19 patients: A case-series and literature review
5341,Approaches and challenges in SARS-CoV-2 vaccine development
5342,Vaccination in the elderly: the challenge of immune changes with aging
5343,Functional responsiveness of memory T cells from COVID-19 patients
5344,Animal models for highly pathogenic emerging viruses
5345,"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and"
5346,SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
5347,Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
5348,Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
5349,"Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections"
5350,SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 31 10
5351,Vaccine confidence in the time of COVID-19
5352,Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
5353,High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2
5354,Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
5355,Inference and missing data
5356,Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post- vaccination ASIA Syndrome
5357,BNT162b2-Elicited Neutralization 921 against New SARS-CoV-2 Spike Variants
5358,Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections
5359,Does environmental quality and weather induce COVID-19: case study of Istanbul
5360,Systemic inflammatory markers associated with cardiovascular disease and acute and chronic exposure to fine particulate matter air pollution (PM2.5) among US NHANES adults with metabolic syndrome
5361,Infectious Diseases (except HIV/AIDS); 2021 juin
5362,Multicenter Study of Antibody Seroprevalence Against COVID-19 in Patients Presenting to Iranian Cancer Centers After One Year of the COVID-19 Pandemic
5363,Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection
5364,COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia
5365,Recognition of Variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
5366,"A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)"
5367,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study
5368,Older Adults May Be Left Out Of Some COVID-19 Trials
5369,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial"
5370,Mutation in a sars-cov-2 haplotype from sub-antarctic chile reveals new insights into the spike's dynamics
5371,Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry
5372,Correlates of protection against SARS-CoV-2 in 416 rhesus macaques
5373,Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region
5374,The effectiveness of the twodose BNT162b2 vaccine: analysis of real-world data
5375,Interferon-gRelease Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response
5376,The immunology of SARS-CoV-2 infections and vaccines
5377,"Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cellstimulating skin-emigrated dendritic cells"
5378,Mapping the antigenic and genetic evolution of influenza virus
5379,Efficient SARS-CoV-2 detection in unextracted oro-nasopharyngeal specimens by rRT-PCR with the Seegene Allplex TM 2019-nCoV assay
5380,WHO. Interim statement on COVID-19 vaccine booster doses
5381,3@A:* =4*58>?>8A:* >4*538?@@A:* 9@*534?;6A:* 3-412-! @@*5@8?=9A:* ;3*54@?@=A:* 9@*5=4?>9A:* 46*5=8?>6A:*
5382,"African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study"
5383,Effectiveness of an Inactivated SARS-CoV-2 Vaccine
5384,World Health Organization. WHO coronavirus disease (COVID-19) dashboard
5385,Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Front Immunol
5386,WHO coronavirus disease (COVID-19) dashboard
5387,Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based
5388,Delta spike P681R mutation enhances SARS-CoV-2 395 fitness over Alpha variant. bioRxiv
5389,"Comparing COVID-19 vaccines for their characteristics, efficacy, and effectiveness against SARS-CoV-2 and variants of concern: a narrative review"
5390,Epidemiologic Surveillance Guide. National Emergency of Public Health Concern due to the COVID-19 disease
5391,Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine
5392,505 12. World Health O. Rabies vaccines: WHO position paper
5393,Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. medRxiv
5394,Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test?
5395,"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study"
5396,"A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease"
5397,"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers"
5398,Effectiveness of the SARS-CoV-2 vaccine program
5399,World Health Organization
5400,Health Vigilance
5401,Ministry of Health
5402,-687 Emerging Infectious Diseases journal -CDC
5403,Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
5404,Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany
5405,Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial
5406,The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
5407,PROSPERO's progress and activities 2012/13
5408,Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy
5409,Neutralizing antibody response and SARS severity
5410,Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
5411,Safety of pandemic H1N1 vaccines in children and adolescents
5412,SARS-CoV-2 vaccine
5413,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey"
5414,Immunological characteristics govern the transition of COVID-19 to endemicity
5415,Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil
5416,"Receptor Binding Domain of SARS-CoV-2 spike protein; SD, standard deviation"
5417,Comparison of intradermal and 565 intramuscular administration of hepatitis B vaccine in neonates
5418,"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"
5419,Antibody tests for identification ofcurrent and pastinfection with SARS-CoV-2. Cochrane Database Syst
5420,Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
5421,Increased transmissibility and global spread of sars-cov-2 variants of concern as at
5422,"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomized controlled, non-inferiority trial"
5423,Induction of production of nitric oxide in microglial cells by insoluble form of aluminium
5424,Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
5425,529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
5426,Endocrine Conditions and COVID-19
5427,"Gholamzadeh Baeis, M. The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data"
5428,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Effectiveness and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial"
5429,Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
5430,Vaccination against persistent viral infection exacerbates CD4+ T-cell-mediated immunopathological disease
5431,Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization
5432,Omicron likely to weaken COVID vaccine protection
5433,The how's and what's of vaccine reactogenicity
5434,CDC. Vaccines: The Basics. Available online
5435,COVID-19: Wäre eine Impfpflicht rechtlich möglich?
5436,UCSF Chimera -a visualization system for exploratory research and analysis
5437,US Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science
5438,"Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study"
5439,C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5440,"T follicular helper cell differentiation, function, and roles in disease"
5441,Weekly epidemiological update on COVID-19 -27
5442,The Profile of the Obstetric Patients with SARS-CoV-2 Infection according to Country of Origin of the Publication: A Systematic Review of the Literature
5443,The safety of COVID-19 mRNA vaccines: a review
5444,Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis
5445,Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)
5446,Years Old): an independent post-marketing study
5447,Use of FTIR spectroscopy and PCA-LDC analysis to identify cancerous lesions within the human colon
5448,vaccine BNT162b1 elicits human antibody and TH1 T cell responses
5449,COVID-19-associated subacute thyroiditis: evidence-based data from a systematic review
5450,Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies
5451,"nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK"
5452,Epi Info TM for Windows
5453,"Comparing COVID-19 vaccines for their 21 characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern"
5454,Emergence of Behçet's disease post-SARS-CoV2-vaccination: two clinical cases in Japan
5455,A New SARS CoV-2 Dual Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
5456,Scadding GK. Allergic rhinitis
5457,Infection-and 855 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
5458,Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (sarscov-2) infection: a randomized clinical trial
5459,Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?
5460,"Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys"
5461,Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
5462,"Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight"
5463,"Systemic IL-15, IFN-gamma, and IP-10/ CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients"
5464,COVID-19: breaking down a global health crisis
5465,"Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI"
5466,Strategies for vaccine prioritization and mass dispensing
5467,Available from: All rights reserved. No reuse allowed without permission
5468,Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
5469,Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
5470,Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2
5471,DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus
5472,Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a crosssectional study from the Big Data Sjögren Project Consortium
5473,Influenza vaccine: where are we and where do we go
5474,Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis
5475,Durable humoral and cellular immune responses 8 months after Ad26. COV2.S vaccination
5476,Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
5477,Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
5478,Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened 662 Workforce
5479,Which type of the promising COVID-19 vaccines produces minimal adverse effects? A retrospective crosssectional study
5480,Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity
5481,SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
5482,Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients
5483,Variant proportions are estimated against total sequences of 633 collected samples of each month. Total samples are varied for each month. Data are subject to change 634 over time and will be updated as more data become available. Variant proportions may not represent 635 national estimates
5484,SARSCoV2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following twodose CoronaVac vaccine regimen
5485,WHO Coronavirus (COVID-19) Dashboard. Available online
5486,Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
5487,Obesity is associated with impaired immune response to influenza vaccination in humans
5488,We have Vaccine for COVID-19! What to Recommend for Pregnant Women?
5489,Immunogenicity and Safety of an Intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population
5490,New and upcoming treatments in antiphospholipid syndrome: A comprehensive review
5491,Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
5492,"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy"
5493,National Comprehensive Cancer Network. Recommendations of the NCCN COVID-19 vaccination advisory committee
5494,Clinical and Analytical Performance of an
5495,Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: epidemiology and outcomes
5496,Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans
5497,Validation of real-time RT-PCR for detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea
5498,Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming
5499,Will the COVID-19 pandemic trigger future occurrence of autoimmunity like Sjögren's syndrome?
5500,Advisory Committee on Imunization Practices (ACIP) (2021)
5501,Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
5502,Commonly used adjuvant human vaccines: advantages and side effects
5503,Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data
5504,Countering Vaccine Hesitancy
5505,COVID-19 vaccines: a review of the safety and efficacy of current clinical trials
5506,Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
5507,The impact of pre-existing comorbidities and therapeutic interventions on COVID-19
5508,Epidemiologic and clinical features of patients with COVID-19 in Brazil. Einstein (São Paulo)
5509,Fear Mounts Trump May Pressure FDA to Rush Covid-19 Vaccine by Election
5510,"Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation"
5511,"Myocardial infarction after aspirin treatment, and Kounis syndrome"
5512,"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil"
5513,Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination
5514,SARS-CoV-2 B.1.1.7 and B.1.351 spike 771 variants bind human ACE2 with increased affinity
5515,Quilombolas têm que recorrer à Justiça e até comprar geladeira para conseguir vacina. Brasil de Fato
5516,Histamine-induced coronary artery spasm: the concept of allergic angina
5517,Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines
5518,Antibody 1010 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
5519,Personalized vaccinology: A review
5520,Sex Differences and COVID-19
5521,Antibody 991 Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 992 Recipients With Minimal Serologic Response to 2 Doses
5522,Immunization related focal neurological syndrome after coronavac vaccination
5523,"Slow spread of SARS-CoV-2 in Southern Brazil over a six-month period: report on eight sequential statewide serological surveys including 35,611 participants"
5524,Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
5525,High seroconversion rate 984 but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients 985 treated with chemotherapy for solid cancers
5526,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
5527,Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study
5528,Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
5529,"Heterogeneity: I 2 = 0%, Q = 1.33"
5530,Title: A randomized clinical trial of a booster dose with low versus standard dose of 1 AZD1222 in adult after 2 doses of inactivated vaccines 2 3
5531,Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination
5532,Hong Kong Special Administrative Region. CHP Vaccination Dashboard
5533,COVID-19 vaccine in pregnant and lactating women: a review of existing evidence and practice guidelines
5534,Healthcare workers should be recieved with the highest effective vaccine available
5535,Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study
5536,SARS-CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv 2021
5537,Effect of previous SARS-CoV-2 infection on humoral and T-cell 487 responses to single-dose BNT162b2 vaccine
5538,Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis
5539,Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile
5540,"COVID-19 and the workplace: implications, issues, and insights for future research and action"
5541,Willingness to receive novel coronavirus vaccine and factors influencing willingness among healthcare workers in Zhejiang province. Zhongguo Yi Miao He Mian Yi
5542,The Capacity of the Indonesian Healthcare System to Respond to COVID-19
5543,Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review
5544,COVID-19 clinical management: living guidance; 2021. Accessed
5545,Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
5546,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5547,Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals
5548,Clinical characteristics of coronavirus disease 2019 in China
5549,Plano nacional de operacionalização da vacinação contra a covid-19
5550,Rio de Janeiro: IBGE
5551,18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine
5552,"Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients"
5553,Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine
5554,Human Coronavirus Types
5555,Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female
5556,Understanding the symptoms of the common cold and influenza
5557,SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women
5558,"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study"
5559,Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation FDA = Food and Drug Administration VOC = Variant of Concern VTM = Viral Transport Media
5560,Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years-United States
5561,Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination
5562,Intradermal vaccination: A potential tool in the battle against the COVID-19 pandemic? Risk Manag
5563,Interferon-γ Release Assay for Accurate Detection of Severe Acute 589
5564,Reconstruction of the full transmission dynamics of COVID-19 in Wuhan
5565,SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines
5566,Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients
5567,Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates
5568,Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City
5569,BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis
5570,An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines
5571,SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
5572,WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations 2021
5573,Estratégia de Vacinação contra o Vírus SARS-CoV-2 COVID-19: Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação 2020
5574,Accessed 12
5575,Cost Utility of Vaccination Against COVID-19 in Brazil
5576,SARS-CoV-2 variants of concern and variants under investigation in England-Technical briefing 17
5577,SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen
5578,Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report
5579,Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
5580,Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
5581,Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki disease cases
5582,Profiles of current COVID-19 vaccines
5583,"Timing and topography of cerebral blood flow, aura, and headache during migraine attacks"
5584,Change in COVID-19 risk over time following vaccination with CoronaVac: a test-negative case-control study
5585,"Daily Corona Virus Disease (COVID-19) Vaccine Situation Report. Department of Disease Control, Ministry of Public Health"
5586,Adesão ao isolamento social em SP. Available at: synthesized across a multi-state health system
5587,Neutralization of VOCs including Delta one year post COVID-19 or vaccine
5588,Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
5589,Current and innovative methods for the diagnosis of COVID 19 infection (Review)
5590,Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
5591,Inflammatory muscle diseases
5592,COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2
5593,Seroprevalence of hospital staff in a province with zero COVID-19 cases
5594,Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome
5595,A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
5596,SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists
5597,Effects of mRNA-based COVID-19 vaccines among young adults
5598,The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 $7 days after the 2nd dose
5599,Confronting the Delta variant of SARS-CoV-2
5600,Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status
5601,Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. 627 medRxiv
5602,Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines
5603,Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study
5604,Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection
5605,Estimation of basic reproduction number for COVID-19 and the reasons for its differences
5606,"Report on Evaluation of Safety, Efficacy and Quality of CoronaVac COVID-19 Vaccine (Vero Cell) Inactivated. 2021"
5607,Pseudotype neutralization assays: From laboratory bench to data analysis
5608,"SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes"
5609,Bronchus-Associated Lymphoid Tissue (BALT) Is Not Present in the Normal Adult Lung But in Different Diseases
5610,"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial"
5611,Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
5612,Measuring inconsistency in meta-analyses
5613,"Safety and immunogenicity of ino-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial"
5614,Tracking coronavirus vaccinations around the world
5615,Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
5616,Cardiovascular outcomes associated with use of clarithromycin: population based study
5617,Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya. Vaccines (Basel). 23 de agosto de 2021
5618,Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers
5619,SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine
5620,"After blocking in 1% normal goat serum for 1 h at 37°C, the sections were stained with anti-SARS-CoV-2 rabbit monoclonal antibody at 4°C overnight, followed by incubation with a horseradish peroxidase HRP-labeled goat anti-rabbit IgG secondary antibody (ZDR-5306, 1:200; ZSGB Bio) for 1 h at 37°C. Finally, the sections were visualized by incubation with 3,3′-diaminobenzidine tetrahydrochloride (DAB) and viewed carefully by an Olympus microscope. CT Macaques were anesthetized with 2% isoflurane. CT imaging was conducted by using an IRIS XL-260 CT scanner"
5621,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study
5622,"Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: A preliminary analysis"
5623,Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 530
5624,Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination
5625,The proximal origin of SARS-CoV-2
5626,Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-Spike Protein-Protein Interaction
5627,Association between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
5628,Research electronic data capture (REDCap)-a metadatadriven methodology and workflow process for providing translational research informatics support
5629,Infective endocarditis in adults
5630,Autoinflammatory disease reloaded: a clinical perspective
5631,"The Royal Society and The British Academy. Covid-19 Vaccine Deployment: Behaviour, Ethics, Misinformation and Policy Strategies"
5632,Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19
5633,The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
5634,COVID-19 WHO Thailand Situation Reports
5635,"Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study"
5636,Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
5637,Safety and Efficacy 448 of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
5638,Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
5639,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial"
5640,Dados abertos. Registro de casos e óbitos por município e data de notificação no Estado de São Paulo
5641,The Brazilian Government's mistakes in responding to the COVID-19 pandemic
5642,COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS AC-TION)
5643,Estimating infectiousness throughout SARS-CoV-2 infection course
5644,Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
5645,Barriers of influenza vaccination intention and behavior-a systematic review of influenza vaccine hesitancy
5646,"Children and increased susceptibility to environmental carcinogens: evidence or empathy? Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research"
5647,Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Sequential immunizations confer cross-protection against variants of
5648,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treating Healthcare Professionals With the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A Structured Summary of a"
5649,"Office of the Communications Authority. The Numbering Plan for Telecommunications Services in Hong Kong (SAR), China. Available online"
5650,COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
5651,The pathogenesis of the antiphospholipid syndrome
5652,What do we know about India's Covaxin vaccine
5653,Differential chemokine expression following respiratory virus infection reflects 1-or 2-biased immunopathology
5654,Sputnik V: general information
5655,Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines
5656,COVID -2019) en Colombia: Instituto Nacional de Salud
5657,Immunodominant B Cell Epitope in a Hotspot Mutation Site and Mechanism of Immune Escape for SARS-CoV-2. medRxiv (2021)
5658,Age-and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany
5659,"Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women"
5660,Remdesivir for the Treatment of Covid-19 -Final Report
5661,Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
5662,Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile
5663,Sensitivity of 431 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
5664,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges
5665,Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)/COVID-19 Detection
5666,Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity
5667,Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. medRxiv (p. 2020.06.30
5668,World Health Organization. Ten Threats to Global Health in 2019
5669,SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
5670,"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HER-ALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial"
5671,National Institutes of Health. Safety and immunogenicity study of inactivated vaccine for prevention of COVID-19
5672,The International Classification of Headache Disorders
5673,SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19
5674,"Understanding the Prevalence and Associated Factors of Behavioral Intention of COVID-19 Vaccination Under Specific Scenarios Combining Effectiveness, Safety, and Cost in the Hong Kong Chinese General Population"
5675,"CDC, Vacines and immunizations. Local Reactions, Systemic Reactions, Adverse Events, And Serious Adverse Events: Janssen COVID-19 Vaccine"
5676,Provisional Analysis of the First 6748 Reported Death Cases in the 5th Wave
5677,The psychological impact of quarantine and how to reduce it: rapid review of the evidence
5678,Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)
5679,Evolution of Antibody Immunity to SARS-CoV-2
5680,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial"
5681,Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel
5682,"COVID-19: fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show"
5683,Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till
5684,The adjuvant gla-af enhances human intradermal vaccine responses
5685,"Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS- CoV-2 vaccine (CoronaVac) on risks of all- cause mortality, emergency department visit, and unscheduled hospitalization Open Access"
5686,Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
5687,Kinetics of viral load and antibody response in relation to COVID-19 severity
5688,COVID-19 pandemic
5689,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia"
5690,Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19
5691,Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an
5692,BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. medRxiv
5693,Guangdong's study of the effectiveness of China's inactivated vaccines against the SARS-CoV-2 B.1.617.2 (delta) variant
5694,Israel's rapid rollout of vaccinations for COVID-19
5695,Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain
5696,Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
5697,SARS-CoV-2 B.1.617.2 890 Delta variant replication and immune evasion
5698,Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review
5699,Characteristics of SARS-CoV-2 and COVID-19
5700,COVID-19 bilgilendirme platformu
5701,Zimbabwe starts vaccinating teens against COVID-19
5702,Omicron variant in southern Africa
5703,"Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study"
5704,2 -Vaccine immunology. Plotkin's vaccines. 7th end. Elsevier
5705,Intradermal ChAdOx1 vaccine following two CoronaVac shots: a case report. Vaccines (Basel)
5706,Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
5707,Vaccine inequality: how rich countries cut Covid deaths as poorer fall behind
5708,Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B117 variant
5709,The Government of the Hong Kong Special Administrative Region
5710,First report of SARS-CoV-2 gamma variant in Turkey
5711,"A Systematic Review of Methods to Improve Attitudes towards Childhood Vaccinations. Cureus 2019, 11, e5067"
5712,Effectiveness of the Coronavac Vaccine in Older Adults During a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test Negative Case-Control Study
5713,Thailand Medicines Regulation Division
5714,The T cell immune response against SARS-CoV-2
5715,Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice
5716,Efficacy and Safety of the mRNA
5717,Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease
5718,MAFFT multiple sequence alignment software version 7: Improvements in performance and usability
5719,Statistical power analysis for the behavioral sciences
5720,The story behind chile's rapid rollout of covid-19 vaccination
5721,An effective COVID-19 vaccine needs to engage T cells
5722,Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant
5723,"Estabelece diretrizes gerais para a instituição de Regiões de Saúde no âmbito do Sistema Único de Saúde (SUS), nos termos do Decreto n. 7.508, de 28 de junho de 2011"
5724,The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol
5725,Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China
5726,COVID-19 spike-host cell receptor GRP78 binding site prediction
5727,The Canadian Paediatric Society. COVID-19 Vaccine for Children
5728,Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
5729,Interim findings from firstdose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
5730,A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals
5731,The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
5732,Mauritius orders Covid-19 doses to cover remaining population
5733,The R Project for Statistical Computing
5734,Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
5735,Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
5736,Combinatorial nano-bio interfaces
5737,The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
5738,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5739,New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin. Dermatol Sin
5740,Links between air pollution and COVID-19 in England
5741,Applied linear statistical models. 4 th ed. Ilinois: Richard D. Irwing
5742,Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test
5743,"WHO Health Emergencies Programme, Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States"
5744,Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
5745,Optimal control of the COVID-19 pandemic: Controlled sanitary deconfinement in Portugal
5746,Republic of Turkey Ministry of Health
5747,Aversion to side effects in preventive medical treatment decisions
5748,The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
5749,Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells
5750,The implications of silent transmission for the control of covid-19 outbreaks
5751,Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
5752,Temporal 867 Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape 868 after Sputnik V Vaccination
5753,Covid-19 Casos e Óbitos
5754,Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
5755,Mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants
5756,Chilean Ministry of Health. Daily official report
5757,CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
5758,Determinants of COVID-19 disease severity in patients with cancer
5759,Evolutionary reversion of live viral vaccines: can genetic engineering subdue it? Virus Evol
5760,High coverage COVID-19 mRNA vaccination 717 rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities
5761,"SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness"
5762,The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data
5763,A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
5764,"Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination"
5765,Heterologous primeboost vaccination with ChAdOx1 nCoV-19 and BNT162b2
5766,"Age in years (mean, IQR) in age between groups using one-way ANOVA. c represents the comparison in dosing 473 interval between groups using Kruskal-Wallis H test"
5767,Vaccine breakthrough infections with SARS-CoV-2 variants. 416
5768,Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
5769,Neutralizing Activities against the Omicron Variant after a 2 Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
5770,Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19
5771,An mRNA Vaccine Against SARS-CoV-2 -Preliminary Report
5772,The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
5773,A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
5774,"COVID-19: structural considerations for virus pathogenesis, therapeutic strategies and vaccine design in the novel SARS-CoV-2 variants era"
5775,Efficacy and safety of COVID-19 Vaccines: a systematic review and meta-analysis of randomized clinical trials
5776,ROCCA observational 1063 study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San 1064 Marino using active surveillance
5777,Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
5778,A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
5779,Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
5780,SARS-CoV-2 vaccines
5781,Duration of Immunity Against Pertussis After Natural Infection or Vaccination
5782,"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations"
5783,Republic of Turkey Ministry of Health (2022) COVID-19 vaccination information platform
5784,Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
5785,Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients
5786,An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in
5787,Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25
5788,Present yourself! By MHC Class I and MHC Class II molecules
5789,Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
5790,cPass TM SARS-CoV-2 Neutralization Antibody Detection Kit. Instructions for Use
5791,Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome)
5792,Determinants of self-perceived health for Canadians aged 40 and older and policy implications
5793,Potently neutralizing and protective human antibodies against SARS-CoV-2
5794,1 Special Administrative Region
5795,Side effects following administration of the first dose of Oxford-AstraZeneca's covishield vaccine in Bangladesh: a cross-sectional study
5796,R: A Language and Environment for Statistical Computing
5797,Antigen-specific immune responses to influenza vaccine in utero
5798,A new SARS-CoV-2 dualpurpose serology test: highly accurate infection tracing and neutralizing antibody response detection
5799,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial"
5800,T resident helper cells promote humoral responses in the lung
5801,Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Guangdong
5802,Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
5803,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5804,Interference Testing in Clinical Chemistry; Approved Guideline
5805,The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience
5806,"Subacute (de Quervain's) thyroiditis: association with HLA-Bw35 antigen and abnormalities of the complement system, immunoglobulins and other serum proteins"
5807,American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol
5808,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (coronavac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5809,Mucosal vaccines-fortifying the frontiers
5810,R-Pharm) Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
5811,safety and immunogenicity of intradermal delivery of a fractional dose mrna-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021. preprint
5812,Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals
5813,Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review
5814,World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines
5815,Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine
5816,Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
5817,Interim Report: Safety and Immunogenicity of an Inactivated Vaccine Against Sars-Cov-2 in Healthy Chilean Adults in A Phase 3 Clinical Trial 2 3 Brief Title: Coronavac03cl Phase 3 Interim Analysis of Safety and Immunogenicity
5818,Single Dose 1022 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv
5819,WHO. Coronavirus disease (COVID-19): Vaccines
5820,Antibody evasion properties of SARS-CoV-2 Omicron sublineages
5821,COVID-19 Vaccine National Implementation Strategy
5822,Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers
5823,Elevated inflammatory Lp-PLA2 and IL-6 link e-waste Pb toxicity to cardiovascular risk factors in preschool children
5824,Ethics and execution of developing a 2nd wave COVID vaccine-Our interim phase I/II VSV-SARS-CoV2 vaccine experience
5825,"Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital"
5826,"preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted"
5827,COVID-19 vaccines: under evaluation
5828,Evolution of antibody immunity to SARS-CoV-2
5829,SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days
5830,WHO. WHO coronavirus disease (COVID-19) dashboard. 2021
5831,Evaluation of COVID-19 vaccine effectiveness
5832,To appear in: Public Health
5833,COVID-19) Emergency Use Authorizations for Medical Devices; Food and Drug Administration
5834,romboembolic events in the South African Ad26.COV2.S vaccine study
5835,"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate"
5836,Plasma neutralization of the SARS-CoV-2 Omicron variant
5837,Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv
5838,Tongue ulcers associated with SARS-CoV-2 infection: A case series
5839,Role of TNF-alpha in CD8+ cytotoxic T lymphocytemediated lysis
5840,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world. medRxiv 2021. preprint
5841,Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis
5842,CoV-2 Variant Classifications and Definitions
5843,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
5844,COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
5845,"Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Republic of"
5846,Checklist for Analytical Cross Sectional Studies
5847,Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
5848,Many Th cell subsets have Fas ligand-dependent cytotoxic potential
5849,The global phosphorylation landscape of SARS-CoV-2 infection
5850,A Review of coronavirus disease-2019 (COVID-19)
5851,Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
5852,Our progress in developing a potential COVID-19 vaccine
5853,Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
5854,"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study"
5855,The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme
5856,The REDCap consortium: building an international community of software platform partners
5857,Plano Nacional de Operacionalização da Vacinação contra Covid-19 -Português (Brasil)
5858,World allergy organization anaphylaxis guidance 2020
5859,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 643 administered in a prime-boost regimen in young and old adults (COV002): a single-644 blind, randomised, controlled, phase 2/3 trial"
5860,"EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines"
5861,Insights Into Neutralizing Antibody Responses in Individuals Exposed to SARS-CoV-2 in Chile
5862,Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
5863,NPHCDA: 16-year-olds can receive COVID vaccine if required for educational purposes
5864,DNA vaccines against COVID-19: perspectives and challenges
5865,"Immune Assays Team § Moderna, Inc. Team § Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team § United States Government (USG)/CoVPN Biostatistics Team § Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial"
5866,Invasion Science and the Global Spread of SARS-CoV-2
5867,SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
5868,Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?
5869,Advances in mRNA vaccines for infectious diseases
5870,"Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model"
5871,Bilateral optic neuritis complicating rabies vaccination
5872,Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines (Basel)
5873,An interactive web-based dashboard to track covid-19 in real time
5874,COVID-19 and older adults: what we know
5875,"Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines (Basel) 2020"
5876,Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine
5877,The X-Files in Immunity: Sex-Based Differences Predispose Immune Responses
5878,Coronavirus Disease 2019 and Vaccination of Children and Adolescents: Prospects and Challenges
5879,"COVID-19 vaccination: What's the evidence for extending the dosing interval? Bmj 2021, 372, n18"
5880,Vacinas contra a covid-19
5881,An 616 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
5882,Effectiveness of COVID-19 vaccines BNT162b2 and mRNA-1273 by days from vaccination: A reanalysis of clinical trial data
5883,Delta to dominate world
5884,The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
5885,COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
5886,Late emergence of macular sparing in a stroke patient
5887,Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial
5888,Evaluation of a rapid antigen test (Panbio ™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients
5889,Development of an Inactivated Vaccine Candidate for SARS-CoV-2
5890,Coronavirus Vaccine Tracker
5891,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial"
5892,Anvisa faz recomendações sobre doses de reforço de vacinas contra Covid-19
5893,COVID-19 Vaccine: Where Are We Now and Where Should We Go?
5894,Se define valores de referencia a pagar por servicios UCI de covid-19 [Internet]Bogóta: Ministerio de de Salud y Protección Social
5895,"Covid-19: Social murder, they wrote-elected, unaccountable, and unrepentant"
5896,Erythema multiforme after SARS-CoV-2 vaccine
5897,Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
5898,Two doses of 800 SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 801 variants of concern than does natural infection
5899,SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
5900,Factors Associated with US Adults' Likelihood of Accepting COVID-19 Vaccination
5901,Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The Lancet. Infectious diseases 21
5902,"Articles Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial"
5903,Ministry of Public Health of Thailand. SARS-CoV-2 variants in Thailand
5904,"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): A randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial"
5905,Hazardous Substances Data Bank: PubChem data source
5906,SARS-CoV-2 spike P681R mutation enhances and 442 accelerates viral fusion
5907,Myocarditis following COVID-19 mRNA vaccination
5908,Bilateral retrobulbar optic neuritis with hepatitis B vaccination
5909,"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by sinovac -PROFISCOV: a structured summary of a study protocol for a randomised controlled trial"
5910,Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of Covid-19 in Brazil: test negative case-control study
5911,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
5912,Effects of climatological parameters on the outbreak spread of COVID-19 in highly affected regions of Spain
5913,Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
5914,Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
5915,Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming
5916,"Safety, Immunogenicity, and Efficacy of COVID-19 Vaccine in Children and Adolescents: A Systematic Review"
5917,Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
5918,"World Health Organization. WHO coronavirus disease (COVID-19) Dashboard, data table, and detailed surveillance data"
5919,Citation: Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
5920,COVID-19 and the Path to Immunity
5921,"The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study in the United States"
5922,BNT162b2 Overall infection N/A N/A 7 86% (78%-91%) 180766/ 51092 SCC BNT162b2 Overall infection N/A N/A 7 71%
5923,Could mixing COVID vaccines boost immune response?
5924,Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
5925,Immunogenicity After Two Doses of Inactivated Virus Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: Prospective Observational Study
5926,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
5927,Ministerio de Salud Gobierno de Chile. Ficha Vacuna Contra Sars-Cov-2
5928,COVID-19 vaccine tracker
5929,A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-Cov-2 Vaccine (BBIBP-Corv) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
5930,Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study
5931,COVID-19 hospitalizations in Brazil's Unified Health System (SUS)
5932,"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
5933,Genetic control of the CD4/CD8 T-cell ratio in humans
5934,"Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands"
5935,"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial"
5936,Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
5937,"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study"
5938,The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
5939,Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
5940,"Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study"
5941,Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies
5942,CDC_ AA_refVal=https%3A%2F%2F Accessed
5943,Effectiveness of an ınactivated SARS-CoV-2 vaccine
5944,Understanding interobserver agreement: The kappa statistic
5945,Neutralizing antibodies against the sars-cov-2 delta and omicron variants following heterologous coronavac plus bnt162b2 booster vaccination
5946,Arvind Subramanian write: Why we need to count 590 the Covid dead
5947,Coronavirus pandemic (COVID-19)
5948,"8%) 2,828 (9.9%)"
5949,Effects of boosted mRNA and adenoviral-vectored vaccines on 2 immune responses to omicron BA.1 and BA.2 following the 3 heterologous CoronaVac/AZD1222 vaccination 4 Running title: Booster response to omicron subvariants 5
5950,The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
5951,The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
5952,Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
5953,Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVİD-19
5954,"Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers"
5955,Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR -/-mice
5956,"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis"
5957,Immune-mediated necrotizing myopathy
5958,"New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil"
5959,A comparison study of SARS-CoV-2 IgG 589 antibody between male and female COVID-19 patients: A possible reason underlying different 590 outcome between sex
5960,Transmission dynamics and epidemiological characteristics of Delta variant infections in China
5961,T-Cell Mediated Immunity After AZD1222 Vaccination: A Polyfunctional Spike-Specific Th1 Response With a Diverse TCR Repertoire
5962,Making a COVID-19 vaccine that works for everyone: Ensuring equity and inclusivity in clinical trials
5963,Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience
5964,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials
5965,The world health organization international clinical trials registered organization registered platform
5966,Sex differences in immunity to viral infections
5967,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a"
5968,COVID-19) Dashboard; 2021. World Health Organization
5969,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort
5970,Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
5971,Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
5972,Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. The Lancet Microbe
5973,TOXBASE: poisons information database for clinical toxicology advice
5974,Myocarditis/pericarditis case definition
5975,"SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants"
5976,The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review
5977,CoV-2 Neutralization Antibody Detection Kit. Food and Drug Administration
5978,"Immunogenicity and Safety of a Third Dose of Coronavac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results From Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials"
5979,Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
5980,Interpretation of subgroup analyses in systematic reviews: a tutorial
5981,"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded"
5982,The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
5983,AstraZeneca's COVID-19 vaccine authorised in five other countries
5984,Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome
5985,Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting
5986,Allergic myocardial infarction following recombinant human insulin
5987,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
5988,The Covid-19 world-Are we there yet?
5989,Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
5990,The immunogenicity against variants of concern and reactogenicity of four COVID-19
5991,Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites
5992,Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
5993,Knowledge about cervical cancer and hpv immunization dropout rate among brazilian adolescent girls and their guardians
5994,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
5995,The role of antibody testing for SARS-CoV-2: is there one?
5996,High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines (Basel). 12 de janeiro de
5997,Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints
5998,National study group for C-E. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant
5999,Special report: The simulations driving the worlds response to COVID-19
6000,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
6001,Situation report 1. World Health Organization
6002,Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
6003,Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
6004,Tracking Coronavirus Vaccinations Around the World
6005,Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
6006,The increase in the risk of severity and fatality rate of COVID-19 in southern Brazil after the emergence of the variant of concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions
6007,"Beigel; mRNA-1273 Study Group, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report"
6008,Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
6009,Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study
6010,How the world is (not) handling surplus doses and expiring vaccines
6011,Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: a clinical dilemma for clinicians and patients
6012,"Challenges and Issues of Anti-SARS-CoV-2 Vaccines. Front. Med. 2021, 8, 664179"
6013,Brazil vaccine drive faces challenges in remote communities
6014,Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy
6015,Antibody-dependent enhancement of coronavirus
6016,A partisan pandemic: state government public health policies to combat COVID-19 in
6017,COVID-19 Vaccine Surveillance Report-Week 41
6018,Intradermal vaccine delivery: will new delivery systems transform vaccine administration?
6019,Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients
6020,Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection
6021,The use of social network in daily pediatric practice and education: Turkish pediatric atelier
6022,"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial"
6023,Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma
6024,Effectiveness of 551 an Inactivated SARS-CoV-2 Vaccine in Chile
6025,B and T cell immune responses elicited by the BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in nursing home residents
6026,Predictors of Nonseroconversion after SARS-CoV-2 Infection
6027,Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production
6028,First month of COVID-19 vaccine safety monitoring-United States
6029,COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses
6030,Antibody response to influenza vaccination in the elderly: a quantitative review
6031,Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine
6032,Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
6033,CoV-2-specific T cells cross-recognize the Omicron variant
6034,Antibody Response to Influenza Vaccination in the Elderly: A Quantitative Review
6035,Epicardial adipose tissue thickness is associated with increased COVID-19 severity and mortality
6036,Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
6037,Active monitoring of early safety of Sputnik V vaccine in
6038,Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a testnegative case-control study. The Lancet Regional Health -Americas. 1:100025
6039,Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic
6040,Vaccination induced neutropenia
6041,Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
6042,"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (Coronavac): interim results of a double blind, randomised, placebocontrolled, phase 3 trial in Turkey"
6043,Duration of protection against mild and severe disease by Covid19 vaccines
6044,A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
6045,Reversible cerebral vasoconstriction syndrome
6046,"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a twodose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials"
6047,COVID-19 Vaccines: Safety Surveillance Manual
6048,Adjusted risk factors for immunogenicity data in non-autoimmune rheumatic diseases (non-ARD) individuals
6049,"Confronting the Delta Variant of SARS-CoV-2, Summer 2021"
6050,Efficacy and safety of COVID-19 vaccines: a systematic review
6051,HLA does not impact on shortmedium-term antibody response to preventive anti-SARS-Cov-2 vaccine
6052,COVID-19: Where do we stand in 2021?
6053,Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
6054,Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis)
6055,Protection against SARS-CoV-2 after Covid-19
6056,A Rarely Seen Type-I Kounis Syndrome Caused By Tetanus Vaccine
6057,Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
6058,Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
6059,Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic
6060,Interim Estimates of 637 Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-638
6061,Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
6062,Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity
6063,Evaluation of mRNA-1273 SARS-CoV-2
6064,"Hesitancy in the time of coronavirus: Temporal, spatial, and sociodemographic variations in COVID-19 vaccine hesitancy"
6065,Physical activity: Benefits and challenges during the COVID-19 pandemic. Scand
6066,Case of bullous pemphigoid following coronavirus disease 2019 vaccination
6067,Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
6068,Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
6069,Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
6070,Socio-demographic and health factors drive the epidemic progression and should guide vaccination strategies for best COVID-19 containment
6071,"Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity"
6072,Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
6073,Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents
6074,Coronavirus biology and 393 replication: implications for SARS-CoV-2
6075,Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses
6076,Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
6077,Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months
6078,Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre
6079,Sinopharm's BBIBP-CorV vaccine effectiveness on preventing hospital admission and deaths: results from a retrospective study in the Emirate of Abu Dhabi
6080,Status report on COVID-19 vaccines development. Curr Infect Dis Rep
6081,Nosocomial Outbreak of Coronavirus Disease 2019 by Possible Airborne Transmission Leading to a Superspreading Event
6082,Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
6083,Sinovac's coronavirus vaccine candidate approved for emergency use in 494
6084,Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response
6085,Half of Americans would get a COVID-19 Vaccine
6086,Infection and death in healthcare workers due to COVID-19: a systematic review
6087,Sentinel surveillance of SARS-CoV-2 in waste water anticipates the occurrence of COVID-19 cases. medRxiv
6088,Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers
6089,Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: a large-scale observational study. SSRN [Preprint
6090,The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series
6091,Preparing for a pandemic: accelerating vaccine availability
6092,Safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern
6093,Snibe Diagnostic Fact Sheet for Healthcare Providers-MAGLUMI 2019-nCoV IgM/IgG 2020
6094,Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech
6095,D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity
6096,Reactivation of herpesvirus infections after vaccinations?
6097,A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)
6098,Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines
6099,EAACI guideline: anaphylaxis (2021 update)
6100,Severe breakthrough
6101,SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients
6102,"Supplementary Figure 1. Reported RT-PCR or Antigen confirmed COVID-19 in the general population of the São Paulo State, Brazil from"
6103,Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 years -Arizona
6104,Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant
6105,Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program
6106,Systematic reviews and meta-analyses CHECK LIST: The PRISMA statement
6107,Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
6108,Vaccine hesitancy: the next challenge in the fight against COVID-19
6109,Covid-19 Vaccine over 6 Months
6110,"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection"
6111,Thyroid Disease Is Associated With Severe Coronavirus Disease 2019 (COVID-19) Infection
6112,Safety and efficacy of NVX-CoV2373 covid-19 vaccine
6113,Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv 2021
6114,"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection"
6115,"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults"
6116,"Yarin Gal, and Jan Kulveit"
6117,Serum neutralising activity against SARS-CoV-2 variants elicited by coronavac
6118,Quantitative Contrasts: The Magnitude of Distinctions
6119,Reported orofacial adverse effects of COVID-19 vaccines: the knowns and the unknowns
6120,Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
6121,National Health Commission of the People's Republic of China. Diagnosis and treatment protocols of pneumonia caused by a novel coronavirus (trial version 8)
6122,CoronaVac Induces Lower Neutralising Activity Against Variants of Concern Than Natural Infection
6123,"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet"
6124,Germinal center reaction: antigen affinity and presentation explain it all
6125,C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
6126,101205. the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine
6127,Evidence Used to Update the List of Underlying Medical Conditions that Increase a Person's Risk of Severe Illness from COVID-19
6128,Vaccines and related biological products advisory committee meeting
6129,Social media and vaccine hesitancy: New updates for the era of COVID-19 and globalized infectious diseases. Hum. Vaccines Immunother
6130,Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients
6131,COVID-19 and solid organ transplantation: a review article
6132,The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
6133,B.1.1.7+E484K and a sub-variant of C.37 [Internet]. 2021 juill
6134,Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant-National Healthcare Safety Network
6135,COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
6136,"The RECOVAC immune-response Study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2021. Online ahead of print"
6137,"Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern, Emerging Microbes & Infections"
6138,Sinovac Says Early Data Show its Covid-19 Vaccine Generated Immune Responses
6139,Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
6140,Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
6141,Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies
6142,mRNA vaccination boosts cross-variant 175 neutralizing antibodies elicited by SARS-CoV-2 infection
6143,"MRA and PPB were supported by Coordination for the Improvement of Higher Education Personnel (88887.356527/2019-00) fellowships, and DAT-T and LSM were supported by CNPq fellowships"
6144,Coronavirus pandemic (covid-19)
6145,Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in
6146,Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings
6147,The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines Citation
6148,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials
6149,The Brazilian National Immunization Program: 46 years of achievements and challenges
6150,Travel and covid: rules and restrictions. Brussels: Your Europe
6151,Cancer immunology and canine malignant melanoma: a comparative review
6152,"Indonesia's Doctors Got Vaccinated With Sinovac, and Got Sick 2021"
6153,"SARS-CoV-2 variants in severely symptomatic and deceased persons who had been vaccinated against COVID-19 in São Paulo, Brazil"
6154,"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"
6155,La OMS caracteriza a COVID-19 como una pandemia
6156,Coronavirus Pandemic (COVID-19). Our World in Data
6157,B cell memory: Understanding COVID-19
6158,Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
6159,Considerable escape of SARS-CoV-2 Omicron to 408 antibody neutralization
6160,Clinical Immunization Safety Assessment Network Hypersensitivity Working G. Irritant skin test reactions to common vaccines
6161,Network meta-analysis: an introduction for clinicians
6162,Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
6163,& Johnson) Vaccines in Preventing
6164,Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database
6165,WHO approval of Chinese coronaVac COVID vaccine will be crucial to curbing pandemic
6166,Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice
